inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading document false gild royaltycontractandothermember gaap productmember gaap productmember gaap productmember gild royaltycontractandothermember gild royaltycontractandothermember gaap commonstockmember gaap additionalpaidincapitalmember gaap additionalpaidincapitalmember gaap retainedearningsmember gaap commonstockmember gaap commonstockmember gaap gaap additionalpaidincapitalmember gaap additionalpaidincapitalmember gaap retainedearningsmember gaap noncontrollinginterestmember gaap retainedearningsmember gaap noncontrollinginterestmember gaap accumulatedothercomprehensiveincomemember gaap additionalpaidincapitalmember gaap accumulatedothercomprehensiveincomemember gaap noncontrollinginterestmember gaap accumulatedothercomprehensiveincomemember gaap gaap noncontrollinginterestmember gaap commonstockmember gaap accumulatedothercomprehensiveincomemember gaap accumulatedothercomprehensiveincomemember gaap accumulatedothercomprehensiveincomemember gaap accumulatedothercomprehensiveincomemember gaap retainedearningsmember gaap commonstockmember gaap additionalpaidincapitalmember gaap noncontrollinginterestmember gaap retainedearningsmember gaap retainedearningsmember gaap commonstockmember gaap commonstockmember gaap noncontrollinginterestmember gaap noncontrollinginterestmember gaap gaap retainedearningsmember gaap additionalpaidincapitalmember gaap retainedearningsmember gaap gaap retainedearningsmember gaap gaap accumulatedothercomprehensiveincomemember srt minimummember gaap machineryandequipmentmember srt maximummember gaap buildingandbuildingimprovementsmember srt maximummember gaap machineryandequipmentmember srt minimummember gaap computerequipmentmember srt maximummember gaap computerequipmentmember gild changeinestimatevariableconsiderationmember gild revenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertymember gild changeinestimatevariableconsiderationmember gild revenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertymember srt europemember gild otherproductsvemlidymember srt europemember gild otherproductsvireadmember gild otherinternationalmember gild hcvproductsvosevimember country gild otherproductszydeligmember gild otherinternationalmember gild hivproductsodefseymember srt europemember gild otherproductsambisomemember srt europemember gild hivproductscompleraevipleramember srt europemember gild royaltycontractandothermember srt europemember gild hivproductsdescovymember country gild royaltycontractandothermember srt europemember gild hivproductsgenvoyamember country gild hivproductstruvadamember country gild productsrevenuesharesymtuzamember srt europemember gild hivproductsbiktarvymember country gild otherproductsyescartamember country srt europemember gaap productmember country gild hivproductsgenvoyamember gild otherproductsranexamember gild otherproductsambisomemember country gild hivproductsatriplamember gild otherinternationalmember gild productsrevenuesharesymtuzamember gild otherinternationalmember gild hcvproductssofosbuvirvelpatasvirmember srt europemember gild otherproductsvireadmember srt europemember gild otherproductsvireadmember gaap productmember gild otherinternationalmember gild hcvproductssofosbuvirvelpatasvirmember srt europemember gild otherproductsyescartamember country gild otherproductsyescartamember gild royaltycontractandothermember gild otherinternationalmember gild otherproductsambisomemember gild hcvproductsvosevimember srt europemember gild otherproductsyescartamember srt europemember gild hivproductsbiktarvymember gild otherinternationalmember gild productsrevenuesharesymtuzamember gaap productmember gild otherinternationalmember gild hcvproductsledipasvirsofosbuvirmember gild otherproductsambisomemember srt europemember gild hcvproductsvosevimember country gild otherproductsyescartamember gild otherinternationalmember gild otherproductsvireadmember country gild hivproductsodefseymember gild otherproductszydeligmember srt europemember gild otherproductsranexamember country gild otherproductsyescartamember srt europemember gild hivproductsstribildmember srt europemember gild hivproductscompleraevipleramember gild otherinternationalmember gild hivproductsbiktarvymember gild otherproductszydeligmember gild otherproductszydeligmember gild otherinternationalmember gild hcvproductsvosevimember gild productsotherhivmember gild hivproductsstribildmember country gild otherproductsothermember country gild hivproductsgenvoyamember srt europemember gild royaltycontractandothermember gild otherinternationalmember gild royaltycontractandothermember country gild productsotherhivmember gild otherinternationalmember gild otherproductszydeligmember country gild hivproductsgenvoyamember gild otherproductsyescartamember gild productsrevenuesharesymtuzamember gild otherinternationalmember gild otherproductsletairismember gild otherproductsothermember gild hcvproductsvosevimember gild otherproductsambisomemember gild otherproductsambisomemember country gild productsotherhivmember gild otherinternationalmember gild otherproductszydeligmember srt europemember srt europemember gild otherproductsothermember gild hivproductsdescovymember country gild hivproductsstribildmember country gild hivproductsodefseymember gild hcvproductssofosbuvirvelpatasvirmember gild productsrevenuesharesymtuzamember srt europemember gild hivproductstruvadamember gild otherproductsvemlidymember gild otherproductsambisomemember gild otherinternationalmember gild hcvproductssofosbuvirvelpatasvirmember gild otherinternationalmember gild hivproductsstribildmember gild otherproductsvireadmember gild otherinternationalmember gild hcvproductsvosevimember srt europemember gild hcvproductssofosbuvirvelpatasvirmember country gild otherproductsothermember gild otherinternationalmember gild otherproductsranexamember srt europemember gild hivproductstruvadamember country gild otherproductsambisomemember country gild royaltycontractandothermember country gild otherproductsothermember srt europemember gild hcvproductsledipasvirsofosbuvirmember country gild otherproductsothermember srt europemember gild otherproductsvemlidymember country gild hivproductstruvadamember gild otherinternationalmember gild hivproductsstribildmember gild otherinternationalmember gild otherproductsothermember gild otherinternationalmember gild otherproductsyescartamember srt europemember gild otherproductsvemlidymember gild hivproductstruvadamember gild otherinternationalmember gild hivproductstruvadamember gild hivproductsatriplamember srt europemember gild otherproductsvireadmember srt europemember gild productsrevenuesharesymtuzamember srt europemember gild otherproductsvemlidymember srt europemember gild otherproductsletairismember srt europemember gild hivproductscompleraevipleramember srt europemember gaap productmember country gild hivproductscompleraevipleramember gild otherinternationalmember gild hivproductsstribildmember gild hcvproductssofosbuvirvelpatasvirmember srt europemember country gild hivproductsstribildmember country gild hcvproductsledipasvirsofosbuvirmember country gild hcvproductsledipasvirsofosbuvirmember srt europemember country gild hivproductsatriplamember gild otherproductsyescartamember gild otherinternationalmember gild hivproductsstribildmember gild otherinternationalmember gild hivproductsdescovymember srt europemember gild otherproductsothermember gild otherinternationalmember gild otherproductsyescartamember country gild otherproductszydeligmember gild hivproductstruvadamember srt europemember gild hcvproductsvosevimember gild hivproductsatriplamember gild otherproductsranexamember country gild otherproductsranexamember srt europemember gild otherproductsambisomemember gild otherinternationalmember gild otherproductsvemlidymember gild otherinternationalmember gild hivproductsgenvoyamember srt europemember gild hcvproductssofosbuvirvelpatasvirmember gild otherinternationalmember gild hivproductstruvadamember country gild hivproductsatriplamember gild hivproductsodefseymember country gild hivproductsodefseymember gild otherinternationalmember gild hivproductsstribildmember gild hcvproductssofosbuvirvelpatasvirmember country gild hivproductsgenvoyamember gaap productmember srt europemember gild otherproductsothermember country gild hivproductsatriplamember country gild hivproductscompleraevipleramember country gild hivproductsdescovymember gild otherproductsranexamember country gild hivproductscompleraevipleramember gild otherproductszydeligmember srt europemember gild otherproductsranexamember gild productsrevenuesharesymtuzamember country gild productsrevenuesharesymtuzamember gild otherinternationalmember gild hcvproductsvosevimember country gild hivproductscompleraevipleramember gild otherinternationalmember gild otherproductsambisomemember gild otherinternationalmember gild hivproductsgenvoyamember gild otherinternationalmember gild otherproductsranexamember gaap productmember srt europemember gild hivproductsgenvoyamember gild otherinternationalmember gild otherproductsranexamember gild otherinternationalmember gild hivproductsbiktarvymember srt europemember gild hcvproductsledipasvirsofosbuvirmember srt europemember gild otherproductszydeligmember gild otherinternationalmember gild hivproductsgenvoyamember srt europemember gild otherproductsambisomemember srt europemember gild hivproductsbiktarvymember srt europemember gild productsotherhivmember srt europemember gild otherproductsvireadmember gild otherinternationalmember gild hivproductsatriplamember gild otherinternationalmember gild otherproductsothermember srt europemember gild otherproductsletairismember gild otherinternationalmember gild hivproductsatriplamember country gild hivproductsdescovymember srt europemember gild hivproductscompleraevipleramember gild hivproductsodefseymember country gild hcvproductssofosbuvirvelpatasvirmember gild otherinternationalmember gild hcvproductsvosevimember gild otherinternationalmember gild hivproductsodefseymember srt europemember gild productsrevenuesharesymtuzamember country gild hivproductsodefseymember gild otherinternationalmember gild hcvproductssofosbuvirvelpatasvirmember gild otherproductsranexamember gild otherinternationalmember gild hivproductstruvadamember gild hivproductsodefseymember gild otherinternationalmember gild hivproductscompleraevipleramember gild hivproductsbiktarvymember srt europemember gild otherinternationalmember gild productsotherhivmember gild otherinternationalmember gild hivproductscompleraevipleramember country gild hivproductsbiktarvymember country gild productsotherhivmember country gild productsotherhivmember srt europemember gild productsrevenuesharesymtuzamember gild hivproductstruvadamember srt europemember gild hivproductsdescovymember gild otherinternationalmember gild otherproductsletairismember gild otherinternationalmember gild hivproductsgenvoyamember country gild otherproductsletairismember country gild hcvproductsledipasvirsofosbuvirmember gaap productmember country gild hivproductsodefseymember gild hcvproductsledipasvirsofosbuvirmember gild otherinternationalmember gild otherproductsletairismember gild otherproductsletairismember gild hivproductsdescovymember gild hcvproductsledipasvirsofosbuvirmember srt europemember gild otherproductsvireadmember gild hivproductsstribildmember gild otherinternationalmember gild royaltycontractandothermember country gild productsotherhivmember srt europemember gild productsotherhivmember gild otherproductsothermember country gild otherproductsvireadmember srt europemember gild hivproductscompleraevipleramember srt europemember gild royaltycontractandothermember srt europemember gild hcvproductssofosbuvirvelpatasvirmember gild otherproductsvemlidymember country gild otherproductsletairismember gild otherinternationalmember gild productsotherhivmember country gild hivproductsdescovymember gild otherinternationalmember gild hcvproductsvosevimember srt europemember gild hivproductsdescovymember country gild hcvproductsledipasvirsofosbuvirmember gild otherinternationalmember gild hcvproductsvosevimember gild otherinternationalmember gild hivproductsbiktarvymember gild hivproductsdescovymember gild hcvproductsvosevimember gild otherinternationalmember gild hivproductsodefseymember country gild otherproductszydeligmember country gild otherproductsletairismember srt europemember gild otherproductsvireadmember country gild otherproductsyescartamember gild otherinternationalmember gaap productmember gild otherinternationalmember gild hivproductsbiktarvymember gaap productmember srt europemember gild otherproductsvireadmember country gild hivproductsatriplamember gild otherinternationalmember gild otherinternationalmember gild productsrevenuesharesymtuzamember country gild otherproductsyescartamember gild hcvproductsledipasvirsofosbuvirmember gild otherinternationalmember gild hivproductsstribildmember srt europemember gild otherproductsletairismember srt europemember gild productsrevenuesharesymtuzamember gild hivproductsgenvoyamember country gild hivproductsbiktarvymember country gild hivproductsodefseymember srt europemember gild hivproductstruvadamember srt europemember gild hivproductsbiktarvymember gild otherinternationalmember gild otherproductsvemlidymember gild otherproductsothermember gild otherproductsletairismember country gild productsotherhivmember gild otherinternationalmember gild hivproductstruvadamember gild otherinternationalmember gild otherproductsranexamember gild otherinternationalmember gild hcvproductsledipasvirsofosbuvirmember gild hcvproductssofosbuvirvelpatasvirmember country gild otherproductsvemlidymember gild otherinternationalmember gild hivproductsgenvoyamember gild otherinternationalmember gild hcvproductsledipasvirsofosbuvirmember country gild otherproductszydeligmember country gild hivproductsstribildmember srt europemember gild hivproductsdescovymember srt europemember gild productsotherhivmember country gild otherproductsranexamember srt europemember gild otherproductsvemlidymember srt europemember country gild hivproductscompleraevipleramember country gild otherproductsvireadmember gild otherproductszydeligmember gild otherproductsvemlidymember country gild hivproductsatriplamember srt europemember gild otherproductsletairismember country gild royaltycontractandothermember gild otherinternationalmember gild hivproductsatriplamember country gild hivproductsatriplamember srt europemember gild hivproductsdescovymember gild otherinternationalmember gild otherproductsvemlidymember gild otherinternationalmember gild otherproductsambisomemember gild hivproductsbiktarvymember gild otherinternationalmember gaap othernoncurrentassetsmember gild equityinvestmentingalapagosmember gild equityinvestmentingalapagosmember gaap othernoncurrentassetsmember gild equityinvestmentingalapagosmember gild equityinvestmentingalapagosmember gaap prepaidexpensesandothercurrentassetsmember gild equityinvestmentingalapagosmember gaap prepaidexpensesandothercurrentassetsmember gild equityinvestmentingalapagosmember gild foreigncurrencyderivativecontractsmember gaap gaap fairvaluemeasurementsrecurringmember gild foreigncurrencyderivativecontractsmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap certificatesofdepositmember gaap gaap fairvaluemeasurementsrecurringmember gild foreigncurrencyderivativecontractsmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap moneymarketfundsmember gaap gaap fairvaluemeasurementsrecurringmember gild deferredcompensationplanmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gild equityinvestmentingalapagosmember gaap gaap fairvaluemeasurementsrecurringmember gild residentialmortgageandassetbackedsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gild foreigncurrencyderivativecontractsmember gaap gaap fairvaluemeasurementsrecurringmember gild deferredcompensationplanmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gild residentialmortgageandassetbackedsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap ustreasurysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gild residentialmortgageandassetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gild foreigncurrencyderivativecontractsmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gild deferredcompensationplanmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap ustreasurysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap moneymarketfundsmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap ustreasurysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap certificatesofdepositmember gaap gaap fairvaluemeasurementsrecurringmember gaap ustreasurysecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gaap ustreasurysecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gild equityinvestmentingalapagosmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gild equityinvestmentingalapagosmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap ustreasurysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap certificatesofdepositmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gild residentialmortgageandassetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap certificatesofdepositmember gaap gaap fairvaluemeasurementsrecurringmember gild deferredcompensationplanmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap certificatesofdepositmember gaap gaap fairvaluemeasurementsrecurringmember gild deferredcompensationplanmember gaap gaap fairvaluemeasurementsrecurringmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gild residentialmortgageandassetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap moneymarketfundsmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gild foreigncurrencyderivativecontractsmember gaap gaap fairvaluemeasurementsrecurringmember gild equityinvestmentingalapagosmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap moneymarketfundsmember gaap gaap fairvaluemeasurementsrecurringmember gild equityinvestmentingalapagosmember gaap gaap fairvaluemeasurementsrecurringmember gaap moneymarketfundsmember gaap gaap fairvaluemeasurementsrecurringmember gaap ustreasurysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gild deferredcompensationplanmember gaap gaap fairvaluemeasurementsrecurringmember gild foreigncurrencyderivativecontractsmember gaap gaap fairvaluemeasurementsrecurringmember gild equityinvestmentingalapagosmember gaap gaap fairvaluemeasurementsrecurringmember gild deferredcompensationplanmember gaap gaap fairvaluemeasurementsrecurringmember gaap certificatesofdepositmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gild deferredcompensationplanmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap moneymarketfundsmember gaap gaap fairvaluemeasurementsrecurringmember gild equityinvestmentingalapagosmember gaap gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gild residentialmortgageandassetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap certificatesofdepositmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gild equityinvestmentingalapagosmember gaap gaap fairvaluemeasurementsrecurringmember gaap ustreasurysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap gaap fairvaluemeasurementsrecurringmember gild foreigncurrencyderivativecontractsmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap usgovernmentagenciesdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap moneymarketfundsmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gild residentialmortgageandassetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap moneymarketfundsmember gaap gaap fairvaluemeasurementsrecurringmember gaap certificatesofdepositmember gaap gaap fairvaluemeasurementsrecurringmember gild residentialmortgageandassetbackedsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap foreigngovernmentdebtsecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap equitysecuritiesmember gaap estimateoffairvaluefairvaluedisclosuremember gaap fairvaluemeasurementsrecurringmember gaap corporatedebtsecuritiesmember gaap gaap fairvaluemeasurementsrecurringmember gaap othernoncurrentassetsmember gaap prepaidexpensesandothercurrentassetsmember gaap cashandcashequivalentsmember gaap prepaidexpensesandothercurrentassetsmember gaap othernoncurrentassetsmember gaap cashandcashequivalentsmember gaap gaap carryingreportedamountfairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember gild gaap gaap carryingreportedamountfairvaluedisclosuremember gaap gaap estimateoffairvaluefairvaluedisclosuremember gaap usgovernmentagenciesdebtsecuritiesmember gild residentialmortgageandassetbackedsecuritiesmember gaap corporatedebtsecuritiesmember gaap foreigngovernmentdebtsecuritiesmember gaap corporatedebtsecuritiesmember gaap ustreasurysecuritiesmember gild marketablesecuritiesnoncurrentmember gild marketablesecuritiescurrentmember gild marketablesecuritiesnoncurrentmember gild marketablesecuritiescurrentmember gaap certificatesofdepositmember gaap usgovernmentagenciesdebtsecuritiesmember gaap certificatesofdepositmember gaap foreigngovernmentdebtsecuritiesmember gaap ustreasurysecuritiesmember gild residentialmortgageandassetbackedsecuritiesmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap nondesignatedmember gaap othercurrentassetsmember gaap nondesignatedmember gaap othernoncurrentliabilitiesmember gaap designatedashedginginstrumentmember gaap othercurrentassetsmember gaap designatedashedginginstrumentmember gaap nondesignatedmember gaap othercurrentliabilitiesmember gaap designatedashedginginstrumentmember gaap othernoncurrentassetsmember gaap designatedashedginginstrumentmember gaap nondesignatedmember gaap othercurrentassetsmember gaap designatedashedginginstrumentmember gaap othernoncurrentassetsmember gaap designatedashedginginstrumentmember gaap othercurrentassetsmember gaap nondesignatedmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap designatedashedginginstrumentmember gaap othernoncurrentliabilitiesmember gaap designatedashedginginstrumentmember gaap othercurrentliabilitiesmember gaap nondesignatedmember srt maximummember gild celldesignlabsinc member gild intangibleassetdaiichisankyomember gild intangibleassetaxicabtageneciloleuceldlbclmember gild celldesignlabsinc member gild celldesignlabsinc member gild paymentstovestedequityawardholdersmember gild paymentstooutstandingcommonstockholdersmember gild kitepharmaincmember gild sharebasedcompensationexpensemember gild paymentstowarrantholdersmember gaap assetstotalmember gaap assetstotalmember gild inventorywritedownsforexcessrawmaterialsmember gild inventorywritedownsforexcessrawmaterialsmember gaap costofsalesmember gaap costofsalesmember gaap costofsalesmember gild axicabtageneciloleuceldlbclmember gild intangibleassetsofosbuvirmember gild intangibleassetsofosbuvirmember gaap inprocessresearchanddevelopmentmember gild indefinitelivedintangibleassetsiprdmember gild ranexamember gaap otherintangibleassetsmember gild ranexamember gaap inprocessresearchanddevelopmentmember gild axicabtageneciloleuceldlbclmember gild intangibleassetsofosbuvirmember gaap otherintangibleassetsmember gild indefinitelivedintangibleassetsiprdmember gaap otherintangibleassetsmember gaap otherintangibleassetsmember gild intangibleassetsofosbuvirmember gild axicabtageneciloleuceldlbclmember gild axicabtageneciloleuceldlbclmember gild ranexamember gild ranexamember gild galapagosmember gild galapagosmember gild othercollaborationarrangementsmember gild janssenpharmaceuticalsmember gild bristolmyerssquibbmember gild galapagosmember gild japantobaccomember gild galapagosmember gild gadetamember gild japantobaccomember gild galapagosmember gild japantobaccomember gild othercollaborationarrangementsmember gild japantobaccomember gild galapagosmember gild upfrontcollaborationandlicensingexpensemember gild japantobaccomember gild janssenpharmaceuticalsmember gild gadetamember gild janssenpharmaceuticalsmember gild janssenpharmaceuticalsmember gild bristolmyerssquibbmember gild othercollaborationarrangementsmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gaap subsequenteventmember gild gaap seniornotesmember gild termloanfacilitiesmember gild gaap unsecureddebtmember gild termloanfacilitiesmember gild gaap unsecureddebtmember gaap seniornotesmember gaap seniornotesmember gild gaap seniornotesmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gaap unsecureddebtmember gild gild gild gaap londoninterbankofferedratelibormember gild gaap londoninterbankofferedratelibormember gild activepharmaceuticalingredientmember gild indenixmember gild junomember gild activepharmaceuticalingredientmember gild indenixmember gild junomember gild activepharmaceuticalingredientmember gild junomember srt minimummember gild junomember srt maximummember gild activepharmaceuticalingredientmember gild gaap subsequenteventmember gild gaap subsequenteventmember gild gaap subsequenteventmember gild gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatedtranslationadjustmentmember gaap accumulatednetgainlossfromdesignatedorqualifyingcashflowhedgesmember gaap accumulatednetgainlossfromdesignatedorqualifyingcashflowhedgesmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatednetgainlossfromdesignatedorqualifyingcashflowhedgesmember gaap accumulatednetgainlossfromdesignatedorqualifyingcashflowhedgesmember gaap accumulatedtranslationadjustmentmember gaap accumulatednetgainlossfromdesignatedorqualifyingcashflowhedgesmember gaap accumulatedothercomprehensiveincomemember gaap accumulatedtranslationadjustmentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatedtranslationadjustmentmember gaap accumulatedtranslationadjustmentmember gaap accumulatednetunrealizedinvestmentgainlossmember gaap accumulatedtranslationadjustmentmember gaap accumulatednetgainlossfromdesignatedorqualifyingcashflowhedgesmember gild publiclyannouncedprogrammember gild publiclyannouncedprogrammember gild publiclyannouncedprogrammember gaap commonstockincludingadditionalpaidincapitalmember gaap commonstockincludingadditionalpaidincapitalmember gaap commonstockincludingadditionalpaidincapitalmember gaap restrictedstockunitsrsumember gaap performancesharesmember gaap performancesharesmember gaap restrictedstockunitsrsumember gaap restrictedstockunitsrsumember gaap performancesharesmember gild gaap commonstockmember srt minimummember gaap performancesharesmember gild fairvalueatvestingdatemember gild restrictedstockandperformanceshareawardsmember gild fairvalueatgrantdatemember gild restrictedstockandperformanceshareawardsmember gaap employeestockoptionmember gild fairvalueatvestingdatemember gild restrictedstockandperformanceshareawardsmember gaap employeestockoptionmember srt maximummember gaap restrictedstockunitsrsumember gild fairvalueatvestingdatemember gild restrictedstockandperformanceshareawardsmember gaap restrictedstockunitsrsumember gaap employeestockmember gild fairvalueatgrantdatemember gild restrictedstockandperformanceshareawardsmember gaap employeestockmember gild fairvalueatgrantdatemember gild restrictedstockandperformanceshareawardsmember srt maximummember gaap employeestockoptionmember gild restrictedstockandperformanceshareawardsmember gaap restrictedstockunitsrsumember gaap performancesharesmember srt maximummember gaap performancesharesmember gaap employeestockoptionmember gaap employeestockoptionmember gild restrictedstockandperformanceshareawardsmember gaap performancesharesmember gaap employeestockmember gaap employeestockmember gaap employeestockoptionmember gaap sellinggeneralandadministrativeexpensesmember gaap researchanddevelopmentexpensemember gaap researchanddevelopmentexpensemember gaap sellinggeneralandadministrativeexpensesmember gaap sellinggeneralandadministrativeexpensesmember gaap researchanddevelopmentexpensemember srt minimummember gaap restrictedstockunitsrsumember srt minimummember gaap employeestockoptionmember gaap nonusmember country country gaap nonusmember country gaap nonusmember srt minimummember gild cardinalhealthincmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild amerisourcebergencorpmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild mckessoncorpmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild cardinalhealthincmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild amerisourcebergencorpmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild mckessoncorpmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild amerisourcebergencorpmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild cardinalhealthincmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild mckessoncorpmember gaap salesrevenuenetmember gaap customerconcentrationriskmember gild intangibleassettransfermember gild intangibleassettransfermember gaap stateandlocaljurisdictionmember gild gild intangibleassettransfermember gild intangibleassettransfermember gaap domesticcountrymember gild intangibleassettransfermember gild favorableepsimpactmember gild unfavorableepsimpactmember gild inventorywritedownsforexcessrawmaterialsmember gild upfrontcollaborationandlicensingexpensemember gild inventorywritedownsforexcessrawmaterialsmember gaap valuationallowanceofdeferredtaxassetsmember gaap allowanceforcreditlossmember gaap allowanceforcreditlossmember gaap allowanceforcreditlossmember gild allowanceforcontractwithcustomermember gild allowanceforcontractwithcustomermember gaap valuationallowanceofdeferredtaxassetsmember gaap allowanceforcreditlossmember gaap valuationallowanceofdeferredtaxassetsmember gild allowanceforcontractwithcustomermember gild allowanceforcontractwithcustomermember gaap valuationallowanceofdeferredtaxassetsmember gild allowanceforcontractwithcustomermember gild allowanceforcontractwithcustomermember gaap allowanceforcreditlossmember gaap valuationallowanceofdeferredtaxassetsmember gaap allowanceforcreditlossmember gaap valuationallowanceofdeferredtaxassetsmember gild allowanceforcontractwithcustomermember gaap allowanceforcreditlossmember gaap valuationallowanceofdeferredtaxassetsmember usd xbrli share xbrli share usd gild security xbrli pure eur xbrli share eur united state security and exchange commission washington form mark one annual report pursuant to section or of the security exchange act of the fiscal year ended december or transition report pursuant to section or of the security exchange act of the transition period from to commission file no gilead science inc exact name of registrant specified in it charter state or other jurisdiction of incorporation irs employer identification no lakeside drive foster city california address of principal executive office zip code registrant telephone number including area code security registered pursuant to section of the act title of each class trading symbol name of each exchange on which registeredcommon stock par value per share gild the nasdaq global select marketindicate by check mark if the registrant is well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or section of the act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the security exchange act of the preceding month or for shorter period that the registrant required to file such report and ha been subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of this chapter during the preceding month or for such shorter period that the registrant wa required to submit and post such file yes no indicate by check mark whether registrant is large accelerated filer an accelerated filer non accelerated filer or smaller reporting company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no the aggregate market value of the voting and non voting common equity held by non affiliate of the registrant based upon the closing price of it common stock on the nasdaq global select market on june wa billion the number of share outstanding of the registrant common stock on february wa document incorporated by reference specified portion of the registrant proxy statement which will be filed with the commission pursuant to regulation in connection with the registrant annual meeting of stockholder to be held on may are incorporated by reference into part iii of this report based on closing price of per share on june excludes share of the registrant common stock held by executive officer director and any stockholder whose ownership exceeds of registrant common stock outstanding at june exclusion of such share not be construed to indicate that any such person posse the power direct or indirect to direct or cause the direction of the management or policy of the registrant or that such person is controlled by or common control with the registrant gilead science inc form annual reporttable of contentspart item staff safety part ii item for registrant common equity related stockholder matter and issuer purchase of equity financial discussion and analysis of financial condition and result of and qualitative disclosure about market statement and supplementary in and disagreement with accountant on accounting and financial and part iii item executive officer and corporate ownership of certain beneficial owner and management and related stockholder relationship and related transaction and director accountant fee and part iv item and financial statement or have right to various trademark copyright and trade name used in business including the following gilead gilead science ambisome atripla biktarvy cayston complera descovy descovy for prep emtriva epclusa eviplera genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada for prep tybost vemlidy viread vosevi yescarta and zydelig lexiscan is registered trademark of astellas llc macugen is registered trademark of bausch health ireland limited symtuza is registered trademark of janssen science ireland uc tamiflu is registered trademark of hoffmann la roche inc this report also refers to trademark service mark and trade name of other company this annual report on form including the section entitled management discussion and analysis of financial condition and result of operation contains forward looking statement regarding future event and our future result that are subject to the safe harbor created under the security act of amended the security act and the security exchange act of amended the exchange act word such expect anticipate target goal project hope intend plan believe seek estimate continue may could should might forecast variation of such word and similar expression are intended to identify such forward looking statement in addition any statement other statement of historical fact are forward looking statement including statement regarding overall trend operating cost and revenue trend liquidity and capital need and other statement of expectation belief future plan and strategy anticipated event or trend and similar expression have based these forward looking statement on our current expectation about future event these statement are not guarantee of future performance and involve risk uncertainty and assumption that are difficult to predict our actual result may differ materially from those suggested by these forward looking statement for various reason including those identified in part item of this annual report on form under the heading risk factor given these risk and uncertainty you are cautioned not to place undue reliance on forward looking statement the forward looking statement included in this report are made only of the date hereof except required under federal security law and the rule and regulation of the security and exchange commission sec we not undertake and specifically decline any obligation to update any of these statement or to publicly announce the result of any revision to any forward looking statement the distribution of this report whether result of new information future event change in assumption or otherwise item businessgilead science inc gilead we our or incorporated in delaware on june is research based biopharmaceutical company that discovers develops and commercializes innovative medicine in area of unmet medical need with each new discovery and investigational drug candidate we strive to transform and simplify care for people with life threatening illness around the world we have operation in more than country worldwide with headquarters in foster city california gilead primary area of focus include viral disease inflammatory and fibrotic disease and oncology we seek to add to our existing portfolio of product through our internal discovery and clinical development program product acquisition in licensing and strategic collaboration our principal productsour innovative medicine represent advancement by offering enhanced mode of delivery more convenient treatment regimen improved resistance profile reduced side effect and greater efficacy our focus on innovation ha allowed to deliver more than marketed product across multiple therapeutic area our principal product and the approved indication in the united state are follows hiv aid biktarvy is an oral formulation dosed once day for the treatment of hiv infection in certain patient biktarvy is single tablet regimen of fixed dose combination of our antiretroviral medication bictegravir emtricitabine and tenofovir alafenamide taf descovy is an oral formulation indicated in combination with other antiretroviral agent for the treatment of hiv infection in certain patient descovy is fixed dose combination of our antiretroviral medication emtricitabine and taf descovy is also approved by food and drug administration fda for pre exposure prophylaxis prep indication to reduce the risk of sexually acquired hiv infection in certain at risk patient odefsey is an oral formulation dosed once day for the treatment of hiv infection in certain patient odefsey is single tablet regimen of fixed dose combination of our antiretroviral medication emtricitabine and taf and rilpivirine marketed by janssen science ireland uc one of the janssen pharmaceutical company of johnson johnson janssen genvoya is an oral formulation dosed once day for the treatment of hiv infection in certain patient genvoya is single tablet regimen of fixed dose combination of our antiretroviral medicine elvitegravir cobicistat emtricitabine and taf stribild is an oral formulation dosed once day for the treatment of hiv infection in certain patient stribild is single tablet regimen of fixed dose combination of our antiretroviral medication elvitegravir cobicistat tenofovir disoproxil fumarate tdf and emtricitabine complera eviplera is an oral formulation dosed once day for the treatment of hiv infection in certain patient the product marketed in the united state complera and in europe eviplera is single tablet regimen of fixed dose combination of our antiretroviral medication tdf and emtricitabine and janssen rilpivirine hydrochloride atripla is an oral formulation indicated complete regimen for the treatment of hiv infection in certain patient atripla is fixed dose combination of our antiretroviral medication tdf and emtricitabine and bristol myers squibb company bm efavirenz truvada is an oral formulation indicated in combination with other antiretroviral agent for the treatment of hiv infection in certain patient it is fixed dose combination of our antiretroviral medication tdf and emtricitabine truvada is also approved by fda for prep indication in combination with safer sex practice to reduce the risk of sexually acquired hiv infection in certain at risk patient liver disease vosevi is an oral formulation of once daily single tablet regimen of sofosbuvir velpatasvir and voxilaprevir for the treatment of chronic hepatitis virus hcv infection in adult with genotype or previously treated with an inhibitor containing regimen or ii with genotype or previously treated with sofosbuvir containing regimen without an inhibitor epclusa is an oral formulation of once daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hcv infection in adult with genotype or without cirrhosis or with compensated cirrhosis or ii with decompensated cirrhosis for use in combination with ribavirin harvoni is an oral formulation of once daily single tablet regimen of ledipasvir and sofosbuvir for the treatment of chronic hcv infection in adult with genotype or without cirrhosis or with compensated cirrhosis ii adult with genotype infection with decompensated cirrhosis in combination with ribavirin iii adult with genotype or are liver transplant recipient without cirrhosis or with compensated cirrhosis in combination with ribavirin or iv certain pediatric patient with genotype or without cirrhosis or with compensated cirrhosis vemlidy is an oral formulation of taf dosed once day for the treatment of chronic hepatitis virus hbv infection in adult with compensated liver disease viread is an oral formulation of tdf dosed once day for the treatment of chronic hbv infection in adult and certain pediatric patient hematology oncology yescarta axicabtagene ciloleucel is chimeric antigen receptor car cell therapy for the treatment of adult patient with relapsed or refractory large cell lymphoma after two or more line of systemic therapy including diffuse large cell lymphoma dlbcl not otherwise specified primary mediastinal large cell lymphoma high grade cell lymphoma and dlbcl arising from follicular lymphoma zydelig idelalisib is an oral formulation of kinase inhibitor for the treatment of patient with relapsed chronic lymphocytic leukemia cll in combination with rituximab for rituximab alone would be considered appropriate therapy due to other co morbidity ii relapsed follicular cell non hodgkin lymphoma fl in patient have received at least two prior systemic therapy or iii relapsed small lymphocytic lymphoma who have received at least two prior systemic therapy other letairis ambrisentan is an oral formulation of an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension pah who group to improve exercise capacity and delay clinical worsening or ii in combination with tadalafil to reduce the risk of disease progression and hospitalization for worsening pah and to improve exercise ability ranexa ranolazine is an oral formulation of an extended release tablet of an antianginal for the treatment of chronic angina ambisome amphotericin liposome for injection is proprietary liposomal formulation of amphotericin an antifungal agent for the treatment of serious invasive fungal infection caused by various fungal specie in adult for information about our product revenue including the amount of revenue contributed by each of the product listed for each of the last three fiscal year see note revenue of the note to consolidated financial statement included in part ii item of this annual report on form commercialization and distributionwe have and international commercial sale operation with marketing subsidiary in more than country our product are marketed through our commercial team and or in conjunction with third party distributor and corporate partner our commercial team promote our product through direct field contact with physician hospital clinic and other healthcare provider we generally grant our third party distributor the exclusive right to promote our product in territory for specified period of time of our agreement with these distributor provide for collaborative effort the distributor and gilead in obtaining and maintaining regulatory approval for the product in the specified territory we sell and distribute most of our product in the united state exclusively through the wholesale channel our product sale to three large wholesaler amerisourcebergen corporation cardinal health inc and mckesson corporation each accounted for more than of total revenue for each of the year ended december and on combined basis in these wholesaler accounted for approximately of our product sale in the united state and approximately of our total worldwide revenue we sell and distribute our product in europe and country outside the united state the product is approved either through our commercial team third party distributor or corporate partner competitionwe operate in highly competitive environment we face significant competition from global pharmaceutical and biotechnology company specialized pharmaceutical firm and generic drug manufacturer our product compete with other commercially available product based primarily on efficacy safety tolerability acceptance by doctor ease of patient compliance ease of use price insurance and other reimbursement coverage distribution and marketing our product mature private insurer and government payer often reduce the amount they will reimburse patient which increase pressure on to reduce price further new branded or generic product are introduced into major market our ability to maintain pricing and market share may be affected for description of our competitor see item risk factor we face significant competition and developmentour research and development philosophy and strategy are to develop best in class drug that improve safety or efficacy for unmet medical need we intend to continue committing significant resource to internal opportunity and external business development activity our product development effort are focused primarily in viral disease inflammatory and fibrotic disease and oncology we have research scientist engaged in the discovery and development of new molecule and technology that we hope will lead to the approval of new medicine that will advance the current standard of care and address unmet medical need the development of our product candidate is subject to various risk and uncertainty these risk and uncertainty include our ability to enroll patient in clinical trial the possibility of unfavorable result of our clinical trial the need to modify or delay our clinical trial or to perform additional trial and the risk of failing to obtain regulatory approval result our product candidate may never be successfully commercialized drug development is inherently risky and many product candidate fail during the drug development process in we continued to invest in and advance our pipeline across our therapeutic area at the end of our pipeline included active clinical study of which phase clinical trial below is summary of our key product candidate and corresponding current stage of development product candidate in viral diseasesproduct candidate descriptionphase capsid inhibitor is evaluated for the treatment of hiv infection selgantolimod selgantolimod tlr agonist is being evaluated for the treatment of chronic hbv infection phase vesatolimod vesatolimod tlr agonist is being evaluated potential cure for hiv infection elipovimab elipovimab broadly neutralizing antibody is being evaluated potential cure for hiv infection pd inhibitor is being evaluated for the treatment of chronic hbv infection product candidate in inflammatory and fibrotic diseasesproduct candidate descriptionphase filgotinib filgotinib inhibitor is being evaluated for the treatment of crohn disease ii ulcerative colitis and iii psoriatic arthritis cilofexor cilofexor fxr agonist is being evaluated for the treatment of primary sclerosing cholangitis glpg glpg an autotaxin inhibitor is being evaluated for the treatment of idiopathic pulmonary fibrosis phase filgotinib filgotinib is being evaluated for the treatment of ankylosing spondylitis and ii uveitis inhibitor is being evaluated for the treatment of ulcerative colitis glpg glpg an adamts inhibitor is being evaluated for the treatment of osteoarthritis selonsertib selonsertib an ask inhibitor is being evaluated for the treatment of diabetic kidney disease cilofexor firsocostat and selonsertib combination cilofexor firsocostat an acc inhibitor and selonsertib combination are being evaluated for the treatment of nonalcoholic steatohepatitis nash glpg glpg is being evaluated for the treatment of systemic sclerosis glpg glpg inhibitor is being evaluated for the treatment of idiopathic pulmonary fibrosis phase glpg glpg is being evaluated for the treatment of inflammatory disease glpg glpg is being evaluated for the treatment of inflammatory disease glpg glpg is being evaluated for the treatment of inflammatory disease glpg glpg is being evaluated for the treatment of inflammatory disease candidate in oncologyproduct candidate descriptionphase axicabtagene ciloleucel axicabtagene ciloleucel is being evaluated for the treatment of second line dlbcl phase axicabtagene ciloleucel axicabtagene ciloleucel is being evaluated for the treatment of indolent non hodgkin lymphoma axicabtagene ciloleucel is also being evaluated for the treatment of first line dlbcl and ii dlbcl in combination with either rituximab or lenalidomide kte kte car cell therapy is being evaluated for the treatment of adult and pediatric acute lymphoblastic leukemia and ii cll phase axicabtagene ciloleucel axicabtagene ciloleucel is being evaluated for the treatment of dlbcl in combination with utomilumab kite kite mage is being evaluated for the treatment of solid tumor kite kite an hpv is being evaluated for the treatment of solid tumor bi specific antibody is being evaluated for the treatment of solid tumor an oral pd inhibitor is being evaluated for the treatment of solid tumor bi specific mab is being evaluated for the treatment of multiple indication in oncology an anti mab is being evaluated for the treatment of multiple indication in oncology ______________________________________________________ optionable partner program optioned partner programin addition to our internal discovery and clinical development program we seek to add to our portfolio of product through product acquisition in licensing and strategic collaboration in we completed strategic partnership licensing deal and equity investment which reflects our commitment to developing our pipeline across range of disease to address area of significant unmet medical need and positioning for the long term growth of our business patent and proprietary rightsu and european patent expirationwe have number of and foreign patent patent application and right to patent related to our compound product and technology but we can not be certain that issued patent will be enforceable or provide adequate protection or that pending patent application will result in issued patent the following table show the estimated expiration date including patent term extension supplementary protection certificate and or pediatric exclusivity where granted in the united state and the european union for the primary typically compound patent for our phase product candidate for our product candidate that are fixed dose combination of single tablet regimen the estimated patent expiration date provided corresponds to the latest expiring compound patent for one of the active ingredient in the single tablet regimen phase product candidate patent expiration product candidate in inflammatory and fibrotic disease filgotinib for the treatment of rheumatoid arthritis crohn disease ulcerative colitis and psoriatic arthritis glpg for the treatment of idiopathic pulmonary fibrosis cilofexor for the treatment of primary sclerosing cholangitis product candidate in oncology axicabtagene ciloleucel for the treatment of second line dlbcl __________________________________________ the composition of matter patent ha expired in the european union in the european union and the united state patent application are pending relating to proprietary manufacturing process of kite gilead company the following table show the actual or estimated expiration date including patent term extension supplementary protection certificate and or pediatric exclusivity where granted in the united state and the european union for the primary typically compound patent for our principal product for our product that are fixed dose combination or single tablet regimen estimated patent expiration date provided correspond to the latest expiring compound patent for one of the active ingredient in the single tablet regimen product patent expiration letairis ranexa atripla truvada descovy vemlidy complera eviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi _________________________________________ these estimated expiration date do not include any potential additional exclusivity patent term extension supplementary protection certificate or pediatric exclusivity that ha not yet been granted __________________________________________ in gilead and watson laboratory inc reached an agreement to settle patent litigation matter related to letairis in gilead and lupin limited reached an agreement to settle patent litigation matter related to ranexa in gilead and teva pharmaceutical reached an agreement to settle the patent litigation concerning patent that protect emtricitabine in our truvada and atripla product for additional information see item risk factor we face significant competition supplementary protection certificate spcs have been granted in several european country the validity of these spcs ha been challenged by several generic manufacturer many of whom launched their competing product in an application for patent term extension wa filed in the united state that if granted would extend the expiration date to at least application for patent term extension are pending in the united state and or spcs are pending in one or more country in the european union for these product the composition of matter patent ha expired in the european union in the european union and the united state patent application are pending relating to proprietary manufacturing process of kite patent protection and certain challenge patent and other proprietary right are important to our business if we have properly drafted and enforceable patent it can be more difficult for our competitor to use our technology to create competitive product and more difficult for our competitor to obtain patent that prevents from using technology we create part of our business strategy we actively seek patent protection both in the united state and internationally and file additional patent application when appropriate to cover improvement in our compound product and technology patent covering certain of the active pharmaceutical ingredient api of most of our hiv product well yescarta are held by third party we acquired exclusive right to these patent in the agreement we have with these party we may obtain patent for certain product many year marketing approval is obtained patent have limited life that may begin to run prior to the commercial sale of the related product the commercial value of the patent may be limited however we may be able to apply for patent term extension or supplementary protection certificate in country for example extension for the patent or supplementary protection certificate on many of our product have been granted in the united state and in number of european country compensating in part for delay in obtaining marketing approval similar patent term extension may be available for other product we are developing but we can not be certain we will obtain them in some country it is also important that we do not infringe the valid patent of third party if we infringe the valid patent of third party our reputation may be harmed and we may be required to pay significant monetary damage we may be prevented from commercializing product or we may be required to obtain license from these third party we may not be able to obtain alternative technology or any required license on reasonable term or at all if we fail to obtain these license or alternative technology we may be unable to develop or commercialize some or all of our product for example we are aware of patent and patent owned by other party that such party may claim to cover the use of sofosbuvir axicabtagene ciloleucel and bictegravir because patent application are confidential for period of time patent is issued we may not know if our competitor have filed patent application for technology covered by our pending application or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent application competitor may have filed patent application or received patent and may obtain additional patent and proprietary right that block or compete with our product in addition if competitor file patent application covering our technology we may have to participate in interference derivation proceeding or litigation to determine the right to patent litigation and interference derivation proceeding are unpredictable and expensive such that even if we are ultimately successful our result of operation may be adversely affected by such event patent relating to pharmaceutical biopharmaceutical and biotechnology product compound and process such those that cover our existing compound product and process and those that we will likely file in the future do not always provide complete or adequate protection future litigation or other proceeding regarding the enforcement or validity of our existing patent or any future patent could result in the invalidation of our patent or substantially reduce their protection from time to time certain individual or entity may challenge our patent our pending patent application and the patent application filed by our collaborative partner may not result in the issuance of any patent or may result in patent that do not provide adequate protection result we may not be able to prevent third party from developing compound or product that are closely related to those which we have developed or are developing in addition certain country do not provide effective enforcement of our patent and third party manufacturer may be able to sell generic version of our product in those country for description of our significant pending legal proceeding see note commitment and contingency legal proceeding of the note to consolidated financial statement included in part ii item of this annual report on form trade secretswe also rely on unpatented trade secret and improvement unpatented internal know and technological innovation for example great deal of our liposomal manufacturing expertise which is key component of our liposomal technology is not covered by patent but is instead protected trade secret we protect these right mainly through confidentiality agreement with our corporate partner employee consultant and vendor these agreement provide that all confidential information developed or made known to an individual during the course of their relationship with will be kept confidential and will not be used or disclosed to third party except in specified circumstance in the case of employee the agreement provide that all invention made by an individual employed by will be our exclusive property we can not be certain that these party will comply with these confidentiality agreement that we have adequate remedy for any breach or that our trade secret will not otherwise become known or be independently discovered by our competitor under some of our agreement invention become jointly owned by and our corporate partner and in other case become the exclusive property of one party in certain circumstance it can be difficult to determine who owns particular invention and dispute could arise regarding those invention if our trade secret or confidential information become known or independently discovered by competitor or if we enter into dispute over ownership of invention our business and result of operation could be adversely affected manufacturing and raw materialsour product are manufactured either at our own facility or by third party contract manufacturer we depend on third party to perform manufacturing activity for the majority of our api and drug product for most of our product including our hiv and hcv product we use multiple third party contract manufacturer that we have primary and back supplier and manufacturing site for yescarta we have established clinical and commercial manufacturing facility for cell processing activity for our future product we continue to develop additional manufacturing capability and establish additional third party supplier to manufacture sufficient quantity of our product candidate to undertake clinical trial and to manufacture sufficient quantity of any product that is approved for commercial sale our manufacturing facility we own or lease manufacturing facility to manufacture and distribute certain product and api for clinical and or commercial us these facility are located in foster city san dimas la verne oceanside and el segundo california dublin and cork ireland hoofddorp netherlands and edmonton canada foster city california we conduct process chemistry research and formulation development activity manufacture api and drug product for our clinical trial and oversee our third party contract manufacturer san dimas and la verne california we manufacture ambisome and also package and label the majority of our commercial product for distribution to the america and pacific rim oceanside california we utilize the facility for clinical manufacturing and process development of our biologics candidate el segundo california we utilize the facility for clinical and commercial manufacturing and processing of yescarta cork and dublin ireland we utilize the cork facility for commercial manufacturing packaging and labeling of our product we also perform quality control testing labeling packaging and final release of many of our product for distribution to the european union and other international market the dublin facility is also responsible for distribution activity for our product edmonton canada we conduct process chemistry research and scale up activity for our clinical development candidate manufacture api for both investigational and commercial product and conduct chemical development activity to improve existing commercial manufacturing process hoofddorp netherlands we utilize the facility for commercial manufacturing and processing of yescarta third party manufacturerswe believe the technology we use to manufacture our product is proprietary for product manufactured by our third party contract manufacturer we have disclosed all necessary aspect of this technology to enable them to manufacture the product for we have agreement with these third party manufacturer that are intended to restrict them from using or revealing this technology but we can not be certain that these third party manufacturer will comply with these restriction for more information about our third party manufacturer see item risk factor manufacturing problem including at our third party manufacturer and corporate partner could cause inventory shortage and delay product shipment and regulatory approval which may adversely affect our result of operation regulation of manufacturing processthe manufacturing process for pharmaceutical product is highly regulated and regulator may shut manufacturing facility that they believe do not comply with regulation we our third party manufacturer and our corporate partner are subject to current good manufacturing practice which are extensive regulation governing manufacturing process stability testing record keeping and quality standard defined by fda and the european medicine agency similar regulation are in effect in other jurisdiction our manufacturing operation are subject to routine inspection by regulatory agency for yescarta we are required by fda to comply with the risk evaluation and mitigation strategy program which includes educating and certifying medical personnel regarding the therapy procedure and the potential side effect profile of our therapy such the potential adverse side effect related to cytokine release syndrome and neurologic toxicity additionally we are required to maintain complex chain of identity and custody with respect to patient material such material move to the manufacturing facility through the manufacturing process and back to the patient access to raw material we need access to certain raw material to conduct our clinical trial and manufacture our product these raw material are generally available from multiple source purchased worldwide and normally available in quantity adequate to meet the need of our business we attempt to manage the risk associated with our supply chain by inventory management relationship management and evaluation of alternative source when feasible for more information see item risk factor we may not be able to obtain material or supply necessary to conduct clinical trial or to manufacture and sell our product which could limit our ability to generate revenue seasonality of operation and backlogour worldwide product sale do not reflect any significant degree of seasonality in end user demand in the united state fluctuation in wholesaler inventory level have impacted our product sale we have observed that strong wholesaler and sub wholesaler purchase of our product in the fourth quarter have resulted in inventory draw down by wholesaler and sub wholesaler in the subsequent first quarter several other factor including government budget annual grant cycle for federal and state fund and other buying pattern have impacted the product sale recorded in particular quarter for more information see item risk factor our inability to accurately predict demand for our product and fluctuation in purchasing pattern or wholesaler inventory make it difficult for to accurately forecast sale and may cause our forecasted revenue and earnings to fluctuate which could adversely affect our financial result and stock price for the most part we operate in market characterized by short lead time and the absence of significant backlog we do not believe that backlog information is material to our business whole government regulationour operation and activity are subject to extensive regulation by numerous government authority in the united state the european union and other country including law and regulation governing the testing manufacture safety efficacy labeling storage record keeping approval advertising and promotion of our product result of these regulation product and product approval process are very expensive and time consuming the regulatory requirement applicable to drug development and approval are subject to change any legal and regulatory change may impact our operation in the future country regulatory agency such fda in the united state and european commission for the european union well the national authority of the european union member state must approve drug before it can be sold in the respective country or country the general process for drug approval in the united state is summarized below many other country including country in the european union have similar regulatory structure preclinical testingbefore we can test drug candidate in human we must study the drug in laboratory experiment and in animal to generate data to support the drug candidate potential benefit and safety we submit this data to fda in an investigational new drug ind application seeking it approval to test the compound in human clinical trialsif fda accepts the ind the drug candidate can be studied in human clinical trial to determine if the drug candidate is safe and effective these clinical trial involve three separate phase that often overlap can take many year and are very expensive these three phase which are subject to considerable regulation are follows phase the drug candidate is given to small number of healthy human control subject or patient suffering from the indicated disease to test for safety dose tolerance pharmacokinetics metabolism distribution and excretion phase the drug candidate is given to limited patient population to determine the effect of the drug candidate in treating the disease the best dose of the drug candidate and the possible side effect and safety risk of the drug candidate it is not uncommon for drug candidate that appears promising in phase clinical trial to fail in the more rigorous and extensive phase clinical trial phase if drug candidate appears to be effective and safe in phase clinical trial phase clinical trial are commenced to confirm those result phase clinical trial are conducted over longer term involve significantly larger population are conducted at numerous site in different geographic region and are carefully designed to provide reliable and conclusive data regarding the safety and benefit of drug candidate it is not uncommon for drug candidate that appears promising in phase clinical trial to fail in the more rigorous and extensive phase clinical trial fda approval processwhen we believe that the data from our clinical trial show an acceptable benefit risk profile we submit the appropriate filing usually in the form of new drug application nda or supplemental nda with fda seeking approval to sell the drug candidate for particular use at fda discretion fda may hold public hearing where an independent advisory committee of expert advisor asks additional question and make recommendation regarding the drug candidate this committee make recommendation to fda that is not binding but is generally followed by fda if fda agrees that the compound ha met the required level of safety and efficacy for particular use it will allow to sell the drug candidate in the united state for that use it is not unusual however for fda to reject an application because it belief that the drug candidate is not safe enough or efficacious enough or because it doe not believe that the data submitted is reliable or conclusive at any point in this process the development of drug candidate can be stopped for number of reason including safety concern and lack of treatment benefit we can not be certain that any clinical trial that we are currently conducting or any that we conduct in the future will be completed successfully or within any specified time period we may choose or fda may require to delay or suspend our clinical trial at any time if it appears that patient are being exposed to an unacceptable health risk or if the drug candidate doe not appear to have sufficient treatment benefit fda may also require phase non registrational study to explore scientific question to further characterize safety and efficacy during commercial use of our drug fda may also require to provide additional data or information improve our manufacturing process procedure or facility or may require extensive surveillance to monitor the safety or benefit of our product candidate if it determines that our filing doe not contain adequate evidence of the safety and benefit of the drug in addition even if fda approves drug it could limit the us of the drug fda can withdraw approval if it doe not believe that we are complying with regulatory standard or if concern about the safety or efficacy are uncovered or occur after approval in addition to obtaining fda approval for each drug we obtain fda approval of the manufacturing facility for any drug we sell including those of company who manufacture our drug for all of these facility are subject to periodic inspection by fda fda must also approve foreign establishment that manufacture product to be sold in the united state and these facility are subject to periodic regulatory inspection our manufacturing facility located in california also must be licensed by the state of california in compliance with local regulatory requirement our manufacturing facility in canada ireland and netherlands also must obtain local license and permit in compliance with local regulatory requirement drug that treat serious or life threatening disease and condition that are not adequately addressed by existing drug and for which the development program is designed to address the unmet medical need may be designated fast track candidate by and may be eligible for priority review drug for the treatment of hiv infection that are designated for use under the president emergency plan for aid relief may also qualify for an expedited review european union regulatory system and approval processin the european union eu our product are subject to variety of eu and eu member state regulation governing clinical trial commercial sale and distribution we are required to obtain marketing authorization in the eu before we can market our medicinal product on the relevant market the conduct of clinical trial in the eu is governed by among others directive ec and the eu good clinical practice rule these impose legal and regulatory obligation that are similar to those provided in applicable law the conduct of clinical trial in the eu must be approved by the competent authority of each eu member state in which the clinical trial take place and positive opinion must be obtained from the relevant ethic committee in the relevant member state in the eu legislator adopted regulation eu no to replace directive ec and to introduce coordinated procedure for authorization of clinical trial this regulation is expected to apply in or marketing authorization holder manufacturer importer wholesaler and distributor of medicinal product placed on the market in the eu are required to comply with number of regulatory requirement including pharmacovigilance good manufacturing practice compliance and the requirement to obtain manufacturing import and or distribution license issued by the competent authority of the eu member state failure to comply with these requirement may lead to the imposition of civil criminal or administrative sanction including suspension of marketing or manufacturing authorization pricing and reimbursementsuccessful commercialization of our product depends in part on the availability of governmental and third party payer reimbursement for the cost of such product and related treatment in the market where we sell our product government health authority private health insurer and other organization generally provide reimbursement in the united state the european union and other significant or potentially significant market for our product and product candidate government authority and third party payer are increasingly attempting to limit or regulate the price of medical product and service significant portion of our sale of the majority of our product are subject to substantial discount from their list price result the price increase we implement from time to time on certain product may have limited effect on our product sale in certain market in addition standard reimbursement structure may not adequately reimburse for innovative therapy our product mature private insurer and government payer often reduce the amount they will reimburse provider which increase pressure on to reduce price further new branded or generic product are introduced into major market our ability to maintain pricing and market share may be affected for more information see item risk factor our existing product are subject to reimbursement from government agency and other third party and we may be required to provide rebate and other discount on our product which may result in an adjustment to our product revenue pharmaceutical pricing and reimbursement pressure may adversely affect our profitability and our result of operation and our inability to accurately predict demand for our product and fluctuation in purchasing pattern or wholesaler inventory make it difficult for to accurately forecast sale and may cause our forecasted revenue and earnings to fluctuate which could adversely affect our financial result and stock price patient assistance programsrecently there ha been enhanced scrutiny of company sponsored patient assistance program including co pay assistance program and manufacturer donation to third party charity that provide such assistance there ha also been enhanced scrutiny by government on reimbursement support offering clinical education program and promotional speaker program if we or our agent and vendor are deemed to have failed to comply with law regulation or government guidance in any of these area we could be subject to criminal and civil sanction any similar violation by our competitor could also negatively impact our industry reputation and increase scrutiny over our business and our product health care fraud and abuse law anti bribery lawswe are subject to various federal and state law pertaining to health care fraud and abuse including anti kickback law and false claim law anti kickback law make it illegal for prescription drug manufacturer to solicit offer receive or pay any remuneration in exchange for or to induce the referral of business including the purchase or prescription of particular drug due to the breadth of the statutory provision and the attention being given to them by law enforcement authority it is possible that certain of our practice may be challenged under anti kickback or similar law false claim law generally prohibit anyone from knowingly presenting or causing to be presented false or fraudulent claim for payment by federal and certain state payer including medicare and medicaid or knowingly making using or causing to be made or used false record or statement material to false or fraudulent claim our sale marketing patient support and medical activity may be subject to scrutiny under these law similarly in europe interaction between pharmaceutical company and physician are subject to strict law regulation industry self regulation code of conduct and physician code of professional conduct applicable including the eu member state anti corruption law and the uk bribery act addition the foreign corrupt practice act and similar worldwide anti bribery law generally prohibit company and their intermediary from making improper payment for the purpose of obtaining or retaining business our policy mandate compliance with these anti bribery law we operate in part of the world that have experienced governmental corruption to some degree in certain circumstance strict compliance with anti bribery law may conflict with local custom and practice or may require to interact with doctor and hospital some of which may be state controlled in manner that is different than local custom despite our training and compliance program our internal control policy and procedure may not protect from reckless or criminal act committed by our employee or agent violation of fraud and abuse law or anti bribery law may be punishable by criminal and or civil sanction including fine and civil monetary penalty well the possibility of exclusion from federal health care program including medicare and medicaid violation can also lead to the imposition of corporate integrity agreement or similar government oversight program healthcare reformthe federal and state government continue to propose and pas legislation designed to regulate the healthcare industry including legislation that seek to indirectly or directly regulate pharmaceutical drug pricing for more information see item risk factor our result of operation may be adversely affected by current and potential future healthcare legislative and regulatory action and law and regulation applicable to the health care industry could impose new obligation on require to change our business practice and restrict our operation in the future employeesas of january we approximately employee we believe we have good relation with our employee environmentwe are subject to number of law and regulation that require compliance with federal state and local regulation for the protection of the environment the regulatory landscape continues to evolve and we anticipate additional regulation in the future law and regulation are implemented and under consideration to mitigate the effect of climate change mainly caused by greenhouse gas emission our business is not energy intensive therefore we do not anticipate being subject to cap and trade system or other mitigation measure that would materially impact our capital expenditure operation or competitive position other informationwe are subject to the information requirement of the security exchange act of exchange act therefore we file periodic report proxy and information statement and other information with the sec the sec maintains website http www sec gov that contains report proxy and information statement and other information regarding issuer that file electronically with the sec the mailing address of our headquarters is lakeside drive foster city california and our telephone number at that location is our website is www gilead com through link on the investor page of our website under sec filing section we make available the following filing free of charge soon reasonably practicable after they are electronically filed with or furnished to the sec our annual report on form quarterly report on form current report on form and any amendment to those report filed or furnished pursuant to section or of the exchange act risk factorsin evaluating our business you should carefully consider the following risk in addition to the other information in this annual report on form manifestation of any of the following risk could materially and adversely affect our business result of operation and financial condition we note these factor for investor permitted by the private security litigation reform act of it is not possible to predict or identify all such factor and therefore you should not consider the following risk to be complete statement of all the potential risk or uncertainty that we face substantial portion of our revenue is derived from sale of our hiv product if we are unable to increase or maintain our hiv sale then our result of operation may be adversely affected we receive substantial portion of our revenue from sale of our product for the treatment and prevention of hiv infection during the year ended december sale of our hiv product accounted for approximately of our total product sale and our hiv product account for higher percentage of our total product sale in than in most of our hiv product contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf and or emtricitabine ftc which belong to the nucleoside class of antiviral therapeutic if the treatment paradigm for hiv change causing nucleoside based therapeutic to fall of favor or if we are unable to maintain or increase our hiv product sale our result of operation would likely suffer and we would likely need to scale back our operation including our future drug development and spending on research and development effort in addition future sale of our hiv product depend in part on the extent of reimbursement of our product by private and public payer we may continue to experience global pricing pressure that could result in larger discount or rebate on our product or delayed reimbursement which negatively impact our product sale and result of operation also private and public payer can choose to exclude our product from their formulary coverage list or limit the type of patient for whom coverage will be provided which would negatively impact the demand for and revenue of our product any change in the formulary coverage reimbursement level or discount or rebate offered on our product to payer may impact our anticipated revenue if we are unable to achieve our forecasted hiv sale our stock price could be adversely impacted we may be unable to sustain or increase sale of our hiv product for any number of reason including but not limited to the reason discussed above and the following our product are used over longer period of time in many patient and in combination with other product and additional study are conducted new issue with respect to safety resistance and interaction with other drug may arise which could cause to provide additional warning or contraindication on our label narrow our approved indication or halt sale of product each of which could reduce our revenue our product mature private insurer and government payer often reduce the amount they will reimburse patient for these product which increase pressure on to reduce price if physician do not see the benefit of our hiv product the sale of our hiv product will be limited new branded or generic product are introduced into major market our ability to maintain pricing and market share may be affected if we fail to develop and commercialize new product or expand the indication for existing product our prospect for future revenue and our result of operation may be adversely affected the success of our business depends on our ability to introduce new product well expand the indication for our existing product to address area of unmet medical need the launch of commercially successful product is necessary to cover our substantial expense and to offset revenue loss when our existing product lose market share due to various factor such competition and loss of patent exclusivity well to provide for the growth of our business there are many difficulty and uncertainty inherent in drug development and the introduction of new product the product development cycle is characterized by significant investment of resource long lead time and unpredictable outcome due to the nature of developing medicine for human use we expend significant time and resource on our product pipeline without any assurance that we will recoup our investment or that our effort will be commercially successful high rate of failure is inherent in the discovery and development of new product and failure can occur at any point in the process including late in the process after substantial investment for example see we face risk in our clinical trial including the potential for unfavorable result delay in anticipated timeline and disruption which may adversely affect our prospect for future revenue growth and our result of operation we can not state with certainty when or whether any of our product candidate under development will be approved or launched whether we will be able to develop license or acquire additional product candidate or product or whether any product once launched will be commercially successful failure to launch commercially successful new product or new indication for existing product could have material adverse effect on our future revenue result of operation and long term success inability to accurately predict demand for our product and fluctuation in purchasing pattern or wholesaler inventory make it difficult for to accurately forecast sale and may cause our forecasted revenue and earnings to fluctuate which could adversely affect our financial result and stock price we may be unable to accurately predict demand for our product including the uptake of new product demand depends on number of factor for example the non retail sector in the united state which includes government institution including state aid drug assistance program adaps the department of veteran affair correctional facility and large health maintenance organization tends to be le consistent in term of buying pattern and often cause quarter over quarter fluctuation that do not necessarily mirror patient demand for our product federal and state budget pressure well the annual grant cycle for federal and state fund may cause purchasing pattern to not reflect patient demand for our product we expect to continue to experience fluctuation in the purchasing pattern of our non retail customer which may result in fluctuation in our product sale revenue and earnings in the future in light of the budget crisis faced by many european country we have observed variation in purchasing pattern induced by cost containment measure in europe we believe these measure have caused some government agency and other purchaser to reduce inventory of our product in the distribution channel which ha decreased our revenue and caused fluctuation in our product sale and earnings we may continue to see this trend in the future we sell and distribute most of our product in the united state exclusively through the wholesale channel during the year ended december approximately of our product sale in the united state were to three wholesaler amerisourcebergen corporation cardinal health inc and mckesson corporation the wholesaler with whom we have entered into inventory management agreement make estimate to determine end user demand and may not be completely effective in matching their inventory level to actual end user demand result change in inventory level held by those wholesaler can cause our operating result to fluctuate unexpectedly if our sale to these wholesaler do not match end user demand in addition inventory is held at retail pharmacy and other non wholesaler location with whom we have no inventory management agreement and no control over buying pattern adverse change in economic condition increased competition or other factor may cause retail pharmacy to reduce their inventory of our product which would reduce their order from wholesaler and consequently the wholesaler order from even if end user demand ha not changed in addition we have observed that strong wholesaler and sub wholesaler purchase of our product in the fourth quarter typically result in inventory draw down by wholesaler and sub wholesaler in the subsequent first quarter inventory in the distribution channel fluctuates from quarter to quarter we may continue to see fluctuation in our earnings and mismatch between prescription demand for our product and our revenue we face significant competition we face significant competition from global pharmaceutical and biotechnology company specialized pharmaceutical firm and generic drug manufacturer our product compete with other available product based primarily on efficacy safety tolerability acceptance by doctor ease of patient compliance ease of use price insurance and other reimbursement coverage distribution and marketing our taf containing hiv product compete primarily with product from viiv healthcare company viiv we also face competition from generic hiv product generic version of efavirenz component of atripla are available in the united state canada and europe we have observed some pricing pressure related to the efavirenz component of our atripla sale tdf one of the active pharmaceutical ingredient in truvada atripla complera eviplera and stribild face generic competition in the european union the united state and certain other country in addition because ftc the other active pharmaceutical ingredient of truvada face generic competition in the european union truvada also face generic competition in the european union and certain other country outside of the united state pursuant to settlement agreement relating to patent that protect truvada and atripla teva pharmaceutical is permitted to launch generic fixed dose combination of ftc and tdf and generic fixed dose combination of ftc tdf and efavirenz in the united state on september our hepatitis virus hcv product compete primarily with product marketed by abbvie inc and merck co inc our hepatitis virus hbv product face competition from existing therapy for treating patient with hbv well generic version of tdf our hbv product also compete with product marketed by bristol myers squibb company and novartis pharmaceutical corporation novartis yescarta competes with car cell therapy marketed by novartis and non car product marketed by roche and is expected to compete with product from other company developing advanced cell therapy yescarta and other commercial product also face competition from certain clinical trial that are enrolling car eligible patient in addition number of company are pursuing the development of technology which are competitive with our existing product or research program these competing company include specialized pharmaceutical firm and large pharmaceutical company acting either independently or together with other pharmaceutical company furthermore academic institution government agency and other public and private organization conducting research may seek patent protection and may establish collaborative arrangement for competitive product or program if any of these competitor gain market share result of new technology commercialization strategy or otherwise it could adversely affect our result of operation and stock price may be required to pay significant damage and royalty payment result of ongoing litigation related to yescarta and biktarvy adverse outcome in ongoing litigation related to our yescarta and biktarvy product could require to pay significant monetary damage and royalty payment for past and future sale we can not predict the ultimate outcome of these litigation matter but the timing and magnitude of any such payment could have material adverse impact on our result of operation financial condition and stock price in october juno therapeutic inc and sloan kettering cancer center collectively juno filed lawsuit in the district court for the central district of california alleging that the commercialization of axicabtagene ciloleucel sold commercially yescarta infringes on patent no the patent jury trial wa held on the patent and in december the jury found that the asserted claim of the patent were valid and that we willfully infringed the asserted claim of the patent the jury also awarded juno damage in amount of million in an up front payment and running royalty from october through the date of the jury verdict the party filed post trial motion in january and will file further briefing during the first quarter of and we expect the judge to rule on these matter later in once the district court ha issued these ruling and ha entered judgment the case may be appealed to the court of appeal for the federal circuit although we can not predict with certainty the ultimate outcome of this litigation we believe the jury verdict to be in error and we also believe that error were made by the court with respect to certain ruling before and during trial if the jury verdict is not upheld on appeal the loss will be zero if the jury verdict is upheld in it entirety on appeal we estimate the upper end of the range of possible loss through december to be approximately billion which consists of the million up front payment determined by the jury ii approximately million which represents estimated royalty on our adjusted revenue from yescarta from october through december and iii enhanced damage requested by juno of up to two time the sum of and ii above result of the jury finding of willfulness this sum excludes cost and pre judgment interest supplemental damage consisting of royalty on sale of yescarta after december through the date of judgment could be subject to the royalty in the jury verdict the prospective royalty proposed by juno or to enhancement any post judgment sale of yescarta would be subject to prospective royalty which we have estimated could be up to and which would be payable on adjusted yescarta revenue after the judgment in until the expiry of the patent in august we expect the judge to rule on the amount of prospective royalty and any enhanced damage in the course of deciding the post trial motion the court determination of prospective royalty and enhanced damage if any can also be appealed if the jury verdict is upheld on appeal the amount we could be required to pay to juno could be significant and such payment could have material adverse impact on our result of operation financial condition and stock price in february viiv filed lawsuit against in the district court of delaware alleging that the commercialization of bictegravir sold commercially in combination with taf and ftc biktarvy infringes on viiv patent no the patent covering viiv dolutegravir bictegravir is structurally different from dolutegravir and we believe that bictegravir doe not infringe the claim of the patent to the extent that viiv patent claim are interpreted to cover bictegravir we believe those claim are invalid the court ha set trial date of september for this lawsuit for more information about this litigation well related litigation in country outside of the united state see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form although we can not predict with certainty the ultimate outcome of this litigation an adverse judgment could result in significant monetary damage and royalty payment on past and future sale which could have material impact on our result of operation financial condition and stock price our result of operation may be adversely affected by current and potential future healthcare legislative and regulatory action legislative and regulatory action affecting government prescription drug procurement and reimbursement program occur relatively frequently in the united state the affordable care act aca wa enacted in to expand healthcare coverage since then numerous effort have been made to repeal amend or administratively limit the aca in whole or in part for example in december the court of appeal for the fifth circuit held that the individual health insurance mandate in the aca is unconstitutional and remanded the case back to the district court to determine whether the other provision of the aca can stand without the individual health insurance mandate the ongoing challenge to the aca and new legislative proposal have resulted in uncertainty regarding the aca future viability and destabilization of the health insurance market the resulting impact on our business is uncertain and could be material effort to control prescription drug price could also have material adverse effect on our business for example in president trump and the secretary of the department of health and human service hhs released the american patient first blueprint and have begun implementing certain portion the initiative includes proposal to increase generic drug and biosimilar competition enable the medicare program to negotiate drug price more directly improve transparency regarding drug price and lower consumer out of pocket cost the trump administration also proposed to establish an international pricing index that would be used benchmark to determine the cost and potentially limit the reimbursement of drug under medicare in addition in december food and drug administration fda issued proposal to implement two pathway for the legal importation of certain prescription drug from canada and prescription drug that are fda approved manufactured abroad authorized for sale in foreign country and originally intended for sale in that foreign country among other pharmaceutical manufacturer industry related proposal congress ha proposed bill to change the medicare part benefit to impose an inflation based rebate in medicare part and to alter the benefit structure to increase manufacturer contribution in some or all benefit phase the volume of drug pricing related bill ha dramatically increased under the current congress and the resulting impact on our business is uncertain and could be material in addition majority of state have enacted legislation that seek to indirectly or directly regulate pharmaceutical drug pricing such by requiring biopharmaceutical manufacturer to publicly report proprietary pricing information or creating review board for recommending price cap or other mean for controlling price of pharmaceutical product purchased by state agency for example in california governor signed prescription drug price transparency state bill into law requiring prescription drug manufacturer to provide advance notice and explanation for price increase of certain drug that exceed specified threshold many other state have proposed or enacted similar legislation in addition many state legislature are considering or have already passed various bill that would reform drug purchasing and price negotiation facilitate the import of lower priced drug from outside the united state and encourage the use of generic drug such initiative and legislation may cause added pricing pressure on our product change to the medicaid program at the federal or state level could also have material adverse effect on our business proposal that could impact coverage and reimbursement of our product including giving state more flexibility to manage drug covered under the medicaid program could have material adverse effect by limiting our product use and coverage furthermore state medicaid program could request additional supplemental rebate on our product for many reason to the extent that private insurer or managed care program follow medicaid coverage and payment development they could use the enactment of these increased rebate to exert pricing pressure on our product and the adverse effect may be magnified by their adoption of lower payment schedule other proposed regulatory action affecting manufacturer could have material adverse effect on our business it is difficult to predict the impact if any of any such proposed legislative and regulatory action or resulting state action on the use and reimbursement of our product in the united state but such action may adversely affect our result of operation many country outside the united state including the european union eu member state have established complex and lengthy procedure to obtain price approval coverage and reimbursement many eu member state review periodically their decision concerning the pricing and reimbursement of medicinal product the outcome of this review can not be predicted and could have an adverse effect on the pricing and reimbursement of our medicinal product in the eu member state reduction in the pricing of our medicinal product in one eu member state could affect the price in other eu member state and have negative impact on our financial result our existing product are subject to reimbursement from government agency and other third party and we may be required to provide rebate and other discount on our product which may result in an adjustment to our product revenue pharmaceutical pricing and reimbursement pressure may adversely affect our profitability and our result of operation successful commercialization of our product depends in part on the availability of governmental and third party payer reimbursement for the cost of such product and related treatment in the market where we sell our product government health authority private health insurer and other organization generally provide reimbursement in the united state the european union and other significant or potentially significant market for our product and product candidate government authority and third party payer are increasingly attempting to limit or regulate the price of medical product and service substantial portion of our product sale is subject to significant discount from list price including rebate that we may be required to pay certain governmental agency in addition standard reimbursement structure may not adequately reimburse for innovative therapy for example for fiscal year the center for medicare and medicaid service cm ha established medicare inpatient reimbursement for yescarta that includes payment for severity adjusted diagnosis related group drg new technology add on payment ntap for yescarta that at most will cover of the cost of yescarta and may cover le than that and in some case an outlier payment taken together the total payment may not be sufficient to reimburse hospital for their cost of care for patient receiving yescarta cm also ha not made decision to how much it will pay for yescarta in fiscal year and beyond if medicare doe not adequately reimburse for the cost of yescarta this could impact the willingness of some hospital to offer the therapy and of doctor to recommend the therapy and could lessen the attractiveness of our therapy to patient which could have an adverse effect on sale of yescarta and on our result of operation additionally in the european union there are barrier to reimbursement in individual country that could limit the uptake of yescarta in addition we estimate the rebate we will be required to pay in connection with sale during particular quarter based on claim data from prior quarter in the united state actual rebate claim are typically made by payer one to three quarter in arrears actual claim and payment may vary significantly from our estimate which can cause an adjustment to our product to the extent our actual or anticipated product revenue fall short of investor expectation our stock price could be adversely impacted for more information concerning the eu pricing and reimbursement regime please see our result of operation may be adversely affected by current and potential future healthcare legislative and regulatory action law and regulation applicable to the health care industry could impose new obligation on require to change our business practice and restrict our operation in the future the health care industry is subject to various federal state and international law and regulation pertaining to drug reimbursement rebate price reporting health care fraud and abuse and data privacy and security in the united state these law include anti kickback and false claim law law and regulation relating to the medicare and medicaid program and other federal and state program the medicaid rebate statute individual state law relating to pricing and sale and marketing practice the health insurance portability and accountability act hipaa and other federal and state law relating to the privacy and security of health information violation of these law or any related regulation may be punishable by criminal and or civil sanction including in some instance substantial fine civil monetary penalty exclusion from participation in federal and state health care program including medicare medicaid veteran administration health program and federal employee health benefit program action against executive overseeing our business and significant remediation measure in addition these law and regulation are broad in scope and they are subject to change and evolving interpretation which could require to incur substantial cost associated with compliance or to alter one or more of our sale or marketing practice violation of these law or allegation of such violation could also result in negative publicity or other consequence that could harm our reputation disrupt our business or adversely affect our result of operation if any or all of these event occur our business and stock price could be materially and adversely affected recently there ha been enhanced scrutiny of company sponsored patient assistance program including co pay assistance program and manufacturer donation to third party charity that provide such assistance there ha also been enhanced scrutiny by government on reimbursement support offering clinical education program and promotional speaker program if we or our agent and vendor are deemed to have failed to comply with law regulation or government guidance in any of these area we could be subject to criminal or civil sanction any similar violation by our competitor could also negatively impact our industry reputation and increase scrutiny over our business and our product in addition government price reporting and payment regulation are complex and we are continually assessing the method by which we calculate and report pricing in accordance with these obligation our methodology for calculation are inherently subjective and may be subject to review and challenge by various government agency which may disagree with our interpretation if the government disagrees with our reported calculation we may need to restate previously reported data and could be subject to additional financial and legal liability described above for description of our government investigation and related litigation see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form yescarta chimeric antigen receptor car cell therapy represents novel approach to cancer treatment that creates significant challenge for which may impact our ability to increase sale of yescarta yescarta car cell therapy involves harvesting cell from the patient blood ii engineering cell to express cancer specific receptor iii increasing the number of engineered cell and iv infusing the functional cancer specific cell back into the patient advancing this novel and personalized therapy creates significant challenge including educating and certifying medical personnel regarding the procedure and the potential side effect profile of our therapy such the potential adverse side effect related to cytokine release syndrome and neurologic toxicity in compliance with the risk evaluation and mitigation strategy program required by fda for yescarta using medicine to manage adverse side effect of our therapy such tocilizumab and corticosteroid which may not be available in sufficient quantity may not adequately control the side effect and or may have detrimental impact on the efficacy of the treatment developing robust and reliable process while limiting contamination risk for engineering patient cell ex vivo and infusing the engineered cell back into the patient and conditioning patient with chemotherapy in advance of administering our therapy which may increase the risk of adverse side effect the use of engineered cell potential cancer treatment is recent development and may not be broadly accepted by physician patient hospital cancer treatment center payer and others in the medical community we may not be able to establish or demonstrate to the medical community or commercial or governmental payer the safety and efficacy of yescarta and potential advantage compared to existing and future therapeutic for challenge related to the reimbursement of yescarta see also our existing product are subject to reimbursement from government agency and other third party and we may be required to provide rebate and other discount on our product which may result in an adjustment to our product revenue pharmaceutical pricing and reimbursement pressure may adversely affect our profitability and our result of operation if we fail to overcome these significant challenge our sale of yescarta result of operation and stock price could be adversely affected we have engaged in and may in the future engage in business acquisition licensing arrangement collaboration disposal of our asset and other strategic transaction which could cause to incur significant expense and could adversely affect our financial condition and result of operation we have engaged in and may in the future engage in business acquisition licensing arrangement collaboration disposal of our asset and other transaction part of our business strategy we may not identify suitable transaction in the future and if we do we may not complete such transaction in timely manner on cost effective basis or at all and may not realize the expected benefit for example if we are successful in making an acquisition the product and technology that are acquired may not be successful or may require significantly greater resource and investment than originally anticipated we also may not be able to integrate acquisition successfully into our existing business and could incur or assume significant debt and unknown or contingent liability we have also acquired and may in the future acquire equity investment in our strategic transaction such in connection with our collaboration with galapagos nv and the value of our equity investment may fluctuate and decline in value further we conduct annual impairment testing of our goodwill and other indefinite lived intangible asset in the fourth quarter and earlier if impairment indicator exist required under generally accepted accounting principle which may result in impairment charge for example during the fourth quarter of and we recognized million and million respectively of impairment charge related to indefinite lived intangible asset acquired in connection with our acquisition of kite pharma inc if we fail to overcome these risk it could cause to incur significant expense and negatively affect profitability which could have an adverse effect on our result of operation we could also experience negative effect on our reported result of operation from acquisition or disposition related charge amortization of expense related to intangible and charge for impairment of long term asset we face risk associated with our global operation which may adversely affect our financial condition and result of operation our operation outside of the united state are accompanied by certain financial political economic and other risk including those listed below foreign currency exchange in approximately of our product sale were outside the united state because significant percentage of our product sale is denominated in foreign currency primarily the euro we face exposure to adverse movement in foreign currency exchange rate overall we are net receiver of foreign currency and therefore we benefit from weaker dollar and are adversely affected by stronger dollar while we use foreign currency exchange forward and option contract to hedge percentage of our forecasted international sale our hedging program doe not eliminate our exposure to currency fluctuation we can not predict future fluctuation in the foreign currency exchange rate of the dollar if the dollar appreciates significantly against certain currency and our hedging program doe not sufficiently offset the effect of such appreciation our result of operation will be adversely affected and our stock price may decline anti bribery we are subject to the foreign corrupt practice act and similar worldwide anti bribery law that govern our international operation with respect to payment to government official our international operation are heavily regulated and require significant interaction with foreign official though our policy mandate compliance with these anti bribery law we operate in part of the world that have experienced governmental corruption to some degree in certain circumstance strict compliance with anti bribery law may conflict with local custom and practice or may require to interact with doctor and hospital some of which may be state controlled in manner that is different than local custom it is possible that certain of our practice may be challenged under these law in addition despite our training and compliance program our internal control policy and procedure may not protect from reckless or criminal act committed by our employee and agent enforcement activity under anti bribery law could subject to administrative and legal proceeding and action which could result in civil and criminal sanction including monetary penalty and exclusion from health care program other risk inherent in conducting global business include our international operation including the use of third party manufacturer distributor and collaboration arrangement outside the united state expose to increased risk of theft of our intellectual property and other proprietary technology particularly in jurisdiction with le robust intellectual property protection than the united state well restrictive government action against our intellectual property and other foreign asset such nationalization expropriation or the imposition of compulsory license we may be subject to protective economic policy taken by foreign government such trade protection measure and import and export licensing requirement which may result in the imposition of trade sanction or similar restriction by the united state or other government our operation may be adversely affected if there is instability disruption or destruction in geographic region where we operate regardless of cause including war terrorism social unrest and political change and instability for example on january the united kingdom uk withdrew from the european union eu which initiated transition period during which the uk and eu will negotiate their future relationship there is uncertainty concerning any change in the law and regulation governing the conduct of clinical trial and marketing of medicinal product in the uk following the country exit from the eu this uncertainty may lead to significant complexity and risk for our company and our ability to research develop and market medicinal product in the eu and the uk see also business disruption from natural or man made disaster may adversely affect our revenue and materially reduce our earnings if we were to encounter any of these risk our global operation may be adversely affected which could have an adverse effect on our overall business and result of operation if significant safety issue arise for our marketed product or our product candidate our reputation may be harmed and our future sale may be reduced which could adversely affect our result of operation the data supporting the marketing approval for our product and forming the basis for the safety warning in our product label were obtained in controlled clinical trial of limited duration and in some case from post approval use our product are used over longer period of time by patient with underlying health problem or other medicine we expect to continue finding new issue related to safety resistance or drug interaction any such issue may require change to our product label such additional warning contraindication or even narrowed indication if any of these were to occur it could reduce the market acceptance and sale of our product regulatory authority have been moving towards more active and transparent pharmacovigilance and are making greater amount of stand alone safety information and clinical trial data directly available to the public through website and other mean such periodic safety update report summary risk management plan summary and various adverse event data safety information without the appropriate context and expertise may be misinterpreted and lead to misperception or legal action which may potentially cause our product sale or stock price to decline further if serious safety resistance or drug interaction issue arise with our marketed product sale of these product could be limited or halted by or by regulatory authority and our result of operation could be adversely affected our operation depend on compliance with complex fda and comparable international regulation failure to obtain broad approval on timely basis or to maintain compliance could delay or halt commercialization of our product the product we develop must be approved for marketing and sale by regulatory authority and once approved are subject to extensive regulation by fda the european medicine agency ema and comparable regulatory agency in other country we are continuing clinical trial for many of our product for currently approved and additional us we anticipate that we will file for marketing approval in additional country and for additional indication and product over the next several year these product may fail to receive such marketing approval on timely basis or at all further how we manufacture and sell our product is subject to extensive regulation and review discovery of previously unknown problem with our marketed product or problem with our manufacturing safety reporting or promotional activity may result in restriction on our product including withdrawal of the product from the market if we fail to comply with applicable regulatory requirement including those related to promotion and manufacturing we could be subject to penalty including fine suspension of regulatory approval product recall seizure of product and criminal prosecution for example under fda rule we are often required to conduct post approval clinical study to ass known serious risk signal of serious risk or to identify an unexpected serious risk in certain circumstance we may be required to implement risk evaluation and mitigation strategy program for our product which could include medication guide patient package insert communication plan to healthcare provider restriction on distribution or use of product and other element fda deems necessary to assure safe use of the drug failure to comply with these or other requirement imposed by fda could result in significant civil monetary penalty and our operating result may be adversely affected we face risk in our clinical trial including the potential for unfavorable result delay in anticipated timeline and disruption which may adversely affect our prospect for future revenue growth and our result of operation we are required to demonstrate the safety and efficacy of product that we develop for each intended use through extensive preclinical study and clinical trial the result from preclinical and early clinical study do not always accurately predict result in later large scale clinical trial even successfully completed large scale clinical trial may not result in marketable product example in february we announced that our kite program an anti cell maturation antigen being evaluated for the treatment of multiple myeloma would not be moving forward we also recently announced that stellar and stellar phase study evaluating the safety and efficacy of selonsertib for the treatment of nonalcoholic steatohepatitis nash not meet the pre specified week primary endpoint if any of our product candidate fails to achieve it primary endpoint in clinical trial if safety issue arise or if the result from our clinical trial are otherwise inadequate to support regulatory approval of our product candidate commercialization of that product candidate could be delayed or halted in addition we may also face challenge in clinical trial protocol design if the clinical trial for any of the product candidate in our pipeline are delayed or terminated our prospect for future revenue growth and our result of operation may be adversely impacted for example we face numerous risk and uncertainty with our product candidate including filgotinib for the treatment of rheumatoid arthritis crohn disease ulcerative colitis and psoriatic arthritis glpg for the treatment of idiopathic pulmonary fibrosis cilofexor for the treatment of primary sclerosing cholangitis and axicabtagene ciloleucel for the treatment of second line diffuse large cell lymphoma each currently in phase clinical trial that could prevent completion of development of these product candidate these risk include our ability to enroll patient in clinical trial the possibility of unfavorable result of our clinical trial the need to modify or delay our clinical trial or to perform additional trial and the risk of failing to obtain fda and other regulatory body approval result our product candidate may never be successfully commercialized further we may make strategic decision to discontinue development of our product candidate if for example we believe commercialization will be difficult relative to other opportunity in our pipeline if these program and others in our pipeline can not be completed on timely basis or at all then our prospect for future revenue growth and our result of operation may be adversely impacted in addition clinical trial involving our commercial product could raise new safety issue for our existing product which could in turn adversely affect our result of operation and harm our business in addition we extensively outsource our clinical trial activity and usually perform only small portion of the start up activity in house we rely on independent third party contract research organization cro to perform most of our clinical study including document preparation site identification screening and preparation pre study visit training program management patient enrollment ongoing monitoring site management and bioanalytical analysis many important aspect of the service performed for by the cro are out of our direct control if there is any dispute or disruption in our relationship with our cro our clinical trial may be delayed moreover in our regulatory submission we rely on the quality and validity of the clinical work performed by third party cro if any of our cro process methodology or result were determined to be invalid or inadequate our own clinical data and result and related regulatory approval may be adversely affected we depend on relationship with third party for sale and marketing performance technology development logistics and commercialization of product failure to maintain these relationship poor performance by these company or dispute with these third party could negatively impact our business we rely on number of collaborative relationship with third party for our sale and marketing performance in certain territory for example we have collaboration arrangement with janssen science ireland uc for odefsey complera eviplera and symtuza in some country we rely on international distributor for sale of certain of our product some of these relationship also involve the clinical development of these product by our partner reliance on collaborative relationship pose number of risk including the risk that we are unable to control the resource our corporate partner devote to our program or product dispute may arise with respect to the ownership of right to technology developed with our corporate partner disagreement with our corporate partner could cause delay in or termination of the research development or commercialization of product candidate or result in litigation or arbitration contract with our corporate partner may fail to provide significant protection or may fail to be effectively enforced if one of these partner fails to perform our corporate partner have considerable discretion in electing whether to pursue the development of any additional product and may pursue alternative technology or product either on their own or in collaboration with our competitor our corporate partner with marketing right may choose to pursue competing technology or to devote fewer resource to the marketing of our product than they do to product of their own development and our distributor and our corporate partner may be unable to pay given these risk there is great deal of uncertainty regarding the success of our current and future collaborative effort if these effort fail our product development or commercialization of new product could be delayed or revenue from product could decline in addition we rely on third party site to collect patient white blood cell known apheresis center shipper courier and hospital for the logistical collection of patient white blood cell and ultimate delivery of yescarta to patient any disruption or difficulty encountered by any of these vendor could result in product loss and regulatory action and harm our yescarta business our reputation to ensure that any apheresis center is prepared to ship cell to our manufacturing facility we plan to conduct quality certification of each apheresis center however apheresis center may choose not to participate in the certification process or we may be unable to complete certification in timely manner or at all which could delay or restrain our manufacturing and commercialization effort result our sale of yescarta may be limited which could harm our result of operation our success depends to significant degree on our ability to defend our patent and other intellectual property right both domestically and internationally we may not be able to obtain effective patent to protect our technology from use by competitor patent and other proprietary right are very important to our business our success depends to significant degree on our ability to obtain patent and license to patent right preserve trade secret and internal know how defend against infringement of our patent and effort to invalidate them and operate without infringing on the intellectual property of others if we have properly drafted and enforceable patent it can be more difficult for our competitor to use our technology to create competitive product and more difficult for our competitor to obtain patent that prevents from using technology we create part of our business strategy we actively seek patent protection both in the united state and internationally and file additional patent application when appropriate to cover improvement in our compound product and technology patent application are confidential for period of time before patent is issued result we may not know if our competitor filed patent application for technology covered by our pending application or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent application in addition if competitor file patent application covering our technology we may have to participate in litigation post grant proceeding before the patent and trademark office uspto or other proceeding to determine the right to patent or validity of any patent granted litigation post grant proceeding before the uspto or other proceeding are unpredictable and expensive and could divert management attention from other operation such that even if we are ultimately successful our result of operation may be adversely affected by such event generic manufacturer have sought and may continue to seek fda approval to market generic version of our product through an abbreviated new drug application anda the application process typically used by manufacturer seeking approval of generic drug for description of our anda litigation see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form the entry of generic version of our product ha and may in the future lead to market share and price erosion and have negative impact on our business and result of operation our success depends in large part on our ability to operate without infringing upon the patent or other proprietary right of third party if we are found to infringe the valid patent of third party we may be required to pay significant monetary damage or we may be prevented from commercializing product or may be required to obtain license from these third party we may not be able to obtain alternative technology or any required license on commercially reasonable term or at all if we fail to obtain these license or alternative technology we may be unable to develop or commercialize some or all of our product for example we are aware of patent and patent application owned by third party that such party may claim cover the use of sofosbuvir axicabtagene ciloleucel or bictegravir see we may be required to pay significant damage and royalty payment result of ongoing litigation related to yescarta and biktarvy see also description of our litigation regarding sofosbuvir axicabtagene ciloleucel bictegravir and tdf or taf in combination with ftc for the use of pre exposure prophylaxis in note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form furthermore we also rely on unpatented trade secret and improvement unpatented internal know how and technological innovation for example great deal of our liposomal manufacturing expertise which is key component of our liposomal technology is not covered by patent but is instead protected trade secret we protect these right mainly through confidentiality agreement with our corporate partner employee consultant and vendor we can not be certain that these party will comply with these confidentiality agreement that we have adequate remedy for any breach or that our trade secret internal know how or technological innovation will not otherwise become known or be independently discovered by our competitor under some of our agreement invention become jointly owned by and our corporate partner and in other case become the exclusive property of one party in certain circumstance it can be difficult to determine who owns particular invention and dispute could arise regarding those invention if our trade secret internal know how technological innovation or confidential information become known or independently discovered by competitor or if we enter into dispute over ownership of invention our business and result of operation could be adversely affected problem including at our third party manufacturer and corporate partner could cause inventory shortage and delay product shipment and regulatory approval which may adversely affect our result of operation in order to generate revenue from our product we must be able to produce sufficient quantity of our product to satisfy demand many of our product are the result of complex manufacturing process the manufacturing process for pharmaceutical product is also highly regulated and regulator may shut down manufacturing facility that they believe do not comply with regulation our product are either manufactured at our own facility or by third party manufacturer or corporate partner we depend on third party to perform manufacturing activity effectively and on timely basis for the majority of our solid dose product we our third party manufacturer and our corporate partner are subject to good manufacturing practice gmp which are extensive regulation governing manufacturing process stability testing record keeping and quality standard defined by fda and ema similar regulation are in effect in other jurisdiction our third party manufacturer and corporate partner are independent entity subject to their own unique operational and financial risk that are out of our control if we or any of these third party manufacturer or corporate partner fail to perform required this could impair our ability to deliver our product on timely basis or receive royalty or could cause delay in our clinical trial and application for regulatory approval further we may have to write off the cost of manufacturing any batch that fails to pas quality inspection or meet regulatory approval in addition we our third party manufacturer and our corporate partner may only be able to produce some of our product at one or limited number of facility and therefore have limited manufacturing capacity for certain product and we may not be able to locate additional or replacement facility on reasonable basis or at all our sale of such product could also be adversely impacted by our reliance on such limited number of facility to the extent these risk materialize and affect their performance obligation to our financial result may be adversely affected our manufacturing operation are subject to routine inspection by regulatory agency if we are unable to remedy any deficiency cited by fda in these inspection our currently marketed product and the timing of regulatory approval of product in development could be adversely affected further there is risk that regulatory agency in other country where marketing application are pending will undertake similar additional review or apply heightened standard of review which could delay the regulatory approval for product in those country if approval of any of our product candidate were delayed or if production of our marketed product were interrupted our anticipated revenue and our stock price may be adversely affected we may not be able to obtain material or supply necessary to conduct clinical trial or to manufacture and sell our product which could limit our ability to generate revenue we need access to certain supply and product to conduct our clinical trial and to manufacture and sell our product if we are unable to purchase sufficient quantity of these material or find suitable alternative material in timely manner our development effort for our product candidate may be delayed or our ability to manufacture our product could be limited which could limit our ability to generate revenue supplier of key component and material must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval and significant delay can occur if the qualification of new supplier is required even after manufacturer is qualified by the regulatory authority the manufacturer must continue to expend time money and effort in the area of production and quality control to ensure full compliance with gmp manufacturer are subject to regular periodic inspection by regulatory authority following initial approval if result of these inspection regulatory authority determines that the equipment facility laboratory or process do not comply with applicable regulation and condition of product approval the regulatory authority may suspend the manufacturing operation if the manufacturing operation of any of the single supplier for our product are suspended we may be unable to generate sufficient quantity of commercial or clinical supply of product to meet market demand which could in turn decrease our revenue and harm our business in addition if delivery of material from our supplier were interrupted for any reason we may be unable to ship certain of our product for commercial supply or to supply our product candidate in development for clinical trial in addition some of our product and the material that we utilize in our operation are manufactured at only one facility which we may not be able to replace in timely manner and on commercially reasonable term or at all problem with any of the single supplier we depend on including in the event of disaster such an earthquake equipment failure or other difficulty may negatively impact our development and commercialization effort significant portion of the raw material and intermediate used to manufacture our antiviral product are supplied by third party manufacturer and corporate partner outside of the united state result any political or economic factor in specific country or region including any change in or interpretation of trade regulation compliance requirement or tax legislation that would limit or prevent third party outside of the united state from supplying these material could adversely affect our ability to manufacture and supply our antiviral product to meet market need and have material and adverse effect on our operating result we were to encounter any of these difficulty our ability to conduct clinical trial on product candidate and to manufacture and sell our product could be impaired which could have an adverse effect on our business import from country where our product are available at lower price and unapproved generic or counterfeit version of our product could have negative impact on our reputation and business price for our product are based on local market economics and competition and sometimes differ from country to country our sale in country with relatively higher price may be reduced if product can be imported and resold into those country from lower price market if our hiv hbv and hcv product which we have agreed to make available at substantially reduced price to certain low and middle income country participating in our gilead access program are re exported into the united state europe or other higher price market our revenue could be adversely affected in addition we have entered into agreement with generic drug manufacturer well licensing agreement with the medicine patent pool united nation backed public health organization which allows generic drug manufacturer to manufacture certain generic version of our product for distribution in certain low and middle income country if generic version of our product produced and or distributed under these agreement are then re exported to the united state europe or other higher price market our revenue could be adversely affected in the european union we are required to permit product purchased in one eu member state to be sold in another eu member state purchase of our product in country where our selling price are relatively low for resale in country in which our selling price are relatively high can affect the inventory level held by our wholesaler and can cause the relative sale level in the various country to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter these quarterly fluctuation may impact our earnings which could adversely affect our stock price and harm our business additionally use of diverted product could occur in country where they have not been approved and patient could source the product outside the legitimate supply chain therefore the product may be handled shipped and stored inappropriately which may affect the efficacy of the product and could harm patient our brand or the commercial or scientific reputation of our product we are also aware of the existence of various buyer club around the world that promote the personal importation of generic version of our hcv and hiv product that have not been approved for use in the country into which they are imported result patient may be at risk of taking unapproved medication which may not be they purport to be may not have the potency they claim to have or may contain harmful substance to the extent patient take unapproved generic version of one or more of our medication and are injured by these generic product our brand or the commercial or scientific reputation of our hcv and hiv product could be harmed further third party may illegally distribute and sell counterfeit version of our product which do not meet the rigorous quality standard of our manufacturing and supply chain we actively take action to discourage the distribution and sale of counterfeit of our product around the world including working with local regulatory and legal authority to enforce law against counterfeit drug raising public awareness of the danger of counterfeit drug and promoting public policy to hinder the sale and availability of counterfeit drug counterfeit drug pose serious risk to patient health and safety and may raise the risk of product recall our reputation and business could suffer result of counterfeit drug sold under our brand name expensive litigation and government investigation have increased our expense which may continue to reduce our earnings we are involved in number of litigation investigation and other dispute related matter that require to expend substantial internal and financial resource we expect these matter will continue to require high level of internal and financial resource for the foreseeable future these matter have reduced and will continue to reduce our earnings and require significant management attention for description of our litigation investigation and other dispute related matter see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form see also we may be required to pay significant damage and royalty payment result of ongoing litigation related to yescarta and biktarvy the outcome of such legal proceeding or any other legal proceeding that may be brought against the investigation or any other investigation that may be initiated and any other dispute related matter are inherently uncertain and adverse development or outcome can result in significant expense monetary damage penalty or injunctive relief against that could significantly reduce our earnings and cash flow and harm our business and reputation we may face significant liability resulting from our product and such liability could materially reduce our earnings the testing manufacturing marketing and use of our commercial product well product candidate in development involve substantial risk of product liability claim these claim may be made directly by consumer healthcare provider pharmaceutical company or others we have limited insurance for product liability that may arise if claim exceed our coverage our financial condition will be adversely affected in addition negative publicity associated with any claim regardless of their merit may decrease the future demand for our product and impair our financial condition for description of our product liability see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form if we fail to attract develop and retain highly qualified personnel our business and operation may be adversely affected our future success will depend in large part on our continued ability to attract develop and retain highly qualified scientific technical and management personnel well personnel with expertise in clinical testing governmental regulation and commercialization we face competition for personnel from other company university public and private research institution government entity and other organization competition for qualified personnel in the biopharmaceutical field is intense and there is limited pool of qualified potential employee to recruit we may not be able to attract and retain quality personnel on acceptable term our ability to do so also depends on how well we maintain strong workplace culture that is attractive to employee particularly during the leadership transition that we are currently experiencing additionally change to immigration and work authorization law and regulation could make it more difficult for employee to work in or transfer to jurisdiction in which we have operation and could impair our ability to attract and retain qualified personnel if we are unsuccessful in our recruitment development and retention effort or we fail to maintain strong workplace culture our business and reputation may be harmed we have recently made significant change to our senior leadership team in we appointed daniel day chairman and chief executive officer andrew dickinson chief financial officer johanna mercier chief commercial officer merdad parsey chief medical officer brett pletcher executive vice president corporate affair and general counsel jyoti mehra executive vice president human resource and christi shaw chief executive officer of kite change in management and other key personnel may lead to potential organizational realignments and additional personnel change which may disrupt our business and adversely affect our operation business disruption from natural or man made disaster may adversely affect our revenue and materially reduce our earnings our worldwide operation third party manufacturer or corporate partner could be subject to business interruption stemming from natural or man made disaster such climate change terrorist attack armed conflict earthquake hurricane flooding fire or actual or threatened public health emergency or effort taken by third party to prevent or mitigate such disaster such public safety power shutoffs and facility shutdown for which we or they may be uninsured or inadequately insured our corporate headquarters in foster city and our santa monica location which together house majority of our activity and our san dimas la verne oceanside and el segundo manufacturing facility are located in california seismically active region we may not carry adequate earthquake insurance and significant recovery time could be required to resume operation our financial condition and operating result could be materially adversely affected in the event of major earthquake we are dependent on information technology system infrastructure and data which may be subject to cyberattacks security breach and legal claim we are dependent upon information technology system infrastructure and data including our kite konnect platform which is critical to ensure chain of identity and chain of custody of yescarta the multitude and complexity of our computer system make them inherently vulnerable to service interruption or destruction malicious intrusion and random attack likewise data privacy or security breach by employee or others pose risk that sensitive data including our intellectual property or trade secret or the personal information of our employee patient customer or other business partner may be exposed to unauthorized person or to the public cyberattacks are increasing in their frequency sophistication and intensity cyberattacks could include the deployment of harmful malware denial of service social engineering and other mean to affect service reliability and threaten data confidentiality integrity and availability our business and technology partner face similar risk and any security breach of their system could adversely affect our security posture while we have invested and continue to invest in the protection of our data and information technology infrastructure there can be no assurance that our effort or the effort of our partner and vendor will prevent future service interruption or identify breach in our system such interruption or breach could adversely affect our business and operation and or cause the loss of critical or sensitive information including personal information which could result in financial legal business or reputational harm to in addition our insurance may not be sufficient in type or amount to cover the financial legal business or reputational loss that may result from an interruption or breach of our system regulator globally are also imposing new data privacy and security requirement including new and greater monetary fine for privacy violation for example the general data protection regulation gdpr that became effective in europe in established regulation regarding the handling of personal data and non compliance with the gdpr may result in monetary penalty of up to four percent of worldwide revenue in addition new domestic data privacy and security law such the california consumer privacy act ccpa that became effective in january and others that may be passed similarly introduce requirement with respect to personal information and non compliance with ccpa may result in liability through private action subject to statutorily defined damage in the event of certain data breach and enforcement the gdpr ccpa and other change new law or regulation associated with the enhanced protection of personal information including in some case healthcare data or other personal information could greatly increase our cost of providing our product and service or even prevent from offering certain service in jurisdiction in which we operate change in our effective income tax rate could reduce our earnings we are subject to income tax in the united state and various foreign jurisdiction including ireland due to economic and political condition various country are actively considering and have made change to existing tax law we can not predict the form or timing of potential legislative and regulatory change that could have material adverse impact on our result of operation for example the united state enacted significant tax reform and certain provision of the new law are complex and will continue to significantly affect in addition significant judgment is required in determining our worldwide provision for income tax various factor may have favorable or unfavorable effect on our income tax rate including but not limited to our portion of the non tax deductible annual branded prescription drug fee the accounting for stock option and other share based award merger and acquisition future level of spending ability to maintain manufacturing and other operational activity in our irish facility change in the mix of earnings in the various tax jurisdiction in which we operate change in overall level of pre tax earnings resolution of federal state and foreign income tax audit the impact on our income tax provision resulting from the above mentioned factor may be significant and could have negative impact on our consolidated result of operation our income tax return are subject to audit by federal state and foreign tax authority we are currently under examination by the internal revenue service for the tax year from to and by various state and foreign jurisdiction there are differing interpretation of tax law and regulation and result significant dispute may arise with these tax authority involving issue of the timing and amount of deduction and allocation of income among various tax jurisdiction resolution of one or more of these exposure in any reporting period could have material impact on the result of operation for that period there can be no assurance that we will continue to pay dividend or repurchase stock our board of director authorized dividend program under which we intend to pay quarterly dividend of per share subject to quarterly declaration by our board of director in the first quarter of our board of director also approved the repurchase of up to billion of our common stock program of which billion is available for repurchase of december in the first quarter of our board of director authorized new billion stock repurchase program program which will commence upon the completion of the program purchase under the program may be made in the open market or in privately negotiated transaction any future declaration amount and timing of any dividend and or the amount and timing of such stock repurchase are subject to capital availability and determination by our board of director that cash dividend and or stock repurchase are in the best interest of our stockholder and are in compliance with all respective law and our agreement applicable to the declaration and payment of cash dividend and the repurchase of stock our ability to pay dividend and or repurchase stock will depend upon among other factor our cash balance and potential future capital requirement for strategic transaction including acquisition debt service requirement result of operation financial condition and other factor beyond our control that our board of director may deem relevant reduction in or elimination of our dividend payment our dividend program and or stock repurchase could have negative effect on our stock price unresolved staff comment not applicable item property our corporate headquarters are located in foster city california where we house our administrative and certain of our activity we also have facility in emeryville oceanside and santa monica california gaithersburg maryland seattle washington edmonton canada and amsterdam netherlands our principal manufacturing facility are in el segundo la verne oceanside and san dimas california edmonton canada cork ireland and hoofddorp netherlands for more information about our manufacturing facility see item business our manufacturing facility our global operation include office in europe north america asia south america africa australia and the middle east we believe that our existing property including both owned and leased site are in good condition and suitable for the conduct of our business we believe our capital resource are sufficient to purchase lease or construct any additional facility required to meet our expected long term growth need item legal proceeding for description of our significant pending legal proceeding please see note commitment and contingency legal proceeding of the note to consolidated financial statement included in part ii item of this annual report on form which is incorporated herein by reference item mine safety disclosure not applicable ii item market for registrant common equity related stockholder matter and issuer purchase of equity security our common stock is traded on the nasdaq global select market under the symbol gild of february we had approximately stockholder of record of our common stock performance graph the following graph compare our cumulative total stockholder return for the past five year to two index the standard poor stock index index and the nasdaq biotechnology index nbi index the stockholder return shown on the graph below is not necessarily indicative of future performance and we do not make or endorse any prediction to future stockholder return comparison of cumulative total return on investment for the past five year ______________________________________________________ this section is not soliciting material is not deemed filed with the sec and is not to be incorporated by reference in any of our filing under the security act or the exchange act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing show the cumulative return on investment assuming an investment of in our common stock the nbi index and the index on december and assuming that all dividend were reinvested compensation plan informationthe following table provides certain information with respect to our equity compensation plan in effect of december in million except per share amount number of common share to be issued upon exercise of outstanding option warrant and right weighted average exercise price of outstanding option warrant and right number of common share remaining available for future issuance under equity compensation plan excluding security reflected in column plan category equity compensation plan approved by security holder equity incentive plan stock purchase plan equity compensation plan approved by security holder compensation plan not approved by security holder total doe not take into account million restricted stock unit performance share award or unit and phantom share which have no exercise price and were granted under our equity incentive plan under our employee stock purchase plan participant are permitted to purchase our common stock at discount on certain date through payroll deduction within pre determined purchase period accordingly these number are not determinable issuer purchase of equity security in the first quarter of our board of director authorized billion share repurchase program program under which repurchase may be made in the open market or in privately negotiated transaction during we repurchased and retired million share of our common stock for billion through open market transaction under the program the table below summarizes our stock repurchase activity for the three month ended december in thousand except per share amount total numberof sharespurchased averageprice paidper share total number ofshares purchasedas part of publiclyannounced program maximum fairvalue of sharesthat may yet bepurchased underthe programoctober october november december _________________________________________ the difference between the total number of share purchased and the total number of share purchased part of publicly announced program is due to share of common stock withheld by from employee restricted stock unit award in order to satisfy applicable tax withholding obligation in the first quarter of our board of director authorized new billion stock repurchase program program which will commence upon the completion of the program purchase under the program may be made in the open market or in privately negotiated transaction selected financial data gilead science inc selected consolidated financial data in million except per share amount year ended december statement of income data total revenue cost and expense from operation for income tax income income attributable to gilead income per share attributable to gilead common stockholder basic used in per share calculation income per share attributable to gilead common stockholder diluted used in per share calculation dividend declared per share december balance sheet data cash cash equivalent and marketable debt security capital asset long term obligation term debt including current portion earnings stockholder equity see management discussion and analysis of financial condition and result of operation included in item of this annual report on form for description of our result of operation for in we adopted accounting standard update no topic revenue from contract with customer using the modified retrospective method such result for reporting period beginning after january are presented under topic while prior period amount are not adjusted and continue to be reported in accordance with our historical accounting under topic revenue recognition in december we recorded deferred tax benefit of billion related to intangible asset transfer from foreign subsidiary to ireland and the united state in we recorded deferred tax charge of million related to transfer of acquired intangible asset from foreign subsidiary to the united state in december we recorded an estimated billion net charge related to the enactment of the tax cut and job act tax reform tax reform also lowered the corporate tax rate in the united state from to effective for tax year beginning after december see note income tax of the note to consolidated financial statement included in item of this annual report on form for additional detail investment in equity security other than equity method investment for which we have not elected the fair value method of accounting are recorded at fair market value if fair value is readily determinable and beginning january unrealized gain and loss are included in other income expense net on our consolidated statement of income for period presented prior to january unrealized gain and loss were included in accumulated other comprehensive income separate component of stockholder equity in we repaid billion principal amount of our senior unsecured note at maturity in we repaid billion principal amount of our senior unsecured note at maturity and repaid billion of term loan borrowed in connection with our acquisition of kite pharma inc in in connection with the acquisition of kite pharma inc we issued billion aggregate principal amount of senior unsecured note and borrowed billion aggregate principal amount term loan facility credit agreement of which billion wa repaid in in we issued billion principal amount of senior unsecured note and repaid million of principal balance of convertible senior note and million of principal balance of senior unsecured note at maturity in we issued billion principal amount of senior unsecured note and repaid million of principal balance of convertible senior note at maturity in we adopted accounting standard update no topic lease which requires lessee to recognize right of use asset and lease liability for operating lease with lease term greater than one year we adopted topic using the modified retrospective method such result for reporting period beginning after january are presented under topic while prior period amount are not adjusted and continue to be reported in accordance with our historical accounting under topic lease see note organization and summary of significant accounting policy and note lease of the note to consolidated financial statement included in item of our annual report on form for further information management discussion and analysis of financial condition and result of operationsthe following management discussion and analysis of financial condition and result of operation md is intended to help the reader understand our result of operation and financial condition md is provided supplement to and should be read in conjunction with our audited consolidated financial statement and the accompanying note to consolidated financial statement and other disclosure included in this annual report on form including the disclosure under part item risk factor additional information related to the comparison of our result of operation between the year and is included in item management discussion and analysis of financial condition and result of operation of our form filed with the sec and is incorporated by reference into this annual report on form our consolidated financial statement have been prepared in accordance with generally accepted accounting principle and are presented in dollar management overviewgilead science inc gilead we our or incorporated in delaware on june is research based biopharmaceutical company that discovers develops and commercializes innovative medicine in area of unmet medical need with each new discovery and investigational drug candidate we strive to transform and simplify care for people with life threatening illness around the world we have operation in more than country worldwide with headquarters in foster city california gilead primary area of focus include viral disease inflammatory and fibrotic disease and oncology we seek to add to our existing portfolio of product through our internal discovery and clinical development program product acquisition in licensing and strategic collaboration our portfolio of marketed product includes ambisome atripla biktarvy cayston complera eviplera descovy descovy for prep emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada for prep tybost vemlidy viread vosevi yescarta and zydelig we also sell and distribute authorized generic version of epclusa and harvoni in the united state through our separate subsidiary asegua therapeutic llc in addition we sell and distribute certain product through our corporate partner under collaborative agreement business highlightsour financial performance in wa solid growth across our hiv franchise continued to drive result we took several significant step to position for future growth including an important research and development collaboration the introduction of new corporate strategy and the hiring of key member of our executive leadership team in we developed new corporate strategy to guide our work we seek to drive growth over the next decade with the ambitious goal of launching new transformative therapy over the next year we continued to make progress with our pipeline we currently have clinical stage program with program either in registrational or in label enabling study of these program four have already received breakthrough therapy designation from food and drug administration fda we achieved sale of billion across our hiv franchise in an increase of from reaching another all time high the continued revenue growth of our hiv product wa driven by the demand for biktarvy and the increase in the number of individual taking our product for pre exposure prophylaxis prep at the end of biktarvy wa available in most major market and in the united state approximately of individual on prep were receiving descovy we entered into transformative collaboration with galapagos nv galapagos in july building on an existing partnership and effectively enabling to double our footprint and accelerate our development of novel treatment for inflammatory and fibrotic disease we submitted regulatory filing for filgotinib to fda and the compound is under priority review for rheumatoid arthritis ra we also submitted filgotinib for approval in europe and japan and actively prepared for competitive launch in all three region we and galapagos continued to advance the phase study of glpg for the treatment of idiopathic pulmonary fibrosis with regard to nonalcoholic steatohepatitis nash after the stellar and atlas study failed to reach their primary endpoint we continued to work to understand the result to determine appropriate next step for these therapy including the potential for combination therapeutic approach in cell therapy kite gilead company kite submitted kte for regulatory approval in the united state and europe treatment for relapsed or refractory mantle cell lymphoma mcl if approved kite will be the first company with two cell therapy on the market we also continued to demonstrate the efficacy of yescarta data shared at the end of showed that approximately half of patient treated with yescarta for refractory large cell lymphoma were still alive three year following treatment in the zuma study confirming yescarta benefit risk profile in addition to cell therapy we continued to grow our research portfolio in immuno oncology our business also expanded geographically including in china where eight product have been approved since and four product vemlidy epclusa harvoni and genvoya have been listed on the national reimbursement drug list effective in january we continued to advance our product pipeline across our therapeutic area with the goal of delivering best in class drug that have the potential to improve the life of patient with serious illness key corporate product pipeline and other update included viral disease licensing and collaboration agreement with the rockefeller university novartis ag and lyndra therapeutic inc approval of vosevi and biktarvy by the china national medical product administration approval of prep indication for descovy by fda approval of biktarvy and epclusa by japan ministry of health labour and welfare mhlw inflammatory and fibrotic disease collaboration with kyverna therapeutic inc glympse bio inc renown institute for health innovation goldfinch bio inc insitro inc novo nordisk and yuhan corporation agreement with eisai co ltd for the distribution and co promotion of filgotinib in japan pending regulatory approval from japan mhlw for the treatment of ra submission of new drug application nda under priority review to fda and submission of nda to japan mhlw for filgotinib topline result from the phase atlas study of combination and monotherapy investigational treatment in patient with bridging fibrosis and compensated cirrhosis due to nash while the study did not meet it primary endpoint we continued to analyze the atlas data to determine appropriate next step for these therapy collaboration with galapagos and equity investment in galapagos to gain access to galapagos current and future product portfolio see note collaborative and other arrangement of the note to consolidated financial statement included in item of this annual report on form for additional information european medicine agency validation of the marketing authorization application for filgotinib the application is now under evaluation by the agency oncology fda acceptance of our biologics license application and granting priority review designation for kte for the treatment of adult patient with relapsed or refractory mcl european medicine agency validation of the marketing authorization application for kte the application is now under evaluation by the agency collaboration with carna bioscience inc nurix therapeutic inc humanigen inc and kiniksa pharmaceutical ltd leadership change we have put in place diverse highly experienced leadership team senior leadership change in included the appointment of daniel day chairman and chief executive officer andrew dickinson executive vice president and chief financial officer merdad parsey chief medical officer christi shaw chief executive officer of kite johanna mercier chief commercial officer the departure of john mchutchison chief scientific officer and head of research and development gregg alton chief patient officer and katie watson executive vice president human resource and the planned retirement of robin washington from role executive vice president and chief financial officer other donation to the center for disease control and prevention of up to million bottle of truvada and descovy annually until for uninsured american at risk for hiv financial highlight total revenue increased to billion and total product sale increased to billion in compared to billion and billion in respectively primarily due to higher sale of our hiv product partially offset by lower sale of ranexa and letairis and our hcv product in the united state product sale were billion in compared to billion in in europe product sale were billion in compared to billion in product sale in other international location were billion in compared to billion in cost of good sold decreased to billion in compared to billion in primarily due to million of lower royalty expense and lower amortization expense related to intangible asset associated with ranexa partially offset by higher inventory write down in and we recorded write down of million and million respectively for moving and excess raw material and work in process inventory primarily due to lower long term demand for our hcv product expense increased to billion in compared to billion in primarily due to up front collaboration and licensing expense of billion related to our collaboration with galapagos well higher personnel cost largely to support our cell therapy business partially offset by lower stock based compensation expense in and we recorded impairment charge of million and million respectively related to in process ipr intangible asset acquired in connection with the acquisition of kite pharma inc selling general and administrative sg expense increased to billion in compared to billion in primarily due to promotional expense in the united state and expense associated with the expansion of our business in japan and china partially offset by lower stock based compensation expense net income attributable to gilead changed to billion or per diluted share in compared to billion or per diluted share in primarily due to pre tax up front collaboration and licensing expense of billion related to our collaboration with galapagos partially offset by the net favorable fluctuation in tax effect of intra entity intangible asset transfer to different tax jurisdiction and an increase in net unrealized gain from equity security the year over year diluted earnings per share were favorably impacted by our stock repurchase activity of december we had billion of cash cash equivalent and marketable debt security compared to billion of december during we generated billion in operating cash flow and paid billion in connection with the collaboration with and equity investment in galapagos which wa classified cash flow from investing activity we also repaid billion of principal amount of debt paid cash dividend of billion and utilized billion on repurchase of common stock in strategy and outlook focus is to create possibility for patient through scientific breakthrough and innovation by leveraging our pillar of durable core business existing pipeline opportunity and our strategy to drive additional growth our strategy includes ambition and priority which enable to achieve those ambition our strategic ambition define what success look like over the next decade and are summarized bring transformative therapy to patient by ii be the biotech employer and partner of choice and iii deliver shareholder value in sustainable and responsible manner our strategic priority reflect how we will deliver those ambition expand internal and external innovation ii strengthen portfolio strategy and decision making iii increase patient benefit and access and iv continue to evolve our culture in we expect underlying growth in our base business which is expected to offset the full year impact of our cardiopulmonary product loss of exclusivity which occurred in and the initial generic version of truvada in the united state in late we will also continue to invest to support the growth of biktarvy our descovy for prep launch preparation for competitive launch of filgotinib in ra in the united state japan and europe and continued investment in our pipeline cell therapy and external partnership our overall plan is now guided by our newly established corporate strategy that provides focus and guide resource and capital allocation priority we expect data read out in including filgotinib for ulcerative colitis kte for acute lymphoblastic leukemia all axicabtagene ciloleucel for indolent cell non hodgkin lymphoma inhl and second line diffuse large cell lymphoma and glpg for osteoarthritis to further augment our product pipeline we continue to pursue opportunity for collaboration partnership and strategic investment that fit into our long term strategic plan our progress on all of these initiative is subject to number of uncertainty including but not limited to the possibility of unfavorable result from new and ongoing clinical trial the continuation of an uncertain global macroeconomic environment additional pricing pressure from payer and competitor slower than anticipated growth in our hiv product an increase in discount chargebacks and rebate due to ongoing contract and future negotiation with commercial and government payer market share and price erosion caused by the introduction of generic version of product containing tenofovir disoproxil fumarate tdf outside the united state and viread letairis and ranexa in the united state inaccuracy in our hcv patient start estimate potential amendment to the affordable care act or other government action that could have the effect of lowering price larger than anticipated shift in payer mix to more highly discounted payer segment and volatility in foreign currency exchange rate of operationstotal revenuesthe following table summarizes the period over period change in our revenue in million except percentage change change product sale contract and other revenue revenue compared to product sale increased by to billion in compared to billion in primarily due to higher sale of our hiv product partially offset by lower sale of ranexa and letairis and our hcv product hiv product sale increased by to billion in compared to billion in primarily due to higher sale volume result of the continued uptake of biktarvy the increase wa partially offset by decrease in sale volume of genvoya and our truvada emtricitabine ftc tdf based product and lower average net selling price hcv product sale decreased by to billion in compared to billion in primarily due to lower average net selling price including decline in medicare price in yescarta sale increased by to million in compared to million in primarily due to higher number of therapy provided to patient and the continued expansion in europe other product sale which include vemlidy viread letairis ranexa zydelig ambisome and cayston decreased by to billion in compared to billion in primarily due to the expected decline in sale of ranexa and letairis after the entry of generic version in the united state in early of our total product sale were generated outside the united state in we faced exposure to movement in foreign currency exchange rate primarily in the euro we used foreign currency exchange contract to hedge percentage of our foreign currency exposure foreign currency exchange net of hedge had an immaterial impact on our product sale in based on comparison using foreign currency exchange rate from we record product sale net of estimated government and other rebate and chargebacks cash discount for prompt payment distributor fee and other related cost these deduction are generally referred to gross to net deduction which totaled billion or of gross product sale in compared to billion or of gross product sale in of the billion in billion or of gross product sale in wa related to government and other rebate and chargebacks and billion wa related to cash discount for prompt payment distributor fee and other related cost product sale in the united state increased by to billion in compared to billion in primarily due to higher sale of our hiv product partially offset by lower sale of ranexa and letairis following the entry of generic version in and lower sale of our hcv product the increase in sale of our hiv product wa primarily due to the continued uptake of biktarvy and an increase in the number of individual taking prep partially offset by the decrease in sale volume of our other hiv product including genvoya atripla and stribild the decrease in sale of our hcv product wa primarily due to lower average net selling price including decline in medicare price in product sale in europe decreased by to billion in compared to billion in primarily due to lower sale of our hcv product and the broader availability of generic version of truvada and atripla the decrease in sale of our hcv product wa primarily due to lower patient start and lower average net selling price the decrease wa partially offset by the continued uptake of biktarvy odefsey and yescarta and favorable net adjustment for government rebate related to sale made in prior year product sale in other international location increased by to billion in compared to billion in primarily due to higher hiv product sale in japan result of acquiring the right to certain product in our hiv portfolio in japan effective january and higher hcv product sale in japan due to the launch of epclusa in following table summarizes the period over period change in our product sale in million except percentage change change complera eviplera hiv share symtuza total hiv sofosbuvir velpatasvir product sale percentage is greater than includes emtriva and tybost represents our revenue from cobicistat emtricitabine ftc and tenofovir alafenamide taf in symtuza darunavir ftc taf fixed dose combination product commercialized by janssen science ireland uc amount consist of sale of harvoni and the authorized generic version of harvoni sold by our separate subsidiary asegua therapeutic llc amount consist of sale of epclusa and the authorized generic version of epclusa sold by our separate subsidiary asegua therapeutic llc includes cayston hepsera and sovaldithe following is additional discussion of sale of our hiv and hcv product descovy ftc taf based product biktarvy descovy genvoya odefsey and revenue share symtuzathe following table summarizes the period over period change in our sale of descovy ftc taf based product in million except percentage change change location of total product sale of hiv product sale descovy ftc taf based product sale increased in all major market in compared to the increase in both the united state and europe wa primarily due to higher demand and shift in product mix toward biktarvy the increase in other international location wa primarily due to higher product sale in japan result of acquiring the right to certain product in our hiv portfolio in japan effective january truvada ftc tdf based product atripla complera eviplera stribild and truvadathe following table summarizes the period over period change in our sale of truvada ftc tdf based product in million except percentage change change location of total product sale truvada ftc tdf based product sale decreased in the united state and europe in compared to the decrease in sale wa primarily due to lower sale volume result of patient switching to newer regimen containing ftc taf partially offset by the increased usage of truvada for prep the decrease in europe sale wa primarily due to lower sale volume of truvada and atripla result of the broader availability of generic version and patient switching to newer regimen containing ftc taf we expect decline in our sale of truvada in the united state patient switch to descovy for prep from truvada for prep and the expected entry of generic version in late hcv product epclusa harvoni sovaldi vosevi and authorized generic of epclusa and harvonithe following table summarizes the period over period change in our sale of hcv product in million except percentage change change location of total product sale the decrease in hcv product sale in the united state in compared to wa primarily due to lower average net selling price including decline in medicare price in the decrease in hcv product sale in europe in compared to wa primarily due to lower patient start and lower average net selling price partially offset by favorable net adjustment for government rebate and discount related to sale made in prior year the decrease in hcv product sale in other international location in compared to wa primarily due to lower sale of sovaldi partially offset by higher sale of epclusa cost of good sold and product gross marginthe following table summarizes the period over period change in our product sale cost of good sold and product gross margin in million except percentage change change product sale of good sold gross margin in cost of good sold decreased by million compared to primarily due to lower royalty expense and lower amortization expense related to the intangible asset associated with ranexa which wa fully amortized in the first quarter of partially offset by higher inventory write down in we recorded inventory write down of million of which million wa related to slow moving and excess raw material and work in process inventory primarily due to lower long term demand for our hcv product in we recorded inventory write down of million of which million wa related to excess raw material primarily due to sustained decrease in demand for harvoni result of shift in the market from harvoni to epclusa royalty expense decreased by million in compared to primarily due to lower sale of atripla ranexa letairis and product containing elvitegravir research and development expense the following table summarizes the period over period change in our expense in million except percentage change change expense expense consist primarily of clinical study performed by contract research organization material and supply payment under collaborative and other arrangement including up front and milestone payment license and fee well expense reimbursement to the collaboration partner ipr impairment charge personnel cost including salary benefit and stock based compensation expense and overhead allocation consisting of various support and infrastructure cost we do not track total expense by product candidate therapeutic area or development phase however we manage our expense by identifying the activity we anticipate will be performed during given period and then prioritizing effort based on scientific data probability of technical and regulatory successful development market potential available human and capital resource and other consideration we continually review our project based on unmet medical need and necessary reallocate resource among our internal portfolio and external opportunity that we believe will best support the long term growth of our business the following table provides breakout of our expense by major cost type in million except percentage change change front collaboration and licensing expense infrastructure and other expense study and outside service impairment charge stock based compensation expense percentage is greater than in expense increased by billion compared to primarily due to billion of up front collaboration and licensing expense related to our collaboration with galapagos well higher personnel cost largely to support our cell therapy business and increased investment in our research project partially offset by lower stock based compensation expense in we recorded an impairment charge of million related to ipr intangible asset acquired in connection with our acquisition of kite pharma inc primarily for the treatment of indolent non hodgkin lymphoma largely driven by change in the estimated market opportunity new therapy or combination of existing therapy were approved in we recorded an impairment charge of million related to ipr intangible asset for the kite program an anti cell maturation antigen being evaluated for the treatment of multiple myeloma due to it discontinuance stock based compensation expense for decreased by million compared to primarily due to the impact of stock based compensation expense associated with our acquisition of kite pharma inc selling general and administrative expense the following table summarizes the period over period change in our sg expense in million except percentage change change expense expense relate to sale and marketing finance human resource legal and other administrative activity expense consist primarily of personnel cost facility and overhead cost outside marketing advertising and legal expense and other general and administrative cost sg expense also include the branded prescription drug bpd fee in the united state we along with other pharmaceutical manufacturer of branded drug product are required to pay portion of the bpd fee which is estimated based on select government sale during the prior year percentage of total industry government sale and is trued up upon receipt of invoice from the internal revenue service in sg expense increased by million compared to primarily due to higher promotional expense in the united state and expense associated with the expansion of our business in japan and china partially offset by lower stock based compensation expense stock based compensation expense for decreased by million compared to primarily due to the impact of stock based compensation expense associated with our acquisition of kite pharma inc bpd fee expense were million million and million in and respectively bpd fee expense are not tax deductible income expense net the following table summarizes the period over period change in our other income expense net in million except percentage change change income expense net change in other income expense net in compared to wa primarily due to higher net unrealized gain of billion from change in the fair value of our equity security largely relating to our equity investment in galapagos starting in january we recorded unrealized gain loss from change in the fair value of our marketable equity security in other income expense net on our consolidated statement of income result of the adoption of accounting standard update no financial instrument overall recognition and measurement of financial asset and financial liability provision for income tax the following table summarizes the period over period change in our provision for income tax in million except percentage change change tax rate provision for income tax decrease in effective tax rate and provision for income tax in compared to wa primarily due to billion deferred tax benefit in related to intangible asset transfer from foreign subsidiary to ireland and the united state the effective tax rate included million deferred tax charge resulting from transfer of acquired intangible asset from foreign subsidiary to the united state the decrease in effective tax rate and provision for income tax in compared to wa primarily due to billion net tax charge in and reduction to the corporate tax rate in result of the enactment of the tax cut and job act tax reform in december the effective tax rate wa further decreased due to million tax benefit recorded in related to settlement of tax examination offset by the million deferred tax charge in discussed above change to the geographic mix of earnings and the tax on global intangible low taxed income enacted part of tax reform see note income tax of the note to consolidated financial statement included in item of this annual report on form for additional detail on tax reform liquidity and capital resourcesthe following table summarizes our cash cash equivalent and marketable debt security and working capital december in million cash equivalent and marketable debt security capital cash equivalent and marketable debt securitiescash cash equivalent and marketable debt security decreased by billion or compared to december during we generated billion in operating cash flow paid billion in connection with our collaboration with and equity investment in galapagos repaid billion of debt paid cash dividend of billion and repurchased million share of our common stock for billion through open market transaction working capitalworking capital decreased by billion or compared to december primarily due to the use of cash noted above under the heading cash cash equivalent and marketable debt security flowsthe following table summarizes our cash flow activity in million provided by used in operating activity activity financing activity provided by operating activitiescash provided by operating activity represents the cash receipt and disbursement related to all of our activity other than investing and financing activity operating cash flow is derived by adjusting our net income for non cash item and change in operating asset and liability cash provided by operating activity increased by million to billion in compared to primarily due to lower tax payment in partially offset by lower collection on account receivable in and the collection of receivable from bristol myers squibb company in following the termination of collaboration pursuant to the term of the existing agreement the tax payment made in included million payment related to the first annual installment of the tax reform transition tax million deemed early payment of the tax reform transition tax and million settlement of tax examination starting in up front and milestone payment related to collaborative and other arrangement are classified cash flow from investing activity in our consolidated statement of cash flow comparative prior year amount were not material and were not reclassified to investing activity from operating activity cash provided by used in investing activitiescash provided by used in investing activity primarily consists of purchase sale and maturity of our marketable debt security capital expenditure up front and milestone payment related to collaborative and other arrangement purchase of equity security and other investment cash used in investing activity wa billion in compared to cash provided by investing activity of billion in the change in cash provided by used in investing activity wa primarily due to higher purchase of marketable debt security and the billion payment made in connection with our collaboration with and equity investment in galapagos partially offset by higher proceeds from sale of marketable debt security the higher purchase of marketable debt security were the result of shift in our investment strategy to investing in longer dated security in compared to in addition we paid japan tobacco inc million during in connection with acquiring the right to market and distribute certain hiv product in japan cash provided by investing activity wa billion in compared to cash used in investing activity of billion in the change in cash provided by used in investing activity wa primarily due to higher proceeds from maturity of our marketable debt security and lower purchase of marketable debt security partially offset by lower proceeds from sale of our marketable debt security in addition billion cash wa used to acquire kite pharma inc in whereas no cash wa used for business combination in cash provided by used in financing activitiescash used in financing activity decreased by billion to billion in compared to primarily due to billion lower repayment of debt and billion lower repurchase of our common stock during cash used in financing activity wa billion in compared to cash provided by financing activity of billion in the change in cash provided by used in financing activity wa primarily due to higher repayment of debt and repurchase of our common stock in in addition we had billion net proceeds from debt issuance to partially fund our acquisition of kite pharma inc in whereas no debt wa issued in debt and credit facilitiesin and we repaid at maturity billion and billion principal amount of senior unsecured note respectively in addition in we repaid billion borrowed under our term loan facility credit agreement at which time the term loan facility credit agreement wa terminated in february we repaid at maturity million principal amount of senior unsecured note of december no amount were outstanding under our billion five year revolving credit facility maturing in may are required to comply with certain covenant under our note indenture and of december we were not in violation of any covenant the summary of our borrowing under various financing arrangement is included in note debt and credit facility of the note to consolidated financial statement included in item of this annual report on form capital return programthe detail of our stock repurchase program and dividend are included in note stockholder equity of the note to consolidated financial statement included in item of this annual report on form stock repurchase programsin the first quarter of our board of director authorized billion stock repurchase program program under which repurchase may be made in the open market or in privately negotiated transaction we started repurchase under the program in april repurchase under the program were million and million share of our common stock for billion and billion in and respectively of december the remaining authorized repurchase amount under the program wa billion in the first quarter of our board of director authorized new billion stock repurchase program program which will commence upon the completion of the program purchase under the program may be made in the open market or in privately negotiated transaction dividendswe declared and paid quarterly cash dividend for an aggregate amount of billion or per share of our common stock and billion or per share of our common stock in and respectively on february we announced that our board of director declared quarterly cash dividend increase of from to per share of our common stock with payment date of march to all stockholder of record of the close of business on march future dividend are subject to declaration by the board of director capital resourceswe believe our existing capital resource supplemented by cash flow generated from our operation will be adequate to satisfy our capital need for the foreseeable future our future capital requirement will depend on many factor including but not limited to the following the commercial performance of our current and future product the progress and scope of our effort including preclinical study and clinical trial the cost timing and outcome of regulatory review the expansion of our sale and marketing capability the possibility of acquiring additional manufacturing capability or office facility the possibility of acquiring other company or new product debt service requirement the establishment of additional collaborative relationship with other company and cost associated with the defense settlement and adverse result of government investigation and litigation we may in the future require additional funding which could be in the form of proceeds from equity or debt financing if such funding is required we can not guarantee that it will be available to on favorable term if at all accounting policy estimate and judgmentsthe discussion and analysis of our financial condition and result of operation is based on our consolidated financial statement included in item of this annual report on form which have been prepared in accordance with generally accepted accounting principle the preparation of these financial statement requires to make estimate and judgment that affect the reported amount of asset liability revenue and expense and related disclosure on an ongoing basis we evaluate and base our estimate on historical experience and on various other market specific and other relevant assumption that we believe to be reasonable under the circumstance the result of which form the basis for making judgment about the carrying value of asset and liability that are not readily apparent from other source actual result may differ significantly from these estimate we believe the following critical accounting policy reflect the more significant judgment and estimate used in the preparation of our consolidated financial statement revenue recognition product sale we recognize revenue from product sale when control of the product transfer generally upon shipment or delivery to the customer or in certain case upon the corresponding sale by our customer to third party upon recognition of revenue from product sale provision are made for various form of variable consideration which include government and other rebate such medicaid reimbursement customer incentive such cash discount for prompt payment distributor fee and expected return of expired product appropriate variable consideration is included in the net sale price only to the extent significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved government and other rebate and chargebacks represent the majority of our variable consideration and require complex and significant judgment by management estimate are assessed each period and updated to reflect current information government and other rebate and chargebacksgovernment and other rebate and chargebacks include amount paid to payer and healthcare provider in the united state including medicaid rebate aid drug assistance program rebate and chargebacks veteran administration and public health service chargebacks and other rebate well foreign government rebate rebate and chargebacks are based on contractual arrangement or statutory requirement which may vary by product by payer and individual payer plan for qualified program that can purchase our product through wholesaler or other distributor at lower contractual price the wholesaler or distributor charge back to the difference between their acquisition cost and the lower contractual price our allowance for government and other rebate and chargebacks are estimated based on product sold historical payer mix and available pertinent third party industry information estimated patient population known market event or trend and for our product sale channel inventory data obtained from our major wholesaler in accordance with our inventory management agreement we also take into consideration available new information regarding change in program regulation and guideline that would impact the amount of the actual rebate and or our expectation regarding future payer mix for these program we believe the methodology that we use to estimate our government and other rebate and chargebacks is reasonable and appropriate given the current fact and circumstance however actual result may differ significantly from our estimate historically our actual government rebate and chargebacks claimed for prior period have varied by le than from our estimate government and other chargebacks that are payable to our direct customer are classified reduction of account receivable in our consolidated balance sheet and totaled million and million at december and respectively government and other rebate that are payable to third party payer and healthcare provider are recorded in accrued government and other rebate on our consolidated balance sheet and totaled billion and billion at december and respectively following table summarizes the consolidated activity and ending balance in our government and other rebate and chargebacks account in million balance at beginning of year decrease increase to product sale payment balance at end of yearyear ended december activity related to sale related to sale prior to ended december activity related to sale related to sale prior to contingencieswe are party to various legal action the most significant of these are described in note commitment and contingency legal proceeding of the note to consolidated financial statement included in item of this annual report on form it is not possible to determine the outcome of these matter we recognize accrual for such action to the extent that we conclude that loss is both probable and reasonably estimable we accrue for the best estimate of loss within range however if no estimate in the range is better than any other then we accrue the minimum amount in the range if we determine that loss is reasonably possible and the loss or range of loss can be estimated we disclose the possible loss significant judgment is required in both the determination of probability and the determination to whether an exposure is reasonably estimable because of the inherent uncertainty and unpredictability related to these matter accrual are based on what we believe to be the best information available at the time of our assessment including the legal fact and circumstance of the case status of the proceeding applicable law and the view of legal counsel upon the final resolution of such matter it is possible that there may be loss in excess of the amount recorded and such amount could have material adverse effect on our result of operation cash flow or financial position we periodically reassess these matter when additional information becomes available and adjust our estimate and assumption when fact and circumstance indicate the need for any change we did not have any material accrual in our consolidated balance sheet for such matter of december and valuation of intangible asset we have acquired and expect to continue to acquire intangible asset through acquisition or consolidation of variable interest entity the identifiable intangible asset are measured at their respective fair value of the acquisition date and may be subject to revision within the measurement period which may be up to one year from the acquisition date the fair value of the asset are generally determined using probability weighted income approach that discount expected future cash flow to present value the estimated net cash flow are discounted using discount rate that is based on the estimated weighted average cost of capital for company with profile similar to our profile and represents the rate that market participant would use to value the intangible asset the discounted cash flow model used in valuing these intangible asset require the use of significant estimate and assumption including but not limited to estimate of revenue and operating profit related to the product or product candidate the probability of technical and regulatory success for unapproved product candidate considering their stage of development the time and resource needed to complete the development and approval of product candidate the life of the potential commercialized product and associated risk including the inherent difficulty and uncertainty in developing product candidate such obtaining fda and other regulatory approval and risk related to the viability of and potential alternative treatment in any future target market we believe the fair value used to record intangible asset acquired are based upon reasonable estimate and assumption given the fact and circumstance of the related valuation date intangible asset related to ipr project are considered to be indefinite lived until the completion or abandonment of the associated effort during the period the asset are considered indefinite lived they are not amortized when development is complete which generally occurs if and when regulatory approval to market product is obtained the associated asset would deemed finite lived and then be amortized based on their respective estimated useful life at that point in time primarily on straight line basis intangible asset are reviewed for impairment on an annual basis well between annual test if we become aware of any event or change that would indicate that it is more likely than not that the fair value of the intangible asset and or ipr project are below their respective carrying amount when performing quantitative impairment assessment we calculate the fair value using discounted cash flow model that require significant estimate and assumption similar to the methodology for determining the acquisition date fair value of intangible asset described above if the carrying value of an intangible asset exceeds it fair value then the intangible asset is written down to it fair value significant judgment is employed in determining these estimate and assumption and change to our estimate and assumption could have significant impact on our result of operation in any given period for example in we recognized an million impairment charge related to ipr project primarily for the treatment of indolent non hodgkin lymphoma due to change in estimated market opportunity there are often major risk and uncertainty associated with ipr project we are required to obtain regulatory approval in order to be able to market these product such approval require completing clinical trial that demonstrate product candidate is safe and effective consequently the eventual realized value of the acquired ipr project may vary from it fair value at the date of acquisition and ipr impairment charge may occur in future period which could have material adverse effect on our result of operation for example in we concluded that the kite program acquired in connection with our acquisition of kite pharma inc did not justify further effort based on the totality of the clinical data gathered and discontinued the program result the carrying value of the ipr relating to the kite program wa written down to zero and we recorded an impairment charge of million see note intangible asset of the note to consolidated financial statement included in item of this annual report on form for additional information on the impairment charge related to our indefinite lived ipr intangible asset provision for income taxeswe estimate our income tax provision including deferred tax asset and liability based on significant management judgment we evaluate the realization of all or portion of our deferred tax asset on quarterly basis we record valuation allowance to reduce our deferred tax asset to the amount that are more likely than not to be realized we consider future taxable income ongoing tax planning strategy and our historical financial performance in assessing the need for valuation allowance if we expect to realize deferred tax asset for which we have previously recorded valuation allowance we will reduce the valuation allowance in the period in which such determination is first made we are subject to income tax in the united state and various foreign jurisdiction including ireland due to economic and political condition various country are actively considering and have made change to existing tax law for example the united state enacted significant tax reform and certain provision of the new law will continue to significantly affect we can not predict the form or timing of potential legislative change that could have material adverse impact on our result of operation in addition significant judgment is required in determining our worldwide provision for income tax we record liability related to uncertain tax position in accordance with the guidance that clarifies the accounting for uncertainty in income tax recognized in an enterprise financial statement by prescribing minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of tax position taken or expected to be taken in tax return an adverse resolution of one or more of these uncertain tax position in any period could have material impact on the result of operation for that period see note income tax of the note to consolidated financial statement included in item of this annual report on form for additional information off balance sheet arrangementswe do not have any off balance sheet arrangement defined in item ii of regulation obligationscontractual obligation represent future cash commitment related to significant enforceable and legally binding obligation and certain purchase obligation that we are likely to continue regardless of the fact that they may be cancelable the expected timing and payment amount presented below are estimated based on existing contract and do not reflect any future modification to or termination of existing contract or anticipated or potential new contract the following table summarizes the aggregate maturity of our contractual obligation of december payment due by period in million total thereafterdebt lease obligation obligation tax payable debt consists of senior unsecured note and includes principal and future interest payment interest payment for our fixed rate senior unsecured note are incurred and calculated based on term of the related note see note debt and credit facility of the note to consolidated financial statement included in item of this annual report on form for additional information see note lease of the note to consolidated financial statement included in item of this annual report on form for additional information amount primarily relate to capital commitment active pharmaceutical ingredient api with minimum purchase commitment and certain inventory related item advertising and commitment significant commitment related to clinical study performed by contract research organization cro are excluded from the table material cro contract are cancelable by in addition the table doe not reflect approximately million of additional minimum purchase commitment resulting from an api contract amended in january in connection with tax reform we recorded federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight year period the amount included in the table above represent the remaining federal income tax payable at december of december our long term income tax payable includes unrecognized tax benefit interest and penalty totaling billion due to the high degree of uncertainty on the timing of future cash settlement and other event that could extinguish these unrecognized tax benefit we are unable to estimate the period of cash settlement and therefore we have excluded these unrecognized tax benefit we have committed to make potential future milestone and other payment to third party part of licensing collaboration development and other arrangement payment under these agreement generally are contingent upon certain future event including achievement of certain developmental regulatory or commercial milestone because the achievement of these event is neither probable reasonably estimable and such potential payment have not been recorded in our consolidated balance sheet they have not been included in the table above recent accounting pronouncementsthe information required by this item is included in note organization and summary of significant accounting policy of the note to consolidated financial statement included in item of this annual report on form item quantitative and qualitative disclosure about market riskwe are exposed to market risk that may result from change in foreign currency exchange rate interest rate credit risk and market price to reduce certain of these risk we enter into various type of foreign currency or interest rate derivative hedging transaction follow investment guideline and monitor outstanding receivables part of our risk management program foreign currency exchange risk we have operation in more than country worldwide result our financial result could be significantly affected by factor such change in foreign currency exchange rate or weak economic condition in the foreign market in which we distribute our product our operating result are exposed to change in foreign currency exchange rate between the dollar and various foreign currency the most significant of which is the euro when the dollar strengthens against these currency the relative value of sale made in the respective foreign currency decrease conversely when the dollar weakens against these currency the relative amount of such sale increase overall we are net receiver of foreign currency and therefore benefit from weaker dollar and are adversely affected by stronger dollar relative to those foreign currency in which we transact significant amount of business approximately of our product sale were denominated in foreign currency during to partially mitigate the impact of change in currency exchange rate on net cash flow from our foreign currency denominated sale we may enter into foreign currency exchange forward and option contract we also hedge certain monetary asset and liability denominated in foreign currency which reduces but doe not eliminate our exposure to currency fluctuation between the date transaction is recorded and the date that cash is collected or paid in general the market risk of these contract are offset by corresponding gain and loss on the transaction being hedged of december and we had open foreign currency forward contract with notional amount of billion and billion respectively hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate at december and december would have resulted in reduction in fair value of these contract of approximately million and million respectively on this date and if realized would negatively affect earnings over the remaining life of the contract the analysis doe not consider the impact that hypothetical change in foreign currency exchange rate would have on anticipated transaction that these foreign currency sensitive instrument were designed to offset interest rate risk our portfolio of available for sale debt security and our fixed rate long term debt create an exposure to interest rate risk with respect to our investment portfolio we adhere to an investment policy that requires to limit amount invested in security based on credit rating maturity industry group and investment type and issuer except for security issued by the government the goal of our investment policy in order of priority are follows safety and preservation of principal and diversification of risk liquidity of investment sufficient to meet cash flow requirement and competitive after tax rate of return the following table summarizes the expected maturity and average interest rate of our interest generating asset and interest bearing liability at december expected maturity total fair value in million except percentage thereafter total asset available for sale debt security interest rate liability fixed rate long term debt including current portion interest rate _________________________________________ amount represent principal balance in addition to the fixed rate long term debt we have billion five year revolving credit facility that matures in may there were no amount outstanding under the five year revolving credit facility of december see note debt and credit facility of the note to consolidated financial statement included in item of this annual report on form for additional information market price risk we hold share of common stock of certain publicly traded biotechnology company primarily in connection with license and collaboration agreement these equity security are measured at fair value with any change in fair value recognized in earnings the fair value of these equity security wa approximately billion and million of december and respectively change in fair value of these equity security are impacted by the volatility of the stock market and change in general economic condition among other factor hypothetical increase or decrease in the stock price of these equity security would increase or decrease their fair value at december and by approximately million and million respectively financial statement and supplementary data gilead science inc index to consolidated financial statement and supplementary datayears ended december and contentsreport of independent registered public accounting firm consolidated financial statement consolidated balance sheet statement of income statement of comprehensive income statement of stockholder equity statement of cash flow to consolidated financial statement quarterly financial information unaudited ii valuation and qualifying account of independent registered public accounting firm to the stockholder and the board of director of gilead science inc opinion on the financial statementswe have audited the accompanying consolidated balance sheet of gilead science inc the company of december and the related consolidated statement of income comprehensive income stockholder equity and cash flow for each of the three year in the period ended december and the related note and financial statement schedule listed in the index at item collectively referred to the consolidated financial statement in our opinion the consolidated financial statement present fairly in all material respect the financial position of the company at december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework and our report dated february expressed an unqualified opinion thereon basis for opinion these financial statement are the responsibility of the company management our responsibility is to express an opinion on the company financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the financial statement we believe that our audit provide reasonable basis for our opinion critical audit mattersthe critical audit matter communicated below are matter arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the financial statement and involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate government and commercial rebatesdescription of the matter more fully described in note the company estimate reduction to it revenue for amount payable to payer and healthcare provider in the united state under various government and commercial rebate program in the period that the related sale occur rebate may vary by product payer and individual payer plan which may not be known at the point of sale estimated reduction to revenue are based on product sold historical payer mix historical discount rate and various other estimated and actual data adjusted for current period expectation auditing the company estimated reduction to revenue for rebate wa complex and involved significant judgment particularly in assessing the reasonableness of estimated payer utilization and discount rate applied to sale during the period these estimate rely heavily on historical data that is adjusted for change in utilization and discount rate over time we addressed the matter in our audit we evaluated and tested the design and operating effectiveness of the company internal control over management estimation and review of reduction from revenue for rebate program including control to ass the utilization rate and discount rate assumption we also tested the completeness and accuracy of data utilized in the control and the accuracy of calculation supporting management estimate to test management estimation methodology for determining the utilization and discount rate our audit procedure included among others evaluating evidence contrary to the estimated amount performing sensitivity analysis on the rate used in the estimate and performing comparison of actual payment related to amount accrued during the current and prior year valuation of in process research and development intangible assetsdescription of the matter at december the company in process research and development ipr intangible asset were billion the company recorded an impairment charge of million during the year discussed in note intangible asset with indefinite useful life related to purchased ipr project are measured at their respective fair value of the acquisition date and are considered indefinite lived until the completion or abandonment of the associated effort the company test indefinite lived intangible asset for impairment on an annual basis and in between annual test if they become aware of any event or change that would indicate the fair value of the asset are below their carrying amount auditing the impairment test wa complex due to the significant judgment required in estimating the fair value of the ipr intangible asset in particular the fair value estimate were sensitive to significant assumption discount rate projected research and development cost probability of technical success addressable patient population projected market share and product profitability which were affected by expected future market or economic condition how we addressed the matter in our audit we evaluated and tested the design and operating effectiveness of the company internal control over the determination of the estimated fair value of the ipr intangible asset for example we tested control over management review of the valuation model and the significant assumption used to develop the fair value estimate of the indefinite lived intangible asset we also tested management control to validate that the data used in the fair value estimate were complete and accurate to test the estimated fair value of the company ipr intangible asset our audit procedure included among others evaluating the company use of appropriate valuation methodology with the assistance of valuation specialist testing the significant assumption discussed above and testing the completeness and accuracy of the underlying data for example we compared the significant assumption to current industry market and economic trend to historical result of the company business and other guideline company within the industry and to other relevant factor in addition to evaluate the probability of technical success we considered the phase of development of the ipr project and the company history of obtaining regulatory approval we also performed sensitivity analysis of the significant assumption to evaluate the change in the estimated fair value of the ipr intangible asset resulting from change in the assumption ernst young llpwe have served the company auditor since san jose california february science inc consolidated balance sheet in million except per share amount december current asset cash and cash equivalent term marketable receivable net of allowance of and and other current current plant and equipment term marketable asset long term asset and stockholder equity current liability account payable government and other accrued portion of long term debt and other obligation current term debt term income tax long term and contingency note stockholder equity preferred stock par value per share share authorized none outstanding common stock par value per share authorized and share issued and outstanding paid in capital other comprehensive gilead stockholder stockholder liability and stockholder equity accompanying note science inc consolidated statement of income in million except per share amount year ended december product sale contract and other revenue revenue and expense cost of good sold and development expense general and administrative expense cost and expense from operation expense other income expense net before provision for income tax for income tax income loss income attributable to noncontrolling interest income attributable to gilead income per share attributable to gilead common stockholder basic used in per share calculation basic income per share attributable to gilead common stockholder diluted used in per share calculation diluted accompanying note science inc consolidated statement of comprehensive income in million year ended december income comprehensive income loss net foreign currency translation gain loss net of tax available for sale debt security net unrealized gain net of tax to net income net of tax net change flow hedge net unrealized gain loss net of tax reclassification to net income net of tax change other comprehensive income loss comprehensive income loss income attributable to noncontrolling interest income attributable to gilead accompanying note science inc consolidated statement of stockholder equity in million except per share amount gilead stockholder equity noncontrollinginterest totalstockholders equity common stock additionalpaid incapital accumulatedothercomprehensive income loss retainedearnings share amount balance at december in noncontrolling interest net income comprehensive loss net of tax issuance under employee stock purchase plan under equity incentive plan based compensation of common stock dividend declared per share balance at december in noncontrolling interest income comprehensive income net of tax under employee stock purchase plan under equity incentive plan based compensation of common stock dividend declared per share cumulative effect from the adoption of new accounting standard at december income loss comprehensive income net of tax under employee stock purchase plan under equity incentive plan based compensation of common stock dividend declared per share cumulative effect from the adoption of new accounting standard note at december accompanying note science inc consolidated statement of cash flow in million year ended december activity net income to reconcile net income to net cash provided by operating activity depreciation expense expense based compensation expense income tax net gain from equity security up front and milestone expense related to collaborative and other arrangement in process research and development impairment write down for slow moving and excess raw material and work in process inventory other in operating asset and liability account receivable net prepaid expense and other payable income tax payable liability net cash provided by operating activity investing activity purchase of marketable debt security proceeds from sale of marketable debt security from maturity of marketable debt security front and milestone payment related to collaborative and other arrangement purchase of equity security acquisition net of cash acquired capital expenditure other net cash used in provided by investing activity financing activity proceeds from debt financing net of issuance cost from issuance of common stock of common stock repayment of debt and other obligation payment of dividend other net cash used in provided by financing activity of exchange rate change on cash and cash equivalent change in cash and cash equivalent cash and cash equivalent at beginning of period and cash equivalent at end of period supplemental disclosure of cash flow information interest paid net of amount capitalized tax paid accompanying note science inc note to consolidated financial organization and summary of significant accounting policiesoverviewgilead science inc gilead we our or incorporated in delaware on june is research based biopharmaceutical company that discovers develops and commercializes innovative medicine in area of unmet medical need with each new discovery and investigational drug candidate we strive to transform and simplify care for people with life threatening illness around the world we have operation in more than country worldwide with headquarters in foster city california gilead primary area of focus include viral disease inflammatory and fibrotic disease and oncology we seek to add to our existing portfolio of product through our internal discovery and clinical development program product acquisition in licensing and strategic collaboration our portfolio of marketed product includes ambisome atripla biktarvy cayston complera eviplera descovy descovy for prep emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvada for prep tybost vemlidy viread vosevi yescarta and zydelig we also sell and distribute authorized generic version of epclusa and harvoni in the united state through our separate subsidiary asegua therapeutic llc in addition we sell and distribute certain product through our corporate partner under collaborative agreement basis of presentationthe accompanying consolidated financial statement include the account of gilead our wholly owned subsidiary and certain variable interest entity for which we are the primary beneficiary all intercompany transaction have been eliminated for consolidated entity where we own or are exposed to le than of the economics we record net income loss attributable to noncontrolling interest in our consolidated statement of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party we ass whether we are the primary beneficiary of variable interest entity vie at the inception of the arrangement and at each reporting date this assessment is based on our power to direct the activity of the vie that most significantly impact the vie economic performance and our obligation to absorb loss or the right to receive benefit from the vie that could potentially be significant to the vie significant accounting policy estimate and judgment the preparation of these consolidated financial statement requires to make estimate and judgment that affect the reported amount of asset liability revenue and expense and related disclosure on an ongoing basis we evaluate our significant accounting policy and estimate we base our estimate on historical experience and on various market specific and other relevant assumption that we believe to be reasonable under the circumstance the result of which form the basis for making judgment about the carrying value of asset and liability that are not readily apparent from other source actual result may differ significantly from these estimate revenue recognition on january we adopted accounting standard update no revenue from contract with customer topic using the modified retrospective method topic supersedes the revenue recognition requirement in topic revenue recognition topic result we have changed our accounting policy for revenue recognition detailed below policy election and practical expedient taken we account for shipping and handling activity that are performed after customer ha obtained control of good fulfillment cost rather than separate performance obligation and if we expect at contract inception that the period between the transfer of control and corresponding payment from the customer will be one year or le we do not adjust the amount of consideration for the effect of significant financing component product saleswe recognize revenue from product sale when control of the product transfer generally upon shipment or delivery to the customer or in certain case upon the corresponding sale by our customer to third party upon recognition of revenue from product sale provision are made for various form of variable consideration which include government and other rebate such medicaid reimbursement customer incentive such cash discount for prompt payment distributor fee and expected return of expired product appropriate variable consideration is included in the net sale price only to the extent significant reversal the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved our payment term to customer generally range from to day variable considerationrebates and chargebackswe estimate reduction to our revenue for amount paid to payer and healthcare provider in the united state including medicaid rebate aid drug assistance program rebate and chargebacks veteran administration and public health service rebate and chargebacks well foreign government rebate rebate and chargebacks are based on contractual arrangement or statutory requirement which may vary by product payer and individual payer plan our estimate are based on product sold historical payer mix and available pertinent third party industry information estimated patient population known market event or trend and for our product sale channel inventory data obtained from our major wholesaler in accordance with our inventory management agreement we also take into consideration available new information regarding change in program regulation and guideline that would impact the amount of the actual rebate and or our expectation regarding future payer mix for these program government and other chargebacks that are payable to our direct customer are classified reduction of account receivable on our consolidated balance sheet government and other rebate that are payable to third party payer and healthcare provider are recorded in accrued government and other rebate on our consolidated balance sheet cash discountswe estimate cash discount based on contractual term historical customer payment pattern and our expectation regarding future customer payment pattern distributor feesunder our inventory management agreement with our significant wholesaler we pay the wholesaler fee primarily for compliance with certain contractually determined covenant such the maintenance of agreed upon inventory level these distributor fee are based on contractually determined fixed percentage of sale product returnswe do not provide our customer with general right of product return but typically permit return if the product is damaged defective or otherwise can not be used when received by the customer or in the case of product sold in the united state and certain other country if the product ha expired we will accept return for product that will expire within six month or that have expired up to one year after their expiration date our estimate for expected return of expired product are based primarily on an ongoing analysis of our historical return pattern historical industry information reporting the return rate for similar product and contractual agreement intended to limit the amount of inventory maintained by our wholesaler royalty contract and other revenuesroyalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sale by our corporate partner occur research and development expensesresearch and development expense consist primarily of personnel cost including salary benefit and stock based compensation clinical study performed by contract research organization cro material and supply payment under collaborative and other arrangement including up front and milestone payment license and option fee well expense reimbursement to the collaboration partner and overhead allocation consisting of various support and infrastructure cost we charge cost including clinical study cost to expense when incurred clinical study cost are significant component of expense most of our clinical study are performed by third party cro we monitor level of performance under each significant contract including the extent of patient enrollment and other activity through communication with our cro we accrue cost for clinical study performed by cro over the service period specified in the contract and adjust our estimate if required based upon our ongoing review of the level of effort and cost actually incurred by the cro all of our material cro contract are terminable by upon written notice and we are generally only liable for actual service completed by the cro and certain non cancelable expense incurred at any point of termination selling general and administrative expensesselling general and administrative sg expense relate to sale and marketing finance human resource legal and other administrative activity sg expense consist primarily of personnel cost facility and overhead cost outside marketing advertising and legal expense and other general and administrative cost sg expense also include the branded prescription drug bpd fee in the united state we along with other pharmaceutical manufacturer of branded drug product are required to pay portion of the bpd fee which is estimated based on select government sale during the prior year percentage of total industry government sale expense the cost of advertising including promotional expense incurred advertising expense were million million and million for the year ended december and respectively cash and cash equivalent we consider highly liquid investment with insignificant interest rate risk and an original maturity of three month or le on the purchase date to be cash equivalent marketable and nonmarketable security marketable debt securitieswe determine the appropriate classification of our marketable debt security at the time of purchase and reevaluate such designation at each balance sheet date all of our marketable debt security are considered available for sale and carried at estimated fair value and reported in cash equivalent short term marketable security or long term marketable security unrealized gain and loss on available for sale debt security are excluded from net income and reported in accumulated other comprehensive income loss aoci separate component of stockholder equity other income expense net includes interest amortization of purchase premium and discount realized gain and loss on sale of security and other than temporary decline in the fair value of security if any the cost of security sold is based on the specific identification method we regularly review all of our investment for other than temporary decline in fair value our review includes the consideration of the cause of the impairment including the creditworthiness of the security issuer the number of security in an unrealized loss position the severity and duration of the unrealized loss whether we have the intent to sell the security and whether it is more likely than not that we will be required to sell the security before the recovery of their amortized cost basis when we determine that the decline in fair value of an investment is below our accounting basis and the decline is other than temporary we reduce the carrying value of the security we hold and record loss for the amount of such decline marketable and non marketable equity securitiesinvestments in equity security other than equity method investment are recorded at fair market value if fair value is readily determinable and beginning january unrealized gain and loss are included in other income expense net on our consolidated statement of income for period presented prior to january unrealized gain and loss were included in aoci separate component of stockholder equity for investment in entity over which we have significant influence but do not meet the requirement for consolidation and have not elected the fair value option we use the equity method of accounting with our share of the underlying income or loss of such entity reported in other income expense net on our consolidated statement of income we have elected the fair value option to account for our equity investment in galapagos nv galapagos over which we have significant influence we believe the fair value option best reflects the underlying economics of the investment see note collaborative and other arrangement for additional information equity security without readily determinable fair value are recorded using the measurement alternative of cost le impairment if any adjusted for observable price change in orderly transaction for identical or similar investment of the same issuer certain investment in equity security of non public company are accounted for using the equity method based on our ownership percentage and other factor that indicate we have significant influence over the investee investment in equity security without readily determinable fair value and investment in non public company that are accounted for using the equity method of accounting are not material for the period presented our investment in equity security are recorded in prepaid and other current asset or other long term asset on our consolidated balance sheet we regularly review our security for indicator of impairment concentration of riskwe are subject to credit risk from our portfolio of cash equivalent and marketable security under our investment policy we limit amount invested in such security by credit rating maturity industry group investment type and issuer except for security issued by the government we are not exposed to any significant concentration of credit risk from these financial instrument the goal of our investment policy in order of priority are follows safety and preservation of principal and diversification of risk liquidity of investment sufficient to meet cash flow requirement and competitive after tax rate of return we are also subject to credit risk from our account receivable related to our product sale trade account receivable are recorded net of allowance for wholesaler chargebacks related to government and other program cash discount for prompt payment and doubtful account estimate of our allowance for doubtful account are determined based on existing contractual payment term historical payment pattern of our customer and individual customer circumstance an analysis of day sale outstanding by geographic region and review of the local economic environment and it potential impact on government funding and reimbursement practice the majority of our trade account receivable arises from product sale in the united state europe japan to date we have not experienced significant loss with respect to the collection of our account receivable we believe that our allowance for doubtful account wa adequate at december certain of the raw material and component that we utilize in our operation are obtained through single supplier certain of the raw material that we utilize in our operation are made at only one facility since the supplier of key component and raw material must be named in new drug application filed with food and drug administration fda for product significant delay can occur if the qualification of new supplier is required if delivery of material from our supplier is interrupted for any reason we may be unable to ship our commercial product or to supply our product candidate for clinical trial inventoriesinventories are recorded at the lower of cost or net realizable value with cost determined on first in first out basis we periodically review our inventory to identify obsolete slow moving excess or otherwise unsaleable item if obsolete slow moving excess or unsaleable item are observed and there are no alternate us for the inventory we record write down to net realizable value through charge to cost of good sold on our consolidated statement of income the determination of net realizable value requires judgment including consideration of many factor such estimate of future product demand product net selling price current and future market condition and potential product obsolescence among others when future commercialization is considered probable and the future economic benefit is expected to be realized based on management judgment we capitalize pre launch inventory cost prior to regulatory approval number of factor are considered including the current status in the regulatory approval process potential impediment to the approval process such safety or efficacy anticipated initiative that could impact the indication in which the compound will be used viability of commercialization and marketplace trend property plant and equipmentproperty plant and equipment is stated at cost le accumulated depreciation and amortization depreciation and amortization are recognized using the straight line method repair and maintenance cost are expensed incurred estimated useful life in year are generally follows descriptionestimated useful life building and improvementsshorter of year or useful lifelaboratory and manufacturing and computer improvementsshorter of useful life or lease termacquisitionswe account for business combination using the acquisition method of accounting which requires that asset acquired including in process research and development ipr project and liability assumed be recorded at their fair value of the acquisition date on our consolidated balance sheet any excess of purchase price over the fair value of net asset acquired is recorded goodwill the determination of estimated fair value requires to make significant estimate and assumption result we may record adjustment to the fair value of asset acquired and liability assumed within the measurement period up to one year from the acquisition date with the corresponding offset to goodwill transaction cost associated with business combination are expensed they are incurred when we determine net asset acquired do not meet the definition of business combination under the acquisition method of accounting the transaction is accounted for an acquisition of asset and therefore no goodwill is recorded and contingent consideration such payment upon achievement of various developmental regulatory and commercial milestone generally is not recognized at the acquisition date in an asset acquisition up front payment allocated to ipr project at the acquisition date and subsequent milestone payment are charged to expense in our consolidated statement of income unless there is an alternative future use goodwill and intangible assetsgoodwill represents the excess of the consideration transferred over the estimated fair value of asset acquired and liability assumed in business combination intangible asset are measured at their respective fair value of the acquisition date and may be subject to revision within the measurement period which may be up to one year from the acquisition date intangible asset related to ipr project are considered to be indefinite lived until the completion or abandonment of the associated effort we do not amortize goodwill and intangible asset with indefinite useful life we test goodwill and indefinite lived intangible asset for impairment on an annual basis and in between annual test if we become aware of any event or circumstance that would indicate the fair value of the asset are below their carrying amount development is successfully completed which generally occurs when regulatory approval is obtained the associated asset are deemed finite lived and amortized over their respective estimated useful life beginning at that point in time intangible asset with finite useful life are amortized over their estimated useful life primarily on straight line basis and are reviewed for impairment when fact or circumstance indicate that the carrying value of these asset may not be recoverable impairment of long lived assetslong lived asset including property plant and equipment and finite lived intangible asset are reviewed for impairment whenever fact or circumstance either internally or externally may indicate that the carrying value of an asset may not be recoverable should there be an indication of impairment we test for recoverability by comparing the estimated undiscounted future cash flow expected to result from the use of the asset to the carrying amount of the asset or asset group if the asset or asset group is determined to be impaired any excess of the carrying value of the asset or asset group over it estimated fair value is recognized an impairment loss foreign currency translation transaction gain and loss and hedging contractsnon entity operation are recorded in the functional currency of each entity result of operation for non dollar functional currency entity are translated into dollar using average currency rate asset and liability are translated using currency rate at period end foreign currency translation adjustment are recorded component of aoci within stockholder equity foreign currency transaction gain and loss are recorded in other income expense net on our consolidated statement of income net foreign currency transaction gain and loss were not material for the year ended december and we hedge portion of our foreign currency exposure related to outstanding monetary asset and liability well forecasted product sale using foreign currency exchange forward contract in general the market risk related to these contract is offset by corresponding gain and loss on the hedged transaction the credit risk associated with these contract is driven by change in interest and currency exchange rate and result varies over time by working only with major bank and closely monitoring current market condition we seek to limit the risk that counterparties to these contract may be unable to perform we also seek to limit our risk of loss by entering into contract that permit net settlement at maturity therefore our overall risk of loss in the event of counterparty default is limited to the amount of any unrealized gain on outstanding contract those contract that have positive fair value at the date of default we do not enter into derivative contract for trading purpose fair value of financial instrumentswe apply fair value accounting for all financial asset and liability and non financial asset and liability that are recognized or disclosed at fair value in the financial statement on recurring basis we define fair value the price that would be received from selling an asset or paid to transfer liability in an orderly transaction between market participant at the measurement date when determining the fair value measurement for asset and liability which are required to be recorded at fair value we consider the principal or most advantageous market in which we would transact and the market based risk measurement or assumption that market participant would use in pricing the asset or liability such risk inherent in valuation technique transfer restriction and credit risk derivative financial instrumentswe recognize all derivative instrument either asset or liability at fair value on our consolidated balance sheet change in the fair value of derivative designated part of hedge transaction are recorded each period in current earnings or aoci change in the fair value of derivative that are not part of hedge transaction are recorded each period in current earnings we ass both at inception and on an ongoing basis whether the derivative that are used in hedging transaction are effective in offsetting the change in cash flow or fair value of the hedged item if we determine that forecasted transaction is probable of not occurring we discontinue hedge accounting for the affected portion of the hedge instrument and any related unrealized gain or loss on the contract is recognized in other income expense net on our consolidated statement of income income taxesour income tax provision is computed under the liability method deferred tax asset and liability are determined based on the difference between the financial statement and tax basis of asset and liability using enacted tax rate in effect for the year in which the difference are expected to reverse significant estimate are required in determining our provision for income tax some of these estimate are based on interpretation of applicable tax law or regulation we record liability related to unrecognized tax benefit in accordance with the guidance that clarifies the accounting for uncertainty in income tax recognized in an enterprise financial statement by prescribing minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of tax position taken or expected to be taken tax return an adverse resolution of one or more of these uncertain tax position in any period could have material impact on the result of operation for that period we have elected to account for the tax on global intangible low taxed income gilti enacted part of the tax cut and job act tax reform component of tax expense in the period in which the tax is incurred period cost method presentation of cash flowsstarting in up front and milestone payment related to collaborative and other arrangement are classified cash flow from investing activity in our consolidated statement of cash flow comparative prior year amount were not material and were not reclassified to investing activity from operating activity recently adopted accounting pronouncementsin february the financial accounting standard board fasb issued accounting standard update no lease asu and subsequently issued supplemental adoption guidance and clarification collectively topic topic amends number of aspect of lease accounting including requiring lessee to recognize right of use asset and lease liability for operating lease with lease term greater than one year topic supersedes topic lease on january we adopted topic using the modified retrospective method result for reporting period beginning after january are presented under topic while prior period amount are not adjusted and continue to be reported in accordance with our historical accounting under topic we elected the package of practical expedient permitted under the transition guidance within topic which allowed to carry forward the historical lease classification retain the initial direct cost for any lease that existed prior to the adoption of the standard and not reassess whether any contract entered into prior to the adoption are lease we also elected to account for lease and nonlease component in our lease agreement single lease component in determining lease asset and liability in addition we elected not to recognize the right of use asset and liability for lease with lease term of one year or le upon adoption of topic we recorded million of right of use asset within other long term asset and million of operating lease liability classified primarily within other long term obligation on our consolidated balance sheet of january the adoption did not have material impact on our consolidated statement of operation or consolidated statement of cash flow see note lease for additional information recently issued accounting pronouncement not yet adoptedin june the fasb issued accounting standard update no financial instrument credit loss measurement of credit loss on financial instrument asu asu requires measurement and recognition of expected credit loss for financial asset in april the fasb issued clarification to asu within asu codification improvement to topic financial instrument credit loss topic derivative and hedging and topic financial instrument the guidance will become effective for beginning in the first quarter of and must be adopted using modified retrospective approach with certain exception we do not expect the adoption of these standard to have material impact on our consolidated financial statement in november the fasb issued accounting standard update no collaborative arrangement topic clarifying the interaction between topic and topic asu asu clarifies that certain transaction between participant in collaborative arrangement should be accounted for under asc when the counterparty is customer in addition the update precludes an entity from presenting consideration from transaction in collaborative arrangement revenue if the counterparty is not customer for that transaction this guidance will become effective for beginning in the first quarter of and will be applied retrospectively to january when we initially adopted topic we do not expect the adoption of this standard to have material impact on our consolidated financial statement revenue disaggregation of revenue the following table disaggregates our product sale by product and geographic region and disaggregates our royalty contract and other revenue by geographic region in million year ended december year ended december year ended december europe other international total europe other international total europe other international totalproduct sale atripla complera eviplera hiv share symtuza ambisome sofosbuvir velpatasvir product sale contract and other revenue revenue includes emtriva and tybost represents our revenue from cobicistat emtricitabine ftc and tenofovir alafenamide taf in symtuza darunavir ftc taf fixed dose combination product commercialized by janssen science ireland uc janssen amount consist of sale of harvoni and the authorized generic version of harvoni sold by our separate subsidiary asegua therapeutic llc amount consist of sale of epclusa and the authorized generic version of epclusa sold by our separate subsidiary asegua therapeutic llc includes cayston hepsera and sovaldi the information for the year ended december ha not been adjusted in accordance with our modified retrospective adoption of topic and continues to be reported in accordance with our historical accounting under topic revenue recognized from performance obligation satisfied in prior periodsrevenues recognized from performance obligation satisfied in prior year related to royalty for license of our intellectual property were million and million for the year ended december and respectively change in estimate for variable consideration related to sale made in prior year resulted in million increase and million decrease in revenue for the year ended december and respectively contract balance our contract asset which consist of unbilled amount primarily from arrangement where the licensing of intellectual property is the only or predominant performance obligation totaled million and million of december and respectively contract liability were not material of december and fair value measurement we determine the fair value of financial and non financial asset and liability using the fair value hierarchy which establishes three level of input that may be used to measure fair value follows level input include quoted price in active market for identical asset or liability level input include observable input other than level input such quoted price for similar asset or liability quoted price for identical or similar asset or liability in market that are not active or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability for our marketable security we review trading activity and pricing of the measurement date when sufficient quoted pricing for identical security is not available we use market pricing and other observable market input for similar security obtained from various third party data provider these input either represent quoted price for similar asset in active market or have been derived from observable market data and level input include unobservable input that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability our level asset and liability include those whose fair value measurement are determined using pricing model discounted cash flow methodology or similar valuation technique and significant management judgment or estimation our financial instrument consist primarily of cash and cash equivalent marketable debt security account receivable foreign currency exchange contract equity security account payable and short term and long term debt cash and cash equivalent marketable debt security and certain equity security and foreign currency exchange contract are reported at their respective fair value in our consolidated balance sheet equity security without readily determinable fair value are recorded using the measurement alternative of cost le impairment if any adjusted for observable price change in orderly transaction for identical or similar investment of the same issuer short term and long term debt are reported at their amortized cost in our consolidated balance sheet the remaining financial instrument are reported in our consolidated balance sheet at amount that approximate current fair value the following table summarizes the type of asset and liability measured at fair value on recurring basis by level within the fair value hierarchy in million december december level level level total level level level totalassets available for sale debt security treasury security of deposit government agency security government security debt security mortgage and asset backed security security equity investment in market publicly traded equity compensation currency derivative contract deferred compensation plan currency derivative contract in the fair value of equity security resulted in net unrealized gain of billion and million for the year ended december and respectively which were included in other income expense net on our consolidated statement of income following table summarizes the classification of our equity investment in galapagos in our consolidated balance sheet in million december december and other current asset long term total note collaborative and other arrangement for additional information on our equity investment in galapagos the following table summarizes the classification of our other equity security in our consolidated balance sheet in million december december and cash equivalent and other current long term available for sale debt security are classified cash equivalent short term marketable security and long term marketable security in our consolidated balance sheet see note available for sale debt security for additional information level inputswe estimate the fair value of level instrument by taking into consideration valuation obtained from third party pricing service the pricing service utilize industry standard valuation model including both income based and market based approach for which all significant input are observable either directly or indirectly to estimate the fair value these input include reported trade of and broker dealer quote on the same or similar security issuer credit spread benchmark security prepayment default projection based on historical data and other observable input substantially all of our foreign currency derivative contract have maturity within an month time horizon and all are with counterparties that have minimum credit rating of or equivalent by global rating moody investor service inc or fitch rating inc we estimate the fair value of these contract by taking into consideration the valuation obtained from third party valuation service that utilizes an income based industry standard valuation model for which all significant input are observable either directly or indirectly these input include foreign currency exchange rate london interbank offered rate libor and swap rate these input where applicable are observable at commonly quoted interval the total estimated fair value of our short term and long term debt determined using level input based on their quoted market value were approximately billion and billion at december and respectively and the carrying value were billion and billion at december and respectively level inputsas of december and the only asset or liability that were measured using level input on recurring basis were our contingent consideration liability which were not material the fair value of our acquired ipr asset are based on probability adjusted discounted cash flow calculation using level fair value measurement and input including estimated revenue cost probability of technical and regulatory success and discount rate amount capitalized ipr are subject to impairment testing until the completion or abandonment of the associated effort during the fourth quarter of we recognized an impairment charge of million associated with the ipr intangible asset acquired in connection with the acquisition of kite pharma inc kite primarily for the treatment of indolent cell non hodgkin lymphoma inhl during the fourth quarter of we recognized an impairment charge of million to write down to zero the carrying value of the kite program an anti cell maturation antigen being evaluated for the treatment of multiple myeloma see note acquisition and note intangible asset for additional information our policy is to recognize transfer into or out of level classification of the actual date of the event or change in circumstance that caused the transfer there were no transfer between level level and level in the period presented available for sale debt security the following table summarizes our available for sale debt security in million december december amortizedcost grossunrealizedgains grossunrealizedlosses estimatedfair value amortizedcost grossunrealizedgains grossunrealizedlosses estimatedfair value treasury security of deposit government agency security government security debt security mortgage and asset backed security following table summarizes the classification of our available for sale debt security in our consolidated balance sheet in million december december and cash equivalent term marketable term marketable following table summarizes our available for sale debt security by contractual maturity in million december amortized cost fair valuewithin one year one year through five five following table summarizes our available for sale debt security that were in continuous unrealized loss position but were not deemed to be other than temporarily impaired in million le than month month or greater total grossunrealizedlosses estimatedfair value grossunrealizedlosses estimatedfair value grossunrealizedlosses estimatedfair valuedecember corporate debt security december treasury security government agency security government security debt security mortgage and asset backed security held total of and position which were in an unrealized loss position of december and respectively on our review of these security we believe we had no other than temporary impairment of december and because we do not intend to sell these security nor do we believe that we will be required to sell these security before the recovery of their amortized cost basis gross realized gain and gross realized loss on available for sale debt security were not material for the year ended december and derivative financial instrumentsour operation in foreign country expose to market risk associated with foreign currency exchange rate fluctuation between the dollar and various foreign currency primarily the euro to manage this risk we may hedge portion of our foreign currency exposure related to outstanding monetary asset and liability well forecasted product sale using foreign currency exchange forward or option contract in general the market risk related to these contract is offset by corresponding gain and loss on the hedged transaction the credit risk associated with these contract is driven by change in interest and currency exchange rate and result varies over time by working only with major bank and closely monitoring current market condition we seek to limit the risk that counterparties to these contract may be unable to perform we also seek to limit our risk of loss by entering into contract that permit net settlement at maturity therefore our overall risk of loss in the event of counterparty default is limited to the amount of any unrealized gain on outstanding contract those contract that have positive fair value at the date of default we do not enter into derivative contract for trading purpose we hedge our exposure to foreign currency exchange rate fluctuation for certain monetary asset and liability of our entity that are denominated in non functional currency the derivative instrument we use to hedge this exposure are not designated hedge and result change in their fair value are recorded in other income expense net on our consolidated statement of income we hedge our exposure to foreign currency exchange rate fluctuation for forecasted product sale that are denominated in non functional currency the derivative instrument we use to hedge this exposure are designated cash flow hedge and have maturity of month or le upon executing hedging contract and quarterly thereafter we ass hedge effectiveness using regression analysis the unrealized gain or loss in aoci are reclassified into product sale when the respective hedged transaction affect earnings the majority of gain and loss related to the hedged forecasted transaction reported in aoci at december are expected to be reclassified to product sale within month the cash flow effect of our derivative contract for the year ended december and are included within net cash provided by operating activity on our consolidated statement of cash flow we had notional amount on foreign currency exchange contract outstanding totaling billion and billion at december and respectively while all our derivative contract allow the right to offset asset and liability we have presented amount on gross basis the following table summarizes the classification and fair value of derivative instrument in our consolidated balance sheet in million december asset derivative liability derivative classification fair value classification fairvaluederivatives designated hedge foreign currency exchange contract other current asset other accrued liability foreign currency exchange contract other long term asset other long term obligation total derivative designated hedge derivative not designated hedge foreign currency exchange contract other current asset other accrued liability total derivative not designated hedge total derivative december asset derivative liability derivative classification fair value classification fairvaluederivatives designated hedge foreign currency exchange contract other current asset other accrued liability foreign currency exchange contract other long term asset other long term obligation total derivative designated hedge derivative not designated hedge foreign currency exchange contract other current asset other accrued liability total derivative not designated hedge total derivative the following table summarizes the effect of our foreign currency exchange contract on our consolidated financial statement in million year ended december designated hedge gain loss recognized in aoci gain loss reclassified from aoci into product sale gain recognized in other income expense net not designated hedge gain loss recognized in other income expense net from time to time we may discontinue cash flow hedge and result record related amount in other income expense net on our consolidated statement of income there wa no discontinuance of cash flow hedge for the year presented of december and we only held foreign currency exchange contract the following table summarizes the potential effect of offsetting derivative by type of financial instrument on our consolidated balance sheet in million gross amount not offset on the consolidated balance sheet description gross amount of recognized asset liability gross amount offset on the consolidated balance sheet amount of asset liability presented on the consolidated balance sheet derivative financial instrument cash collateral received pledged net amount legal offset of december derivative asset liability of december derivative asset liability acquisition kite pharma inc in october the acquisition date we completed tender offer for all of the outstanding common stock of kite for per share in cash result kite became our wholly owned subsidiary the acquisition of kite help establish our foundation for improving the treatment of hematological malignancy and solid tumor the consideration transferred for the acquisition wa million consisting of million in cash to the outstanding kite common stockholder million cash payment to vested equity award holder million to warrant holder and million representing the portion of the replaced stock based award attributable to the pre combination period in addition million wa excluded from the consideration transferred representing the portion of the replaced stock based award attributable the post combination period replacement award which is expected to be recognized through of december unrecognized compensation cost related to the replacement award wa not material the acquisition of kite wa accounted for business combination using the acquisition method of accounting this method requires among other thing that asset acquired and liability assumed be recognized at fair value of the acquisition date the determination of estimated fair value requires to make significant estimate and assumption during we recorded million reduction to goodwill primarily due to revision of deferred income tax result of finalization of kite pre acquisition federal income tax return the fair value estimate for the asset acquired and liability assumed have been completed the following table summarizes the acquisition date fair value of asset acquired and liability assumed and the consideration transferred in million cash and cash equivalent intangible asset indefinite lived intangible asset ipr acquired income tax other asset acquired liability assumed net identifiable net asset consideration transferred intangible assetswe acquired intangible asset primarily related to ipr for axicabtagene ciloleucel kite program and kte formerly kte being evaluated for the treatment of acute lymphoblastic leukemia all which had an estimated aggregate fair value of million of the acquisition date intangible asset related to ipr project are considered to be indefinite lived asset until the completion or abandonment of the associated effort in october axicabtagene ciloleucel now known commercially yescarta wa approved by fda for the treatment of adult patient with relapsed or refractory diffuse large cell lymphoma dlbcl after two or more line of systemic therapy upon fda approval of yescarta million of the purchased ipr wa reclassified finite lived intangible asset and is being amortized over an estimated useful life of year using the straight line method in we recognized an impairment charge of million primarily related to axicabtagene ciloleucel for the treatment of inhl in we recognized an impairment charge of million to write down to zero the carrying value of the kite program see note intangible asset for additional information additionally we acquired an outlicensing arrangement with daiichi sankyo company limited which had an estimated fair value of million of the acquisition date this definite lived intangible asset is being amortized over an estimated useful life of year on straight line basis the fair value wa determined by estimating the probability weighted net cash flow attributable to the outlicense discounted to present value using discount rate that represents the estimated rate that market participant would use to value this intangible asset goodwill the million goodwill represents the excess of the consideration transferred over the fair value of asset acquired and liability assumed and represents the future economic benefit arising from other asset acquired that could not be individually identified and separately recognized none of the goodwill is deductible for income tax purpose cell design lab inc in december we acquired all of the issued and outstanding stock of cell design lab inc privately held company cell design lab which wa in addition to the approximately of share in cell design lab we obtained in the acquisition of kite with this acquisition we gained new technology platform that will enhance effort in cellular therapy the cash consideration totaled million net of acquired cash additionally the shareholder of cell design lab other than are eligible to receive contingent development and regulatory milestone based payment of up to million our equity interest in cell design lab had carrying value of million the transaction wa accounted for an asset acquisition result million wa expensed acquired ipr within research and development expense on our consolidated statement of income inventoriesthe following table summarizes our inventory in million december material in process good reported inventory long term asset reported other long term asset primarily consisted of raw material of december and during the year ended december we recorded inventory write down of million of which million wa related to slow moving and excess raw material and work in progress inventory primarily due to lower long term demand for our hepatitis virus hcv product during the year ended december we recorded inventory write down of million of which million wa related to excess raw material primarily due to sustained decrease in demand for harvoni inventory write down recorded for the year ended december were not material property plant and equipmentthe following table summarizes our property plant and equipment in million december and land improvement and improvement including leasehold improvement and manufacturing equipment and computer equipment in progress accumulated depreciation and amortization total and computer equipment includes capitalized software we had unamortized capitalized software cost on our consolidated balance sheet of million and million of december and respectively capitalized interest on construction in progress is included in property plant and equipment interest capitalized in and wa not material intangible asset the following table summarizes our intangible asset net in million december december gross carryingamount accumulatedamortization foreign currency translation adjustment net carrying amount gross carryingamount accumulatedamortization foreign currency translation adjustment net carrying amountfinite lived asset intangible asset sofosbuvir asset axicabtagene ciloleucel dlbcl asset ranexa finite lived asset lived asset ipr intangible asset amortization expense related to finite lived intangible asset wa billion billion and million for the year ended december and respectively and is primarily included in cost of good sold on our consolidated statement of income amount capitalized ipr are subject to impairment testing until the completion or abandonment of the associated effort during the fourth quarter of we performed quantitative impairment testing of our ipr intangible asset using probability weighted income approach that discount expected future cash flow to present value the estimated net cash flow were discounted using discount rate of which is based on the estimated weighted average cost of capital for company with profile similar to our profile and represents the rate that market participant would use to value the intangible asset the discounted cash flow model used in valuing these intangible asset also require the use of level fair value measurement and input including estimated revenue cost and probability of technical and regulatory success in comparison to the assessment we used lower estimated revenue in due to change in the estimated market opportunity new therapy or combination of existing therapy were approved the lower estimated revenue reduced the fair value of the ipr intangible asset primarily related to axicabtagene ciloleucel for the treatment of inhl below carrying value resulting in the recognition of an impairment charge of million which wa recorded within research and development expense on our consolidated statement of income in we concluded that the kite program did not justify further effort based on the totality of the clinical data gathered and discontinued the program result the carrying value of the ipr relating to the kite program wa written down to zero and we recorded an impairment charge of million within research and development expense on our consolidated statement of income no ipr impairment charge were recorded in the following table summarizes the estimated future amortization expense associated with our finite lived intangible asset of december in million fiscal other financial informationother accrued liabilitiesthe following table summarizes the component of other accrued liability in million december and employee benefit tax payable payment for marketing related right acquired from japan tobacco inc accrued expense collaborative and other arrangement we enter into collaborative and other similar arrangement with third party for the development and commercialization of certain product and product candidate these arrangement involve two or more party who are active participant in the operating activity of the collaboration and are exposed to significant risk and reward depending on the commercial success of the activity these arrangement may include non refundable up front payment payment by for option to acquire certain right contingent obligation by for potential development and regulatory milestone payment and or sale based milestone payment royalty payment revenue or profit sharing arrangement cost sharing arrangement and equity investment galapagosfilgotinib collaborationin we closed license and collaboration agreement with galapagos clinical stage biotechnology company based in belgium for the development and commercialization of filgotinib selective inhibitor being evaluated for inflammatory disease indication the filgotinib agreement upon closing we made an up front license fee payment and an equity investment in galapagos by subscribing for million new ordinary share of galapagos at price of per share the equity investment net of issuance premium wa million under the term of the filgotinib agreement amended in we have an exclusive worldwide royalty bearing sublicensable license for filgotinib and product containing filgotinib of december galapagos is eligible to receive from potential future development and regulatory milestone based payment of up to million sale based milestone payment of up to million plus tiered royalty on global net sale ranging from to with the exception of certain co commercialization territory where profit would be shared equally the co commercialization territory are the uk germany france italy spain belgium the netherlands and luxembourg we share global development cost for filgotinib equally for the period presented the payment between galapagos and for the development cost and milestone were not material termination of the agreement may be on country by country basis and will depend on the circumstance including expiration of royalty term or in the co commercialization territory sale of generic product or material breach by either party we may also terminate the entire agreement without cause following certain period global collaborationin august we closed an option license and collaboration agreement the collaboration agreement and subscription agreement the subscription agreement each with galapagos pursuant to which the party entered into global collaboration that cover galapagos current and future product portfolio other than filgotinib upon closing we paid billion for the license and option right and for million new ordinary share of galapagos at subscription price of per share with fair value of billion which included an issuance discount of million calculated based on galapagos closing stock price on the date of closing of the subscription agreement the remaining billion of the payment wa recorded within research and development expense on our consolidated statement of income pursuant to the subscription agreement we were issued warrant that confer the right to subscribe from time to time for number of new share to be issued by galapagos sufficient to bring the number of share owned by to of the issued and outstanding share at the time of our exercise in the fourth quarter of we exercised warrant to subscribe for million ordinary share of galapagos at per share and purchased share on the open market with an aggregate fair value of million which brought the number of share owned by to million or approximately of the share then issued and outstanding our equity investment in galapagos is classified other long term asset on our consolidated balance sheet it is subject to contractual lock up provision we are subject to year standstill restricting our ability to acquire voting security of exceeding more than of the then issued and outstanding voting security of galapagos we agreed not to without the prior consent of galapagos dispose of any equity security of galapagos prior to the second anniversary of the closing of the subscription agreement or dispose of any equity security of galapagos thereafter until the fifth anniversary of the closing of the subscription agreement if after such disposal we would own le than of the then issued and outstanding voting security of galapagos subject to certain exception and termination event we have two designees appointed to galapagos board of director we have elected the fair value option to account for our equity investment in galapagos whereby the investment is marked to market through earnings in each reporting period based on the market price of galapagos share we believe the fair value option best reflects the underlying economics of the investment see note fair value measurement for additional information under the collaboration agreement we have an exclusive license for the development and commercialization of glpg phase candidate for idiopathic pulmonary fibrosis in our territory and have an option to participate in the development and commercialization of glpg phase candidate for osteoarthritis and galapagos other current and future clinical program that have entered clinical development during the first ten year of the collaboration subject to extension in certain circumstance we may exercise our option for program after the receipt of data package from completed qualifying phase study for such program or in certain circumstance the first phase study if glpg receives marketing approval in the united state we will pay galapagos million well tiered royalty described below if we exercise our option to the glpg program we will pay million option exercise fee and galapagos would be eligible to receive up to million in development regulatory and commercial milestone well tiered royalty described below with respect to all other program in galapagos current and future pipeline if we exercise our option to program we will pay million option exercise fee per program in addition galapagos will receive tiered royalty ranging from to on net sale in our territory of each galapagos product optioned by including glpg and glpg if we exercise our option for program the party will share equally in development cost and mutually agreed commercialization cost incurred subsequent to our exercise of the option galapagos retains exclusive commercialization right for the optioned program in the european union the uk iceland norway lichtenstein and switzerland and we have exclusive commercialization right for all other country globally except for glpg where we will only acquire the right we may terminate the collaboration in it entirety or on program by program and country by country basis with advance notice well following other customary termination event janssencomplera eviplera and odefseyin we entered into license and collaboration agreement with janssen science ireland uc janssen formerly tibotec pharmaceutical to develop and commercialize fixed dose combination of our truvada and janssen non nucleoside reverse transcriptase inhibitor rilpivirine this combination wa approved in the united state and european union in and is sold under the brand name complera in the united state and eviplera in the european union the agreement wa amended in to expand the collaboration to include another product containing janssen rilpivirine and our emtricitabine and tenofovir alafenamide odefsey under the amended agreement janssen granted an exclusive license to complera eviplera and odefsey worldwide but retained right to distribute both combination product in certain country outside of the united state neither party is restricted from combining it drug with any other drug product except those which are similar to the component of complera eviplera and odefsey we are responsible for manufacturing complera eviplera and odefsey and have the lead role in registration distribution and commercialization of both product except in the country where janssen distributes janssen ha exercised right to co detail the combination product in some of the country where we are the selling party under the financial provision of the amendment the selling party set the price of the combined product and the party share revenue based on the ratio of the net selling price of the party component subject to certain restriction and adjustment we retain specified percentage of janssen share of revenue including up to in major market sale of these product are included in product sale and janssen share of revenue are included in cost of good sold on our consolidated statement of income cost of good sold relating to janssen share were million million and million for the year ended december and respectively termination of the agreement may be on product or country basis and will depend on the circumstance including withdrawal of product from the market material breach by either party or expiry of revenue share payment term we may terminate the agreement without cause with respect to the country where we sell the product in which case janssen ha the right to become the selling party for such country if the product ha launched but ha been on the market for fewer than year we amended license and collaboration agreement with janssen to develop and commercialize fixed dose combination of janssen darunavir and our cobicistat emtricitabine and tenofovir alafenamide this combination wa approved in the united state and european union in july and september respectively and is sold under the brand name symtuza under the term of the amendment we granted janssen an exclusive license to symtuza worldwide janssen is responsible for manufacturing registration distribution and commercialization of symtuza worldwide we are responsible for the intellectual property related to cobicistat emtricitabine and tenofovir alafenamide gilead compound and are the exclusive supplier of the gilead compound neither party is restricted from combining it drug with any other drug product except those which are similar to the component of symtuza janssen set the price of symtuza and the party share revenue based on the ratio of the net selling price of the party component subject to certain restriction and adjustment the intellectual property license and supply obligation related to the gilead compound are accounted for single performance obligation the license wa deemed to be the predominant item to which the revenue share relates we recognize our share of the symtuza revenue in the period when the corresponding sale of symtuza by janssen occur we record our share of the symtuza revenue product sale on our consolidated statement of income primarily because we supply the gilead compound to janssen for symtuza see note revenue for revenue recognized for the period presented termination of the agreement may be on product or country basis and will depend on the circumstance including withdrawal of product from the market material breach by either party or expiry of revenue share payment term janssen may terminate the agreement without cause on country by country basis in which case gilead ha the right to become the selling party for such country if the product ha launched but ha been on the market for fewer than year janssen may also terminate the entire agreement without cause japan tobacco in japan tobacco inc japan tobacco granted exclusive right to develop and commercialize elvitegravir novel hiv integrase inhibitor in all country of the world excluding japan where japan tobacco retained such right and paid royalty to based on it product sale in japan under the agreement we are responsible for seeking regulatory approval in our territory and are required to use diligent effort to commercialize elvitegravir for the treatment of hiv infection we bear all cost and expense associated with such commercialization effort and pay royalty to japan tobacco based on our product sale japan tobacco also marketed and distributed certain other product in our hiv portfolio in japan and paid royalty to based on these product sale we received approval for stribild and genvoya elvitegravir containing product in and respectively our sale of these product are included in product sale royalty due to japan tobacco based on our product sale are included in cost of good sold royalty due from japan tobacco based on it product sale in japan are included in royalty contract and other revenue on our consolidated statement of income royalty expense recognized were million million and million for the year ended december and respectively royalty income recognized wa not material for the period presented effective in december we entered into an agreement with japan tobacco to acquire the right to market and distribute certain product in our hiv portfolio in japan and to expand our right to develop and commercialize elvitegravir to include japan we are responsible for the marketing of the product of january under the term of the agreement we paid japan tobacco million in cash of which million wa paid an up front payment in and the remaining million wa paid in we recognized an intangible asset of million reflecting the estimated fair value of the marketing related right acquired from japan tobacco with the remaining million recorded prepaid and other current asset on our consolidated balance sheet the intangible asset is being amortized over nine year representing the period over which the majority of the benefit are expected to be derived from the applicable product in our hiv portfolio the amortization expense is classified selling expense and recorded selling general and administrative expense on our consolidated statement of income termination of the agreement may be on product or country basis and will depend on the circumstance including material breach by either party or expiry of royalty payment term we may also terminate the entire agreement without cause gadetain july we entered into collaboration arrangement with gadeta privately held company based in utrecht the netherlands to develop gamma delta cell receptor therapy for various cancer under the financial term we provide funding for the collaboration and gadeta is eligible to receive future payment upon achievement of certain regulatory milestone in addition we made an upfront purchase of equity in gadeta from gadeta shareholder and may acquire additional equity in gadeta upon achievement of certain milestone we also have the exclusive option to acquire the remaining equity in gadeta million adjusted for closing cash transaction expense and closing indebtedness the option is exercisable at our discretion gadeta is vie and we are it primary beneficiary because we have the power to direct the activity of gadeta that most significantly impact it economic performance and result of the financial term described above upon the initial consolidation of gadeta we recorded asset of million primarily intangible asset related to ipr and million to noncontrolling interest on our consolidated balance sheet gadeta doe not meet the definition of business defined in asc business combination and result no goodwill wa recognized bristol myers squibb companynorth americawe had collaboration arrangement with bristol myers squibb company bm to develop and commercialize single tablet regimen containing our truvada and bm sustiva efavirenz in the united state and canada this combination is sold under the brand name atripla we and bm structured this collaboration joint venture that operated limited liability company which we consolidated on december we terminated bm participation in the collaboration following the launch of generic version of sustiva in the and became the sole owner of the joint venture bm is not permitted to commercialize atripla in the united state and canada but is entitled to receive from certain fee based on net sale of atripla in and on declining annual scale bm supply sustiva to at cost plus markup during this three year period but may terminate the supply agreement after notice period bm notified of their voluntary termination of the supply agreement in for the year ended december and we recorded million and million respectively of fee expense within cost of good sold on our consolidated statement of income europegilead science ireland uc our wholly owned subsidiary and bm have collaboration agreement which set forth the term and condition under which we and bm commercialize and distribute atripla in the european union iceland liechtenstein norway and switzerland collectively the european territory the party formed limited liability company which we consolidate to manufacture atripla for distribution in the european territory using efavirenz that it purchase from bm at bm estimated net selling price of efavirenz in the european territory the party also formed limited liability company to hold the marketing authorization for atripla in the european territory starting in except for limited number of activity that are jointly managed the party no longer coordinate detailing and promotional activity in the european territory we are responsible for manufacturing product distribution inventory management and warehousing and have primary responsibility for regulatory activity through our local subsidiary we have primary responsibility for order fulfillment collection of receivables customer relation and handling of sale return in all the territory where we and bm promote atripla in general the party share revenue and out of pocket expense in proportion to the net selling price of the component of atripla truvada and efavirenz of december and efavirenz purchased from bm at bm estimated net selling price of efavirenz in the european territory wa included in inventory on our consolidated balance sheet in september bm elected to voluntarily terminate the agreement effective march post termination bm is not permitted to commercialize atripla in the european territory but is entitled to receive from certain fee based on net sale of atripla on declining annual scale for three year period following the effective date of the termination other collaboration arrangement that are not individually significant during and we entered into several collaborative and other similar arrangement including equity investment and licensing arrangement that we do not consider to be individually material cash outflow related to these arrangement totaled million and million for the year ended december and respectively we recorded up front collaboration and licensing expense related to these arrangement of million and million for the year ended december and respectively within research and development expense on our consolidated statement of income and the remaining amount were recorded in current and other long term asset on our consolidated balance sheet we made no material cash payment related to individually insignificant collaboration arrangement entered into in under the financial term of these arrangement we may be required to make payment upon achievement of various developmental regulatory and commercial milestone which could be significant future milestone payment if any will be reflected in our consolidated statement of income when the corresponding event become probable in addition we may be required to pay significant royalty on future sale if product related to these arrangement are commercialized the payment of these amount however is contingent upon the occurrence of various future event which have high degree of uncertainty of occurrence debt and credit facility the following table summarizes the carrying amount of our borrowing under various financing arrangement in million december type of borrowing issue date due date interest rate unsecured september march month libor unsecured march april unsecured september september unsecured september september month libor unsecured november february unsecured september september unsecured march april unsecured december december unsecured september march unsecured september september unsecured september september unsecured march april unsecured november february unsecured september march unsecured september march unsecured september september unsecured september september unsecured december december unsecured march april unsecured november february unsecured september march unsecured september march debt net current portion long term debt net unsecured noteswe did not enter into any borrowing in or in in connection with our acquisition of kite we issued billion aggregate principal amount of senior unsecured note of which million of principal balance wa repaid at maturity in and the remaining billion wa repaid at maturity in we collectively refer to our senior unsecured note issued in september the note in september the note in march and november the note and in march and december the note our senior note in and we repaid at maturity million and billion of principal balance related to the note and note respectively in february we repaid at maturity million of principal balance related to the note our senior note may be redeemed at our option at redemption price equal to the greater of of the principal amount of the note to be redeemed and ii the sum determined by an independent investment banker of the present value of the remaining scheduled payment of principal and interest on the note to be redeemed exclusive of interest accrued to the date of redemption discounted to the redemption date on semiannual basis at the treasury rate plus make whole premium defined in the indenture our senior note maturing after also have call feature exercisable at our option to redeem the note at par in whole or in part one to six month immediately preceding maturity in each case accrued and unpaid interest is also required to be redeemed to the date of redemption in the event of the occurrence of change in control and downgrade in the rating of our senior note below investment grade by moody investor service inc and global rating the holder may require to purchase all or portion of their note at price equal to of the aggregate principal amount of the note repurchased plus accrued and unpaid interest to the date of repurchase we are required to comply with certain covenant under our senior note and of december and we were not in violation of any covenant expense on our senior note related to the contractual coupon rate and amortization of the debt discount and issuance cost wa billion billion and billion in and respectively credit facilitiesin in connection with our acquisition of kite we borrowed billion against our term loan credit facility of which billion wa repaid in and the remaining billion wa repaid in the term loan credit facility agreement wa terminated in in we entered into billion five year revolving credit facility agreement maturing in may the five year revolving credit agreement the revolving credit facility can be used for working capital requirement and for general corporate purpose including without limitation acquisition of december and there were no amount outstanding under the five year revolving credit agreement the five year revolving credit agreement contains customary representation warranty affirmative and negative covenant and event of default at december we were not in violation of any covenant loan under the five year revolving credit agreement bear interest at either the eurodollar rate plus the applicable percentage or ii the base rate plus the applicable percentage each defined in the five year revolving credit agreement we may terminate or reduce the commitment and may prepay any loan under the five year revolving credit agreement in whole or in part at any time without premium or penalty contractual maturity of financing obligationsas of december the aggregate future principal maturity of financing obligation for each of the next five year based on contractual due date are follows in million maturity lease our operating lease consist primarily of property and equipment for our administrative manufacturing and activity we determine if an arrangement contains lease at inception right of use asset and lease liability are recognized at the commencement date based on the present value of the lease payment over the lease term which is the non cancelable period stated in the contract adjusted for any option to extend or terminate when it is reasonably certain that we will exercise that option some of our lease include option to extend the term for up to year and some include option to terminate the lease within one year after the lease commencement date right of use asset are adjusted for prepaid lease payment lease incentive and initial direct cost incurred of december we do not have material finance lease most of our operating lease do not provide an implicit interest rate we generally utilize collateralized incremental borrowing rate applied in portfolio approach when relevant based on the information available at the commencement date to determine the lease liability operating lease expense for the minimum lease payment is recognized on straight line basis over the lease term operating lease expense including variable cost and short term lease were million for the year ended december operating lease expense under the prior lease standard wa million and million for the year ended december and respectively the following table summarizes balance sheet and other information related to our operating lease of december in million except weighted average amount classification amountright of use asset net other long term asset liability current other accrued liability liability noncurrent other long term obligation average remaining lease term yearsweighted average discount rate following table summarizes other supplemental information related to our operating lease in million year ended december paid for amount included in the measurement of lease liability of use asset obtained in exchange for lease liability following table summarizes maturity analysis of our operating lease liability showing the aggregate lease payment of december in million fiscal year undiscounted lease payment imputed interest total discounted lease payment following table summarizes the aggregate undiscounted non cancelable future minimum lease payment for operating lease under the prior lease standard of december in million fiscal total minimum lease payment commitment and contingency legal proceedingswe are party to various legal action the most significant of these are described below we recognize accrual for such action to the extent that we conclude that loss is both probable and reasonably estimable we accrue for the best estimate of loss within range however if no estimate in the range is better than any other then we accrue the minimum amount in the range if we determine that loss is reasonably possible and the loss or range of loss can be estimated we disclose the possible loss unless otherwise noted it is not possible to determine the outcome of these matter and we can not reasonably estimate the maximum potential exposure or the range of possible loss we did not have any material accrual for the matter described below in our consolidated balance sheet of december and litigation related to sofosbuvirin we acquired pharmasset inc pharmasset through the acquisition we acquired sofosbuvir nucleotide analog that act to inhibit the replication of the hcv in we received approval from fda for sofosbuvir now known commercially sovaldi sofosbuvir is also included in all of our marketed hcv product we have received number of litigation claim regarding sofosbuvir while we have carefully considered these claim both prior to and following the acquisition and believe they are without merit we can not predict the ultimate outcome of such claim or range of loss we are aware of patent and patent application owned by third party that have been or may in the future be alleged by such party to cover the use of our hcv product if third party obtain valid and enforceable patent and successfully prove of those patent by our hcv product we could be required to pay significant monetary damage we can not predict the ultimate outcome of intellectual property claim related to our hcv product we have spent and will continue to spend significant resource defending against these claim litigation with idenix pharmaceutical inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique and universit montpellier iiin idenix udsg centre national de la recherche scientifique and universit montpellier ii sued in district court for the district of delaware alleging that the commercialization of sofosbuvir infringes patent no the patent we prevailed at all phase of litigation concerning the patent and in the supreme court denied idenix petition for certiorari also in idenix and udsg sued in the district court for the district of massachusetts alleging that the commercialization of sofosbuvir infringes patent no the patent and the patent in the court transferred the massachusetts litigation to the district court for the district of delaware prior to trial in idenix committed to give covenant not to sue with respect to any claim arising out of the patent related to sofosbuvir and withdrew that patent from the trial jury trial wa held in on the patent and the jury found that we willfully infringed the asserted claim of the patent and awarded idenix billion in past damage in the judge invalidated idenix patent and vacated the jury award of billion in past damage idenix appealed this decision to the court of appeal for the federal circuit cafc and in october the cafc issued an opinion affirming the trial court decision that the patent is invalid idenix ha petitioned for rehearing by the cafc en banc and may seek review by the supreme court litigation with the university of minnesotathe university of minnesota the university ha obtained patent no the patent which purport to broadly cover nucleoside with antiviral and anticancer activity in the university filed lawsuit against in the district court for the district of minnesota alleging that the commercialization of sofosbuvir containing product infringes the patent we believe the patent is invalid and will not be infringed by the continued commercialization of sofosbuvir in the court granted our motion to transfer the case to california we have also filed four petition for inter partes review with the patent and trademark office uspto patent trial and appeal board ptab alleging that all asserted claim are invalid for anticipation and obviousness in the district court for the northern district of california stayed the litigation until after the ptab rule on our petition for inter partes review litigation related to axicabtagene ciloleucelwe own patent and patent application that protect our axicabtagene ciloleucel chimeric dna segment third party may have or may obtain right to patent that allegedly could be used to prevent or attempt to prevent from commercializing axicabtagene ciloleucel or to require to obtain license in order to commercialize axicabtagene ciloleucel in october juno therapeutic inc and sloan kettering cancer center collectively juno filed lawsuit against in the district court for the central district of california alleging that the commercialization of axicabtagene ciloleucel sold commercially yescarta infringes on patent no the patent jury trial wa held on the patent and in december the jury found that the asserted claim of the patent were valid and that we willfully infringed the asserted claim of the patent the jury also awarded juno damage in amount of million in an up front payment and running royalty from october through the date of the jury verdict the party filed post trial motion in january and will file further briefing during the first quarter of and we expect the judge to rule on these matter later in once the district court ha issued these ruling and ha entered judgment the case may be appealed to the cafc although we can not predict with certainty the ultimate outcome of this litigation we believe the jury verdict to be in error and we also believe that error were made by the court with respect to certain ruling before and during trial in assessing whether we should accrue liability for this litigation in our consolidated financial statement we considered various factor including the legal and factual circumstance of the case the jury verdict the district court pre and post trial order the current status of the proceeding applicable law the view of legal counsel and the likelihood that the jury verdict will be upheld on appeal result of this review we have determined in accordance with applicable accounting standard that it is not probable that we will incur material loss result of this litigation if the jury verdict is not upheld on appeal the loss will be zero if the jury verdict is upheld in it entirety on appeal we estimate the upper end of the range of possible loss through december to be approximately billion which consists of the million up front payment determined by the jury ii approximately million which represents estimated royalty on our adjusted revenue from yescarta from october through december and iii enhanced damage requested by juno of up to two time the sum of and ii above result of the jury finding of willfulness this sum excludes cost and pre judgment interest supplemental damage consisting of royalty on sale of yescarta after december through the date of judgment could be subject to the royalty in the jury verdict the prospective royalty proposed juno or to enhancement any post judgment sale of yescarta would be subject to prospective royalty which we have estimated could be up to and which would be payable on adjusted yescarta revenue after the judgment in until the expiry of the patent in august we expect the judge to rule on the amount of prospective royalty and any enhanced damage in the course of deciding the post trial motion the court determination of prospective royalty and enhanced damage if any can also be appealed litigation related to bictegravirin viiv healthcare company viiv filed lawsuit against in the district court of delaware alleging that the commercialization of bictegravir sold commercially in combination with tenofovir alafenamide and emtricitabine biktarvy infringes viiv patent no the patent covering viiv dolutegravir bictegravir is structurally different from dolutegravir and we believe that bictegravir doe not infringe the claim of the patent to the extent that viiv patent claim are interpreted to cover bictegravir we believe those claim are invalid the court ha set trial date of september for this lawsuit in viiv also filed lawsuit against in the federal court of canada alleging that our activity relating to our bictegravir compound have infringed viiv canadian patent no the patent which wa issued to shionogi co ltd and viiv the patent is the compound patent covering viiv dolutegravir we believe that bictegravir doe not infringe the claim of the patent in january the court held summary trial to ass viiv infringement allegation the court decision is expected in march in november and december viiv filed lawsuit in france germany ireland and the uk asserting the relevant national designation of european patent no in australia asserting australian patent no in japan asserting japanese patent no and in korea asserting korean patent no and these patent all relate to molecule which viiv claim would act integrase inhibitor we believe that bictegravir doe not infringe the claim of any of viiv patent in all jurisdiction to the extent that the claim of viiv patent are interpreted to cover bictegravir we believe that those claim are invalid we can not predict the ultimate outcome of intellectual property claim related to bictegravir litigation relating to pre exposure prophylaxisin august we filed petition requesting inter partes review of patent no patent and patent collectively hhs patent by ptab the hhs patent are assigned to the department of health and human service and purport to claim process of protecting primate host from infection by an immunodeficiency retrovirus by administering combination of emtricitabine and tenofovir or tdf prior to exposure of the host to the immunodeficiency retrovirus process commonly known pre exposure prophylaxis prep in november the department of justice filed lawsuit against in the district court of delaware alleging that the sale of truvada and descovy for use prep infringes the hhs patent in february ptab declined to institute our petition for inter partes review of the hhs patent although we can not predict with certainty the ultimate outcome of this litigation we believe that truvada and descovy do not infringe the hhs patent and that the hhs patent are invalid over prior art description of truvada use for prep and post exposure prophylaxis and because physician and patient were using the claimed method year before the center for disease control and prevention filed the application for the patent litigation with generic manufacturersas part of the approval process for some of our product fda granted new chemical entity nce exclusivity period during which other manufacturer application for approval of generic version of our product will not be approved generic manufacturer may challenge the patent protecting product that have been granted nce exclusivity one year prior to the end of the nce exclusivity period generic manufacturer have sought and may continue to seek fda approval for similar or identical drug through an abbreviated new drug application anda the application form typically used by manufacturer seeking approval of generic drug the sale of generic version of our product earlier than their patent expiration would have significant negative effect on our revenue and result of operation to seek approval for generic version of product nce status generic company may submit it anda to fda four year after the branded product approval starting in december we received letter from lupin ltd apotex inc shilpa medicare ltd sunshine lake pharma co ltd laurus lab natco pharma ltd and cipla ltd collectively generic manufacturer indicating that they have submitted andas to fda requesting permission to market and manufacture generic version of certain of our tenofovir alafenamide taf containing product between them these generic manufacturer seek to market generic version of odefsey descovy and vemlidy some generic manufacturer have challenged the validity of four patent listed on the orange book and associated with taf while others have challenged the validity of two of our orange book listed patent associated with taf we are evaluating the letter and intend to enforce and defend our intellectual property patent claimsin several party filed opposition in the european patent office epo requesting revocation of one of our granted european patent covering sofosbuvir that expires in in the epo upheld the validity of certain claim of our sofosbuvir patent we have appealed this decision seeking to restore all of the original claim and several of the original opposing party have also appealed requesting full revocation the appeal hearing is scheduled for july in several party filed opposition in the epo requesting revocation of our granted european patent relating to sofosbuvir that expires in the epo conducted an oral hearing for this opposition in and upheld the claim two of the original opposing party have appealed requesting full revocation in several party filed opposition in the epo requesting revocation of our granted european patent covering taf that expires in in the epo upheld the validity of the claim of our taf patent three party have appealed this decision in several party filed opposition in the epo requesting revocation of our granted european patent relating to taf hemifumarate that expires in in the epo upheld the validity of the claim of our taf hemifumarate patent three party have appealed this decision in three party filed opposition in the epo requesting revocation of our granted european patent covering cobicistat that expires in in the epo upheld the validity of the claim of our cobicistat patent two party have appealed this decision the appeal process may take several year for all epo opposition proceeding while we are confident in the strength of our patent we can not predict the ultimate outcome of these opposition if we are unsuccessful in defending these opposition some or all of our patent claim may be narrowed or revoked and the patent protection for sofosbuvir taf taf hemifumarate and cobicistat in the european union could be substantially shortened or eliminated entirely if our patent are revoked and no other european patent are granted covering these compound our exclusivity may be based entirely on regulatory exclusivity granted by the european medicine agency if we lose patent protection for any of these compound our revenue and result of operation could be negatively impacted for the year including and succeeding the year in which such exclusivity is lost government investigation and related litigationin we received subpoena from the attorney office for the northern district of california requesting document related to the manufacture and related quality and distribution practice of complera atripla truvada viread emtriva hepsera and letairis we cooperated with the government inquiry in the department of justice informed that following an investigation it declined to intervene in false claim act lawsuit filed by two former employee also in the former employee served first amended complaint and the district court for the northern district of california issued an order granting in it entirety without prejudice our motion to dismiss the first amended complaint in the plaintiff filed second amended complaint and the district court issued an order granting our motion to dismiss the second amended complaint the plaintiff then filed notice of appeal in the court of appeal for the ninth circuit ninth circuit in the ninth circuit granted our motion to stay the case pending an appeal to the supreme court and we filed petition for writ of certiorari to the supreme court in the solicitor general submitted brief for the united state to the supreme court stating it intention to file motion to dismiss under the federal false claim act in january the supreme court denied the petition and the case ha been remanded to the district court in march the department of justice filed motion to dismiss the second amended complaint the district court granted the department of justice motion to dismiss in november dismissing relators federal false claim act claim in we received subpoena from the attorney office for the district of massachusetts requesting document related to our support of organization that provide financial assistance to patient and document concerning our provision of financial assistance to patient for our hcv product we are cooperating with this inquiry in we received subpoena from the attorney office for the district of massachusetts requesting document related to our copay coupon program and medicaid price reporting methodology we are cooperating with this inquiry in we received voluntary request for information from the attorney office for the eastern district of pennsylvania requesting information related to our reimbursement support offering clinical education program and interaction with specialty pharmacy for sovaldi and harvoni in we received another voluntary request for information related to our speaker program and advisory board for our hcv and hepatitis virus product we are cooperating with these voluntary request in october the department of justice informed that following an investigation it declined to intervene in false claim act lawsuit against relating to hepatitis speaker program and advisory board brought by two plaintiff in the district court for the eastern district of pennsylvania notwithstanding the government declination plaintiff have continued to pursue the lawsuit and served with the seconded amended complaint in november although we can not predict the ultimate outcome of this lawsuit we believe the action is without merit and we intend to vigorously defend against it we received subpoena from the california department of insurance and the alameda county district attorney office requesting document related to our marketing activity reimbursement support offering clinical education program and interaction with specialty pharmacy for harvoni and sovaldi we are cooperating with this inquiry in we also received subpoena from the attorney office for the southern district of new york requesting document related to our promotional speaker program for hiv we are cooperating with this inquiry product liabilitywe have been named defendant in one class action lawsuit and various product liability lawsuit related to viread truvada atripla complera and stribild plaintiff allege that viread truvada atripla complera and or stribild caused them to suffer kidney and or bone injury the lawsuit which are pending in state or federal court in california delaware or florida involve thousand of plaintiff plaintiff in these case seek damage and other relief on various ground for alleged personal injury and economic loss we intend to vigorously defend ourselves in these action while we believe these case are without merit we can not predict the ultimate outcome if plaintiff are successful in their claim we could be required to pay significant monetary damage antitrust and consumer protectionwe along with japan tobacco bm and johnson johnson inc have been named defendant in class action lawsuit filed in related to various drug used to treat hiv including drug used in combination antiretroviral therapy plaintiff allege that we and the other defendant engaged in various conduct to restrain competition in violation of federal and state antitrust law and state consumer protection law the lawsuit consolidated action pending in the district court for the northern district of california seek to bring claim on behalf of nationwide class of end payor purchaser similar lawsuit wa also recently filed in the district court for the southern district of florida which may also be consolidated plaintiff seek damage permanent injunctive relief and other relief we intend to vigorously defend ourselves in this action while we believe this action is without merit we can not predict the ultimate outcome if plaintiff are successful in their claim we could be required to pay significant monetary damage or could be subject to permanent injunctive relief other matterswe are party to various legal action that arose in the ordinary course of our business we do not believe that these other legal action will have material adverse impact on our consolidated business financial position or result of operation other commitment in the normal course of business we enter into various firm purchase commitment primarily related to active pharmaceutical ingredient api and certain inventory related item of december these commitment for the next five year were approximately million in million in million in million in and million in the amount related to api represent minimum purchase commitment actual payment for the purchase of api and certain inventory related item were million in billion in and billion in in january we amended an api contract which increased our firm purchase commitment by approximately million stockholder equity stock repurchase program in the first quarter of our board of director authorized billion stock repurchase program program under which repurchase may be made in the open market or in privately negotiated transaction of december the remaining authorized repurchase amount under the program wa billion the following table summarizes our stock repurchase under the program in million except per share amount year ended december repurchased and retired price per share addition to repurchase from the program we repurchased share of common stock withheld by from employee restricted stock award to satisfy our applicable tax withholding obligation which are immaterial and excluded from the table above use the par value method of accounting for our stock repurchase under the par value method common stock is first charged with the par value of the share involved the excess of the cost of share acquired over the par value is allocated to additional paid in capital apic based on an estimated average sale price per issued share with the excess amount charged to retained earnings the following table summarizes the reduction of common stock and apic and the charge to retained earnings result of our stock repurchase in million year ended december of common stock and apic to retained earnings the first quarter of our board of director authorized new billion stock repurchase program program which will commence upon the completion of the program purchase under the program may be made in the open market or in privately negotiated transaction dividendsthe following table summarizes cash dividend declared on our common stock in million except per share amount dividend per share amount dividend per share amountfirst quarter quarter quarter quarter restricted stock and performance share award or unit have dividend equivalent right entitling holder to dividend equivalent to be paid upon vesting for each share of the underlying uniton february we announced that our board of director declared quarterly cash dividend of per share of our common stock with payment date of march to all stockholder of record of the close of business on march future dividend are subject to declaration by the board of director preferred stockwe have million share of authorized preferred stock issuable in series our board is authorized to determine the designation power preference and right of any such series there wa no preferred stock outstanding of december and other comprehensive income the following table summarizes the change in aoci by component net of tax in million foreign currency translation unrealized gain and loss on available for sale debt security unrealized gain and loss on cash flow hedge totalbalance at december to retained earnings result of the adoption of new accounting standard balance at january net unrealized loss gain to net income current period other comprehensive loss income at december unrealized gain to net income net current period other comprehensive income loss at december amount reclassified to net income for gain and loss on cash flow hedge are recorded part of product sale on our consolidated statement of income see note derivative financial instrument for additional information the amount reclassified to net income for gain and loss on available for sale debt security are recorded part of other income expense net on our consolidated statement of income the income tax impact allocated to each component of other comprehensive income wa not material for the period presented employee benefit we provide share based compensation in the form of various type of equity based award including restricted stock unit rsus performance share award or unit psus and stock option compensation expense is recognized on the consolidated statement of income based on the estimated fair value of the award on the grant date the estimated fair value of rsus is based on the closing price of our common stock for psus estimated fair value is based on either the monte carlo valuation methodology or the stock price on the date of grant for stock option award estimated fair value is based on the black scholes option valuation model equity incentive planin may our stockholder approved and we adopted the gilead science inc equity incentive plan amended the plan the plan is broad based incentive plan that provides for the grant of equity based award including stock option restricted stock unit restricted stock award and performance share award to employee director and consultant the plan authorized the issuance of total of million share of common stock of december total of million share remain available for future grant under the plan stock option the plan provides for option grant designated either non qualified or incentive stock option all stock option granted after january have been non qualified stock option employee stock option generally vest over three or four year all option are exercisable over period not to exceed the contractual term of ten year from the date the stock option are issued and are granted at price not le than the fair market value of our common stock on the grant date stock option exercise are settled with common stock from the plan previously authorized and available pool of share following table summarizes activity and related information under our stock option plan all option grant presented in the table had exercise price not le than the fair value of the underlying common stock on the grant date share in million weighted averageexercise price in dollar weighted average remaining contractual term year aggregate intrinsic value in million outstanding at december granted forfeited expired exercised outstanding at december at december to vest net of estimated forfeiture at december intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted average exercise price multiplied by the number of option outstanding or exercisable total intrinsic value of option exercised wa million for million for and million for the weighted average grant date fair value of the stock option granted wa per share for per share for and per share for the weighted average grant date fair value of stock option granted in wa higher due to replacement award granted in connection with our acquisition of kite and cell design lab of december there wa million of unrecognized compensation cost related to stock option which is expected to be recognized over an estimated weighted average period of year restricted stock and performance share awardswe grant time based rsus to certain employee part of our annual employee equity compensation review program well to new hire employee and to non employee member of our board rsus are share based award that entitle the holder to receive freely tradable share of our common stock upon vesting rsus generally vest over three or four year from the date of grant the fair value of an rsu is equal to the closing price of our common stock on the grant date we grant psus which vest upon the achievement of specified market or performance goal which could include achieving total shareholder return compared to pre determined peer group or achieving revenue target the actual number of common share ultimately issued is calculated by multiplying the number of psus by payout percentage ranging from to and these award generally vest only when committee or subcommittee of our board ha determined that the specified market and performance goal have been achieved the fair value of each psu is estimated at the date of grant or when performance objective are defined for the grant depending on the term of the award fair value on the date of grant is determined based on either the monte carlo valuation methodology or the closing stock price on the date of grant in addition we have also granted other psus to certain of our employee under the plan the vesting of these award is subject to the achievement of specified individual performance goal typically within one to two year period the fair value of such an award is equal to the closing price of our common stock on the grant date the following table summarizes our rsu and psu activity and related information in million except per share amount rsus psus share weighted averagegrant date fair value per share share weighted averagegrant date fair value per share outstanding at december at december weighted average grant date fair value per share excludes share related to grant that currently have no grant date the performance objective have not yet been defined weighted average grant date fair value of rsus granted wa per share for per share for and per share for the weighted average grant date fair value of psus granted wa per share for per share for and per share for the total grant date fair value of our vested rsus and psus wa million for million for and million for and total fair value of the respective vesting date wa million for million for and million for of december there wa million of unrecognized compensation cost related to unvested rsus and psus which is expected to be recognized over weighted average period of year employee stock purchase planunder our employee stock purchase plan and the international employee stock purchase plan together amended the espp employee can purchase share of our common stock based on percentage of their compensation subject to certain limit the purchase price per share is equal to the lower of of the fair market value of our common stock on the offering date or the purchase date the espp offer six month look back feature well an automatic reset feature that provides for an offering period to be reset to new lower priced offering if the offering price of the new offering period is le than that of the current offering period espp purchase are settled with common stock from the espp previously authorized and available pool of share during million share were issued under the espp for million total of million share of common stock have been authorized for issuance under the espp and there were million share available for issuance under the espp of december stock based compensationthe following table summarizes total stock based compensation expense included on our consolidated statement of income in million year ended december of good sold and development expense general and administrative expense based compensation expense included in total cost and expense tax effect stock based compensation expense net of tax income tax effect for the year ended december included million income tax expense following the court of appeal decision in altera corp commissioner which requires related party in an intercompany cost sharing arrangement to share expense related to stock based compensation see income tax for additional information stock based compensation is recognized expense over the requisite service period on our consolidated statement of income using the straight line expense attribution approach reduced for estimated forfeiture we estimate forfeiture based on our historical experience the requisite service period could be shorter than the vesting period if an employee is retirement eligible assumptionsfair value of option granted under our plan and purchase under our espp were estimated at grant or purchase date using black scholes option valuation model the black scholes option valuation model wa developed for use in estimating the fair value of traded option which have no vesting restriction and are fully transferable in addition option valuation model require the input of highly subjective assumption including expected stock price volatility and expected award life we used the following assumption to calculate the estimated fair value of the award year ended december volatility stock option espp expected term in year stock option free interest rate stock option espp expected dividend yield the fair value of stock option granted wa calculated using the single option approach we use blend of historical volatility along with implied volatility for traded option on our common stock to determine our expected volatility the expected term of stock based award represents the weighted average period the award are expected to remain outstanding we estimate the weighted average expected term based on historical cancellation and historical exercise data related to our stock option well the contractual term and vesting term of the award the risk free interest rate is based upon observed interest rate appropriate for the term of the stock based award the dividend yield is based on our history and expectation of dividend payouts deferred compensationwe maintain retirement saving plan under which eligible employee may defer compensation for income tax purpose under section of the internal revenue code the gilead science plan in certain foreign subsidiary we maintain defined benefit plan required by local regulatory requirement our total matching contribution expense under the gilead science plan and other defined benefit plan wa million during million during and million during we maintain deferred compensation plan under which our director and key employee may defer compensation amount deferred by participant are deposited into rabbi trust the total asset and liability associated with the deferred compensation plan were million of december and million of december net income per share attributable to gilead common stockholdersbasic net income per share attributable to gilead common stockholder is calculated based on the weighted average number of share of our common stock outstanding during the period diluted net income per share attributable to gilead common stockholder is calculated based on the weighted average number of share of our common stock and other dilutive security outstanding during the period the potentially dilutive share of our common stock resulting from the assumed exercise of outstanding stock option and equivalent were determined under the treasury stock method potential share of common stock excluded from the computation of diluted net income per share attributable to gilead common shareholder because their effect would have been antidilutive were million million and million during and respectively following table show the calculation of basic and diluted net income per share attributable to gilead common stockholder in million except per share amount year ended december income attributable to gilead used in per share calculation basic effect of stock option and equivalent used in per share calculation diluted income per share attributable to gilead common stockholder basic income per share attributable to gilead common stockholder diluted segment informationwe have one operating segment which primarily focus on the discovery development and commercialization of innovative medicine in area of unmet medical need our chief executive officer ceo the chief operating decision maker manages and allocates resource to the operation of our company on an entity wide basis managing and allocating resource on an entity wide basis enables our ceo to ass the overall level of resource available and how to best deploy these resource across function and project based on unmet medical need and necessary reallocate resource among our internal portfolio and external opportunity to best support the long term growth of our business see note revenue for summary of disaggregated revenue by product and geographic region revenue from major customersthe following table summarizes revenue from each of our customer who individually accounted for or more of our total revenue percentage of total revenue year ended december corp cardinal health inc mckesson corp long lived assetsthe net book value of our property plant and equipment le office and computer equipment in the united state wa billion of december billion of december and billion of december the corresponding amount in international location wa million of december million of december and million of december all individual international location accounted for le than of the total balance income tax income before provision for income tax consists of the following in million year ended december before provision for income tax provision for income tax consists of the following in million year ended december current current current for income tax provision for income tax included billion deferred tax benefit related to intangible asset transfer from foreign subsidiary to ireland and the united state in the fourth quarter of we completed an intra entity asset transfer of certain intangible asset from foreign subsidiary to ireland the transaction resulted in step up of the irish tax deductible basis in the transferred asset and accordingly created temporary difference where the tax basis exceeded the book basis of such intangible asset result we recognized deferred tax asset of billion on our consolidated financial statement the tax deduction for amortization of the asset will be recognized in the future and any amortization not deducted for tax purpose will be carried forward indefinitely under irish tax law we expect to be able to realize the deferred tax asset resulting from this intra entity asset transfer the impact of the intangible asset transfer from foreign subsidiary to the united state wa not material the provision for income tax included million deferred tax charge related to transfer of acquired intangible asset from foreign subsidiary to the united state this transaction did not result in step up of the tax deductible basis and result we recognized deferred tax liability of million for the temporary difference where the book basis exceeded the tax basis of these acquired intangible asset the provision for income tax included billion provisional charge to income tax expense related to tax reform enacted in december tax reform made significant change to the internal revenue code of amended which include but are not limited to corporate tax rate decrease from to effective for tax year beginning after december repatriation tax on deemed repatriated earnings of foreign subsidiary implementation of modified territorial tax system which ha the effect of subjecting earnings of our foreign subsidiary to taxation on gilti we elected to account for the tax on gilti under the period cost method the reconciliation between the federal statutory tax rate applied to income before tax and our effective tax rate is summarized follows year ended december statutory rate state tax net of federal benefit foreign earnings at different rate research and other credit tax on foreign earnings deferred tax intra entity transfer of intangible asset transition tax deferred tax revaluation settlement of tax examination other effective tax rate income tax reflect the net tax effect of temporary difference between the carrying amount of asset and liability for financial reporting purpose and the amount used for income tax purpose significant component of our deferred tax asset and liability are follows in million december tax asset net operating loss carryforwards based compensation and accrual not currently deductible of tax basis over book basis of intangible asset up front and milestone payment and other credit carryforwards net deferred tax asset before valuation allowance allowance total deferred tax asset tax liability property plant and equipment excess of book basis over tax basis of intangible asset other total deferred tax liability net deferred tax asset liability the valuation allowance wa million and million at december and respectively the decrease of our valuation allowance in wa primarily related to reduction in net operating loss carryforwards under the asset recognition framework and the corresponding valuation allowance with respect to certain foreign jurisdiction at december we had federal net operating loss carryforwards of approximately million the federal net operating loss carryforwards will start to expire in if not utilized we also had federal tax credit carryforwards of approximately million which will start to expire in if not utilized in addition we had state net operating loss and tax credit carryforwards of approximately billion and million respectively the state net operating loss will start to expire in if not utilized and state tax credit carryforwards is carried forward indefinitely utilization of net operating loss and tax credit may be subject to an annual limitation due to ownership change limitation provided in the internal revenue code of amended and similar state provision this annual limitation may result in the expiration of the net operating loss and credit before utilization we file federal state and foreign income tax return in the united state and in many foreign jurisdiction for federal income tax purpose the statute of limitation is open for and onwards and and onwards for california income tax purpose for certain acquired entity the statute of limitation is open for all year from inception due to our utilization of their net operating loss and credit carried over from prior year our income tax return are subject to audit by federal state and foreign tax authority we are currently under examination by the irs for the tax year from to and by various state and foreign jurisdiction there are differing interpretation of tax law and regulation and result significant dispute may arise with these tax authority involving issue of the timing and amount of deduction and allocation of income among various tax jurisdiction we periodically evaluate our exposure associated with our tax filing position of the total unrecognized tax benefit billion and billion at december and if recognized would reduce our effective tax rate in the period of recognition interest and penalty related to unrecognized tax benefit included part of provision for income tax on our consolidated statement of income were million for the year ended december interest and penalty related to unrecognized tax benefit for the year ended december and respectively were not material accrued interest and penalty related to unrecognized tax benefit were million and million at december and respectively of december we believe that it is reasonably possible that our unrecognized tax benefit may materially change in the next month due to potential resolution with tax authority an estimate of the range of the reasonably possible change can not be determined at this time june the ninth circuit court of appeal ninth circuit issued an opinion in altera corp commissioner reversing the prior decision of the united state tax court and requiring related party in an intercompany cost sharing arrangement to share expense related to stock based compensation in july the taxpayer requested rehearing before the full ninth circuit and the request wa denied in november result we recorded cumulative income tax expense of million in the fourth quarter of on february the taxpayer requested hearing before the supreme court of the united state and such although the final outcome of the case is still uncertain we recorded income tax expense in the fourth quarter of based on the ninth circuit denial the following is rollforward of our total gross unrecognized tax benefit in million year ended december beginning of period position related to current year addition tax position related to prior year addition settlement lapse of statute of limitation balance end of period quarterly financial information unaudited in million except per share amount quarter quarter quarter total revenue profit on product sale income loss income loss attributable to gilead income loss per share attributable to gilead common stockholder basic income loss per share attributable to gilead common stockholder diluted total revenue profit on product sale income income attributable to gilead income per share attributable to gilead common stockholder basic net income per share attributable to gilead common stockholder diluted _________________________________________ amount for the third quarter of included up front collaboration and licensing expense of billion or per basic and diluted share related to the collaboration with galapagos see note collaborative and other arrangement for additional detail amount for the fourth quarter of included billion favorable tax effect related to intra entity intangible asset transfer and million of pre tax net gain from equity security partially offset by an million pre tax impairment charge related to in process research and development ipr intangible asset acquired in connection with the acquisition of kite and pre tax write down of million for slow moving and excess raw material and work in process inventory see note fair value measurement note inventory note intangible asset and note income tax for additional detail amount for the fourth quarter of included net favorable impact of per basic share and per diluted share from the factor noted above in footnote amount for the fourth quarter of included an million pre tax impairment charge related to ipr intangible asset acquired in connection with the acquisition of kite million non cash tax charge related to transfer of acquired intangible asset from foreign subsidiary to the united state and pre tax write down of million for excess raw material primarily due to sustained decrease in demand for harvoni see note inventory note intangible asset and note income tax for additional detail amount for the fourth quarter of included an unfavorable impact of per basic share and per diluted share from the factor noted above in footnote science inc schedule ii valuation and qualifying account in million balance at beginning of period addition charged to expense deduction balance at end of periodyear ended december account receivable allowance return allowance allowance for deferred tax asset ended december account receivable allowance return allowance allowance for deferred tax asset ended december account receivable allowance return allowance allowance for deferred tax asset allowance are for doubtful account cash discount and chargebacks change in and disagreement with accountant on accounting and financial disclosure not applicable item control and procedure evaluation of disclosure control and procedure an evaluation of december wa carried out under the supervision and with the participation of our management including our chief executive officer and chief financial officer of the effectiveness of our disclosure control and procedure which are defined in rule under the security exchange act of amended the exchange act control and other procedure of company that are designed to ensure that the information required to be disclosed by company in the report that it file or submits under the exchange act is recorded processed summarized and reported within the time period specified in the security and exchange commission rule and form and that such information is accumulated and communicated to the company management including it chief executive officer and chief financial officer appropriate to allow timely decision regarding required disclosure based upon that evaluation our chief executive officer and chief financial officer concluded that our disclosure control and procedure were effective at december management report on internal control over financial reporting our management is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule of the exchange act our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statement for external purpose in accordance with generally accepted accounting principle all internal control system no matter how well designed have inherent limitation and can provide only reasonable assurance that the objective of the internal control system are met under the supervision and with the participation of our management including our chief executive officer and chief financial officer we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criterion established by the committee of sponsoring organization of the treadway commission coso in it internal control integrated framework based on our evaluation we concluded that our internal control over financial reporting wa effective of december our independent registered public accounting firm ernst young llp ha audited our consolidated financial statement included in item of this annual report on form and have issued report on our internal control over financial reporting of december their report on the audit of internal control over financial reporting appears below change in internal control over financial reporting our management including our chief executive officer and chief financial officer ha evaluated any change in our internal control over financial reporting that occurred during the quarter ended december and ha concluded that there wa no change during such quarter that ha materially affected or is reasonably likely to materially affect our internal control over financial reporting of independent registered accounting firmto the stockholder and the board of director of gilead science inc opinion on internal control over financial reporting we have audited gilead science inc internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework the coso criterion in our opinion gilead science inc the company maintained in all material respect effective internal control over financial reporting of december based on the coso criterion we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of the company of december and the related consolidated statement of income comprehensive income stockholder equity and cash flow for each of the three year in the period ended december and the related note and financial statement schedule listed in the index at item and our report dated february expressed an unqualified opinion thereon basis for opinion the company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation of internal control over financial reporting company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate ernst young llpsan jose californiafebruary other informationnot applicable part iii item director executive officer and corporate governance the information required by this item concerning our director and executive officer is incorporated by reference to the section of our definitive proxy statement to be filed with the security and exchange commission pursuant to regulation in connection with our annual meeting of stockholder the proxy statement under the heading the gilead board of director nominee board structure executive officer and if applicable delinquent section report our written code of ethic applies to all of our director and employee including our executive officer including without limitation our principal executive officer principal financial officer principal accounting officer or controller or person performing similar function the code of ethic is available on our website at http www gilead com in the investor section under corporate governance we intend to disclose future amendment to certain provision of the code of ethic and waiver of the code of ethic granted to executive officer and director on the website within four business day following the date of the amendment or waiver item executive compensation the information required by this item is incorporated by reference to the section of the proxy statement under the heading executive compensation committee of our board of director compensation committee report and compensation of non employee board member item security ownership of certain beneficial owner and management and related stockholder matter the information required by this item is incorporated by reference to item of our annual report on form under the heading equity compensation plan information and the section of the proxy statement under the heading security ownership of certain beneficial owner and management item certain relationship and related transaction and director independence the information required by this item is incorporated by reference to the section of the proxy statement under the heading the gilead board of director and board process item principal accountant fee and service the information required by this item is incorporated by reference to the section of the proxy statement under the heading principal accountant fee and service part iv item exhibit and financial statement schedule the following document are filed part of this annual report on form index list to consolidated financial statement report of independent registered public accounting consolidated financial statement consolidated balance statement of statement of comprehensive statement of stockholder statement of cash to consolidated financial schedule ii is included on page of this report all other schedule are omitted because they are not required or the required information is included in the financial statement or note thereto exhibit the following exhibit are filed herewith or incorporated by reference exhibitfootnoteexhibit number description of document restated certificate of incorporation of registrant amended and restated bylaw of registrant reference is made to exhibit and exhibit indenture related to senior note dated of march between registrant and well fargo national association trustee first supplemental indenture related to senior note dated of march between registrant and well fargo national association trustee including form of senior note second supplemental indenture related to senior note dated of december between registrant and well fargo national association trustee including form of note form of note third supplemental indenture related to senior note dated of march between registrant and well fargo national association trustee including form of note form of note fourth supplemental indenture related to senior note dated of november between registrant and well fargo national association trustee including form of note form of note form of note fifth supplemental indenture dated of september between registrant and well fargo bank national association trustee including form of note form of note form of note form of note and form of note sixth supplemental indenture dated of september between registrant and well fargo bank national association trustee including form of note form of note form of note form of note and form of note description of registrant security gilead science inc equity incentive plan amended and restated may form of employee stock option agreement under equity incentive plan for grant made in form of employee stock option agreement under equity incentive plan for grant made in through form of employee stock option agreement under equity incentive plan for grant commencing in form of global employee stock option agreement under equity incentive plan year vest for grant commencing in form of non employee director stock option agreement under equity incentive plan for grant made in through form of non employee director stock option agreement under equity incentive plan for grant made in form of non employee director stock option agreement non under equity incentive plan for grant made in form of non employee director stock option agreement under equity incentive plan for grant made in through form of non employee director stock option agreement under equity incentive plan for grant commencing in form of performance share award agreement tsr goal with director retirement provision under equity incentive plan for grant made in through form of performance share award agreement tsr goal non under equity incentive plan for grant made in through form of performance share award agreement tsr goal under equity incentive plan for grant commencing in form of performance share award agreement revenue goal under equity incentive plan for grant made in through form of performance share award agreement revenue goal with director retirement provision under equity incentive plan for grant made in through form of performance share award agreement revenue goal under equity incentive plan for grant commencing in form of employee restricted stock unit issuance agreement under equity incentive plan for grant made in through form of employee restricted stock unit issuance agreement under equity incentive plan for grant commencing in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for grant commencing in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for grant commencing in form of non employee director restricted stock unit issuance agreement under equity incentive plan for grant commencing in gilead science inc employee stock purchase plan amended and restated january gilead science inc deferred compensation plan amended and restated april gilead science inc severance plan amended and restated july gilead science inc corporate bonus plan amended and restated january gilead science inc retention program for executive officer offer letter between registrant and robin washington dated april offer letter between registrant and laura hamill dated august severance and general release agreement between registration and laura hamill dated june transition and severance agreement between registrant and gregg alton dated july transition and severance agreement between registrant and john mchutchison dated july offer letter between registrant and daniel day dated november offer letter between registrant and johanna mercier dated may stock option agreement for daniel day under equity incentive plan performance share award agreement for daniel day for tsr goal in under equity incentive plan performance share award agreement for daniel day for revenue goal in under equity incentive plan form of restricted stock unit issuance agreement for daniel day in under equity incentive plan form of indemnity agreement entered into between registrant and it director and executive officer form of employee proprietary information and invention agreement entered into between registrant and certain of it officer and key employee form of employee proprietary information and invention agreement entered into between registrant and certain of it officer and key employee revised september amendment agreement dated october between registrant the institute of organic chemistry and biochemistry iocb and rega stichting rega together with the following exhibit the license agreement dated december between registrant iocb and rega the license agreement the license agreement dated october between registrant iocb and rega the october license agreement and the license agreement dated december between registrant iocb and rega the december license agreement amendment agreement between registrant and iocb rega dated december amending the license agreement and the december license agreement sixth amendment agreement to the license agreement between iocb rega and registrant dated august amending the october license agreement and the december license agreement seventh amendment agreement to the license agreement between iocb rega and registrant dated july amending the october license agreement and the december license agreement exclusive license agreement by and between registrant successor to triangle pharmaceutical inc glaxo group limited the wellcome foundation limited glaxo wellcome inc and emory university dated may royalty sale agreement by and among registrant emory university and investor trust custodial service ireland limited solely in it capacity trustee of royalty pharma dated july amended and restated license agreement by and between registrant emory university and investor trust custodial service ireland limited solely in it capacity trustee of royalty pharma dated july amended and restated evg license agreement by and between japan tobacco inc and registrant dated november master agreement by and between registrant gilead science and japan tobacco inc dated november amended and restated collaboration agreement by and among registrant gilead science ireland uc formerly gilead science limited and janssen ireland dated december license agreement by and among kite pharma inc cabaret biotech ltd and dr zelig eshhar dated december option license and collaboration agreement by and between galapagos nv and registrant dated july subsidiary of registrant consent of independent registered public accounting firm certification of chief executive officer required by rule or rule of the security exchange act of amended certification of chief financial officer required by rule or rule of the security exchange act of amended certification of chief executive officer and chief financial officer required by rule or rule and section of chapter of title of the united state code in xbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document sch inline xbrl taxonomy extension schema document cal inline xbrl taxonomy extension calculation linkbase document def inline xbrl taxonomy extension definition linkbase document lab inline xbrl taxonomy extension label linkbase document pre inline xbrl taxonomy extension presentation linkbase document the cover page from the company annual report on form for the fiscal year ended december formatted in inline xbrl filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant current report on form filed on april and incorporated herein by reference filed an exhibit to registrant current report on form filed on december and incorporated herein by reference filed an exhibit to registrant current report on form filed on march and incorporated herein by reference filed an exhibit to registrant current report on form filed on november and incorporated herein by reference filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant current report on form filed on december and incorporated herein by reference filed an exhibit to registrant registration statement on form no amended and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended march and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to triangle pharmaceutical inc quarterly report on form filed on november and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant amendment no to annual report on form filed on april and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to kite pharma inc registration statement on form no filed on june and incorporated herein by reference management contract or compensatory plan or arrangement filed herewith furnished herewith certain confidential portion of this exhibit were omitted by mean of marking such portion with an asterisk the mark this exhibit ha been filed separately with the secretary of the security and exchange commission without the mark pursuant to registrant application requesting confidential treatment under rule under the security exchange act of amended certain confidential portion of this exhibit were omitted by mean of marking such portion with the mark because the identified confidential portion are not material and ii would be competitively harmful if publicly disclosed item form summarynone pursuant to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized gilead science inc by daniel day daniel daychairman and chief executive officerpower of attorney know all person by these present that each person whose signature appears below constitutes and appoints daniel day and brett pletcher and each of them true and lawful attorney in fact and agent with full power of substitution and resubstitution for or her and in his or her name place and stead in any and all capacity to sign any and all amendment to this report and to file the same with all exhibit thereto and other document in connection therewith with the security and exchange commission granting unto said attorney in fact and agent and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith fully to all intent and purpose might or could do in person hereby ratifying and confirming that all said attorney in fact and agent or any of them or their or his substitute or substitute may lawfully do or cause to be done by virtue hereof pursuant to the requirement of the security exchange act of amended this report ha been signed below by the following person on behalf of the registrant and in the capacity and on the date indicated title date daniel day chairman and chief executive officer february day principal executive officer andrew dickinson executive vice president and chief financial officer february dickinson principal financial officer diane wilfong senior vice president and chief accounting officer february wilfong principal accounting officer john cogan director february cogan ph kelly kramer director february kramer kevin lofton director february lofton harish manwani director february manwani richard whitley director february whitley gayle wilson director february wilson per wold olsen director february wold olsen represents majority of the board of copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next